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ABSTRACT
Evaluation of novel sigma receptor antagonists against METH-induced neurotoxicity:
in vivo and in vitro studies
NIDHI KAUSHAL
Methamphetamine (METH) is a highly addictive psychostimulant drug of abuse, causing
hyperthermia and neurotoxicity at high doses. Currently, there is no clinically proven
pharmacotherapy to treat these effects of METH, necessitating identification of potential novel
therapeutic targets. Earlier studies showed that METH binds to sigma receptors in the brain at
physiologically relevant concentrations, where it acts in part as an agonist. AC927 (1-(2phenethyl)piperidine oxalate), CM156 (3-(4-(4-cyclohexylpiperazin-1-yl)butyl)benzo[d]thiazole2(3H)-thione) and SN79 (6-acetyl-3-(4-(4-(4-florophenyl)piperazin-1-yl)butyl)benzo[d]oxazol2(3H)-one) were synthesized as putative sigma receptor antagonists with nanomolar affinity and
selectivity for sigma receptors over 29-80 other binding sites. AC927, CM156 and SN79
pretreatment afforded protection against METH-induced hyperthermia and striatal dopaminergic
and serotonergic neurotoxicity in male Swiss Webster mice (measured as depletions in striatal
dopamine and serotonin levels, and reductions in striatal dopamine and serotonin transporter
expression levels). To elucidate the mechanism of neuroprotection provided by sigma receptor
antagonists, differentiated NG108-15 cells were used as a cell culture model. METH, at
physiologically relevant micromolar concentrations, caused apoptosis in NG108-15 cells. At
higher concentrations necrotic cell death was observed. At earlier time points, METH caused
generation of reactive oxygen/nitrogen species like hydrogen peroxide and nitric oxide and also
release of dopamine from the cells. At later time points, caspase-3, -8 and -9 activation was
observed indicating activation of both extrinsic and intrinsic caspase-dependent apoptotic
pathways. Sigma receptor antagonism attenuated these neurotoxic mediators and cell death.
Additionally, DTG, a sigma receptor agonist shifted the dose response curve of METH-induced
cell death (especially necrosis) towards left further confirming the involvement of sigma
receptors in the neurotoxic effect of METH. Among the two subtypes of sigma receptors, sigma2 receptors are highly upregulated in tumor cells and are implicated in cell death mechanism.
Both CM398 and CM775, sigma-2 receptor antagonists also attenuated METH-induced
neurotoxicity, providing further evidence for involvement of this subtype in METH-induced cell
death mechanisms. In addition to activation of cell death mediators, METH also causes increase
in body temperature. METH treatment in NG108-15 cells maintained at 40 ºC versus 37 ºC
caused a significant and synergistic increase in cell death, indicating that increase in
temperature exacerbates METH-induced toxicity. SN79 was able to attenuate the enhanced cell
death observed in the METH treated cells at 40 ºC. This can have important implications in in
vivo systems where sigma receptor antagonism can protect against toxicity induced by METH at
elevated temperature. This study provided evidence for the potential application of sigma
receptor antagonists as drug development against METH-induced neurotoxicity, in addition to
providing a mechanistic basis of neuroprotection.
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CHAPTER 1
BACKGROUND AND SPECIFIC AIMS

1

1.1 Methamphetamine
Methamphetamine (METH) is one of the amphetamine analogs and a psychomotor
stimulant. It is a widely abused substance worldwide mainly due to its ease of synthesis from
over the counter drugs and its long half life (10-12 h). Due to these factors, it ranks second
worldwide after Cannabis as the most extensively abused drug, with an estimated 15-16
million users worldwide (Krasnova and Cadet, 2009).
Apart from its immediate stimulant effects such as euphoria and enhanced energy,
METH causes harmful effects upon exposure to repeated or large doses. Some of these
harmful effects include hyperthermia, addiction, altered neurological and cognitive functions,
psychosis, depression, and neurodegeneration (Krasnova and Cadet, 2009).
The neurodegenerative and neurotoxic effects have been studied using neuroimaging
and postmortem studies in humans, depicting damage to dopaminergic and serotonergic
neurons in several regions of the brain. This damage can be measured as reductions in
dopamine transporters (DAT), serotonin transporters (SERT), and dopamine and serotonin (5HT) levels (Krasnova and Cadet, 2009). In addition, in certain postmortem studies, apoptotic
markers like caspase 3 have also been reported (Kitamura et al., 2007). These
neurodegenerative effects are a cause of concern because they are implicated in some of the
neuropsychiatric symptoms observed due to METH (Volkow et al., 2001; Scott et al., 2007). In
addition, retrospective studies have shown that many Parkinson’s disease patients were
former abusers of METH (Garwood et al., 2006; Kuehn, 2011). Figure 1.1 shows the
comparison of DAT levels in a METH user and control brain 80 days after detoxification.
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Figure 1.1 Striatal distribution volume of DAT ligand in METH abuser

(Volkow et al., 2001)
1.2 Models and markers of METH-induced neurotoxicity
METH-induced neurotoxic damage has been studied by researchers in in vivo and in
vitro models. In vivo models include rodents and non-human primates. A 4×METH (4
injections of METH at 2 hour intervals) is a commonly used dosing regimen for studying
METH’s neurotoxic effects as it mimics the binge pattern of METH intake by addicts
(Villemagne et al., 1998). In addition, a bolus dose of METH administration has also been
used, but it leads to a higher mortality rate (Fukumura et al., 1998). The neurotoxic regimen of
METH causes damage to neurons in several brain regions like the striatum, cortex, and
hippocampus (Deng et al., 2001). Some of the earlier methods used to detect damage were
ATP loss and decrease in regional cerebral glucose utilization (Chan et al., 1994; Huang et
al., 1999). METH mainly causes degeneration of nerve terminals which have previously been
detected using Fluoro jade staining (Schmued and Bowyer, 1997). Damage to dopamine
nerve terminals is observed as a decrease in the levels of dopamine, tyrosine hydroxylase,
3

DAT, and vesicular monoamine transporters (VMAT2) (Krasnova and Cadet, 2009). Similarly,
damage to serotonin nerve terminals is observed as a decrease in the levels of 5-HT,
tryptophan hydroxylase, and SERT (Krasnova and Cadet, 2009). In addition, it has been
recently observed that METH can also cause apoptosis in these brain regions (Deng et al.,
2001; Krasnova and Cadet, 2009).
In vitro studies have been done using primary neuronal cells (fetal mesencephalic
dopamine neurons, midbrain neuronal cells, mesencephalic dopamine cells) (Bennett et al.,
1993; Cubells et al., 1994; Kanthasamy et al., 2006) and immortalized neuronal cells
(neuroblastoma NBP2 cells, CATH.a cells, PC12 cells, human neuroblastoma SH-SY5Y cells,
immortalized rat mesencephalon cells) (Adams et al., 1996; Cadet et al., 1997; Hom et al.,
1997; Choi et al., 2002; Wang et al., 2008) as models to further understand the mechanisms
involved in METH-induced neurotoxicity and cell death (Krasnova and Cadet, 2009). Apoptotic
and necrotic types of cell death and some of their mechanisms have been studied using
makers like TUNEL staining (Samantaray et al., 2006), Hoechst staining (Larsen et al., 2002),
annexin V, propidium iodide (Deng et al., 2002), reactive oxygen species (ROS) (Cubells et
al., 1994), proapoptotic factors like Bax, Bid, AIF, and caspase levels (Jayanthi et al., 2004).

1.3 Mechanisms of action of METH
Classically, METH is known to cause an enormous increase in dopamine release by
the blockade and reversal of DAT (Barr et al., 2006). METH also enters the neuron passively
or via DAT and impairs VMAT2 which are present on synaptic vesicles containing the
neurotransmitter dopamine. This excessive dopamine in the synapse and cytoplasm causes
production of ROS through autooxidation as well as enzyme-mediated reactions (Wrona et al.,
1995; Wrona and Dryhurst, 1998; LaVoie and Hastings, 1999a; LaVoie and Hastings, 1999b).
This excessive ROS can cause nerve terminal degeneration (by lipid peroxidation and
4

oxidation of proteins and phospholipids) and cell death via apoptosis or necrosis (Krasnova
and Cadet, 2009). Figure 1.2 shows a simplistic mechanism of METH-induced neurotoxicity.
Figure 1.3 shows some mechanisms by which dopamine can lead to ROS generation.

Figure 1.2: Mechanisms of METH-induced neurotoxicity
METH

Dopamine release

Dopamine oxidation

ROS production
DA nerve terminal damage
Apoptosis/cell death

Figure 1.3: Mechanisms of formation of ROS from dopamine
MAO
DA + O2 + H2O

DOPAC + NH3 + H2O2

DA + O2

SQ• + O2• + 2H+

DA + O2• + 2H+

SQ• + H2O2

H2O2 + Fe2+

OH• + OH- + Fe2+ (Fenton Reaction)

(DA: Dopamine, MAO: Monoamine oxidase, SQ•: Dopamine quinone)
Apart from the dopamine system, similar damage is seen in the 5-HT system with ROS
generation being the major cause (Kita et al., 2003).
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1.4 METH and sigma receptors
Until today, there is no effective treatment for psychostimulant abuse. Exploration of a
novel target for medication development, and to better understand the mechanisms of METHinduced neurotoxicity led to the discovery that METH interacts with sigma (σ) receptors at
physiologically relevant concentrations (Table 1.1) (Itzhak, 1993; Nguyen et al., 2005). σ
Receptors seem to play an important role in many of the effects of METH. They are found to
be present in the organs that mediate the actions of METH (e.g. brain, heart, lungs)
(Waterhouse et al., 1997). Additionally and more specifically, they are present in the areas of
the brain that are damaged by METH (Gundlach et al., 1986).

Table 1.1: Binding affinity of METH for σ receptors
σ-1 Receptors (µM) σ-2 Receptors (µM)
METH

2.16 ± 0.25

46.67 ± 10.34
(Nguyen et al., 2005)

Previous studies underscored the importance of targeting σ receptors to attenuate some of
the behavioral effects of METH in rodent models:
1.4.1

Locomotor stimulant effect: σ-1 Receptor antisense and antagonists like BD1047 (N[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(dimethylamino)ethylamine) and BD1063 (1[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine) attenuate METH-induced locomotor
stimulation (Nguyen et al., 2005).

1.4.2

Sensitization: σ Receptor antagonists like MS377 [(R)-(1)-1-(4-chlorophenyl)-3-[4-(2methoxyethyl)piperazin-1-yl]methyl-2-pyrrolidinone-L-tartrate] and BMY14802 (alpha(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine-butanol)
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prevent

the

development of behavioral sensitization to METH (Ujike et al., 1992; Takahashi et al.,
2000).
1.4.3

Self administration: Chronic self administration of METH in rats causes an upregulation
of σ-1 receptors and mRNA in various brain regions including the substantia nigra,
frontal cortex, cerebellum, midbrain, and hippocampus (Stefanski et al., 2004; Hayashi
et al., 2010).

1.5 σ Receptors
σ Receptors are a unique group of drug binding sites (Matsumoto et al., 2003). They
were first proposed by the group of Martin in 1976 (Martin et al., 1976). They were called σ
after the first letter ‘S’ of SKF-10047, which was then considered a prototypic σ ligand. σ
Receptors represent a unique class of proteins that are non-opioidergic and non-N-methyl-Daspartate (NMDA) receptors (Vaupel, 1983). They possess a unique drug binding profile and
anatomical distribution which is very different from the other mammalian proteins (Matsumoto
et al., 2003; Guitart et al., 2004). They are found extensively in the brain and periphery
(Guitart et al., 2004). Through various biochemical and pharmacological experiments, the two
subtypes of σ receptors, σ-1 and σ-2, were characterized (Bowen et al., 1989; Hellewell and
Bowen, 1990; Walker et al., 1992).
1.5.1

σ-1 Receptors: They have been cloned and are not homologous to any known protein

except for sharing 30% homology with fungal sterol isomerase (Moebius et al., 1996), but do
not possess isomerase activity. They have a 223 amino acid sequence with a double
transmembrane structure (Kekuda et al., 1996; Prasad et al., 1998; Seth et al., 1998) and a
molecular weight of 25 kDa (Hellewell and Bowen, 1990). Following the binding of ligands, σ-1
receptors have been shown to operate via protein-protein interactions and translocation
between subcellular compartments through chaperone-like functions (Hayashi and Su, 2003a;
7

Hayashi and Su, 2007; Su et al., 2010), modulation of G-protein coupled receptors, ion
channels and signaling molecules like IP3, protein kinases and calcium (Morin-Surun et al.,
1999; Aydar et al., 2002; Hayashi and Su, 2003a; Hayashi and Su, 2007).
1.5.2

σ-2 Receptors: In contrast to σ-1 receptors, much less is known about σ-2 receptors,

due to a lack of selective ligands and also because they have not yet been cloned. Using
photoaffinity labeling studies, σ-2 receptors have been found to be 18-22 kDa in molecular
weight (Hellewell et al., 1994). At the cellular level, they are localized in lipid rafts, the plasma
membrane, endoplasmic reticulum (ER), mitochondria, and lysosomes of cells (Gebreselassie
and Bowen, 2004; Zeng et al., 2007). σ-2 Receptors are highly upregulated in rapidly dividing
tumor cell lines and have a role in cell death signaling via sphingolipid products (Mach et al.,
1997; Bowen, 2000), calcium signaling (Vilner and Bowen, 2000; Cassano et al., 2009), and
oxidative stress (Ostenfeld et al., 2005; Hornick et al., 2010). Recent studies also show that
they can be valuable in chemotherapy and for tumor imaging studies (John et al., 1999;
Bowen, 2000; Tu et al., 2010).
A recent study has proposed σ-2 receptors to be a binding site in the PGRMC1 (progesterone
receptor membrane component 1) complex (Xu et al., 2011). PGRMC1 like σ- 2 receptors are
highly expressed in tumor cells in comparison to normal cells (Bowen, 2000; Cahill, 2007).
They both are studied as important cancer biomarkers and potential therapeutic targets for
anticancer drugs (Bowen, 2000; Cahill, 2007; Mir et al., 2011). This study is very promising
given the lack of molecular biology tools to study σ-2 receptors. The novel compounds used in
this study are selective for σ-2 over σ-1 receptors. However, additional selectivity profile of
those tested compounds over other non-sigma sites may have to be determined in order to
further establish the claim.
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1.6 Sigma receptor ligands: agonist/antagonist
Several functional studies have been conducted in different systems to characterize
agonists and antagonists at σ receptors. In classical pharmacological terms, an agonist at a
receptor produces a response, whereas an antagonist is able to inhibit the action of agonist
without producing any effect on its own. An antagonist causes a concentration-dependent
parallel rightward shift in the dose response curve of an agonist. Among some of the early
studies, classical σ ligands like di-o-tolylguanidine (DTG), (+)-pentazocine, and (+)-SKF 10047
caused a dystonic reaction when injected into the red nucleus of rats, and also increased the
burst duration of red nucleus neurons following electrical stimulation of cerebellorubrospinal
circuits (Matsumoto et al., 1990; Matsumoto et al., 1999). Data such as these suggested that
classical compounds, such as DTG and (+)-pentazocine, act as agonists at σ receptors. In
contrast, other σ compounds like BD1047 and BD1063 decreased the burst duration of red
nucleus neurons following stimulation of cerebellorubrospinal circuits (Matsumoto et al.,
1999). In addition, when tested in vivo, BD1047 and BD1063 did not show any behavioral
effects when injected into the red nucleus of rats, but they prevented the dystonic reactions
produced by putative σ receptor agonists such as DTG (Matsumoto et al., 1995). Therefore,
these latter compounds were termed as putative antagonists.
Using these types of classical designations, the putative agonist actions of many
compounds, including DTG and (+)-pentazocine, were demonstrated in other model systems.
Putative antagonist actions of compounds such as BD1047 and BD1063 were also confirmed.
As one example, σ receptor agonists have also been shown to modulate the activity of Gproteins by indirectly enhancing GTPγS binding (Joseph and Bowen, 1998). σ Receptor
antagonists such as BD1047 and BD1063 do not produce any effects on their own, but are
able to attenuate these agonist-stimulated effects on GTPγS binding (Joseph and Bowen,
1998). Similar patterns have also been shown with regard to σ receptor agonist-induced
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cognitive enhancing effects which can be prevented by σ receptor antagonists (Hashimoto et
al., 2007). σ Receptor agonists can also promote NGF-induced neurite outgrowth, and this
effect is attenuated in the presence of antagonists (Takebayashi et al., 2002).
Recent studies suggest that, at a subcellular level sigma-1 receptor acts as a ligandoperated chaperone at the mitochondria associated ER membrane (MAM) (Hayashi and Su,
2007). At MAM, sigma-1 receptor is found to be associated with another chaperone protein,
BiP. Sigma-1

receptor agonists like (+)Pentazocine, (+)SKF-10047 and PRE-084 cause

sigma-1 and BiP dissociation, whereas sigma-1 receptor antagonists like NE-100,
Progesterone and haloperidol inhibit agonist induced dissociation of sigma-1 and BiP
(Hayashi and Su, 2007).
In some later studies, these antagonists were also able to attenuate various behavioral
effects of cocaine (Matsumoto et al., 2003), presumably by interfering with the access of
cocaine to one of its binding sites, the σ receptor (Sharkey et al., 1988). This antagonistic
effect through σ receptors against cocaine was confirmed by the use of antisense
oligonucleotides (ONs) targeting σ-1 receptors, which led to a reduction in the expression of
σ-1 receptors in the brain by about 40% (Matsumoto et al., 2001; Matsumoto et al., 2002;
Matsumoto et al., 2003). By reducing access of drugs to their target sites, the antisense ONs
would be expected to act functionally like pharmacological antagonists. This was indeed
confirmed, where reductions in σ-1 receptors by antisense ONs also resulted in the
attenuation of the behavioral effects of cocaine (Matsumoto et al., 2001). Similar effects were
also observed with behavioral effects of METH (as mentioned before), where σ receptor
antisense ONs or antagonists attenuated the METH-induced locomotor stimulant (Nguyen et
al., 2005) and sensitized response (Ujike et al., 1992; Takahashi et al., 2000). Similar
confirmation of effects by putative antagonists and antisense ONs were obtained in other
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model systems, including the cognitive enhancing and neurite outgrowth effects mentioned
above. Together, the body of literature provides converging lines of evidence to support the
designation of antagonist and agonist effects of σ receptor ligands, which were first assigned
using classical pharmacological definitions. Therefore, with regard to their actions through σ
receptors, METH is considered a σ receptor agonist, whereas σ receptor ligands that can
block the effects of METH are considered putative antagonists. For all of these definitions,
validation of the robustness of the effects across multiple model systems is important.
1.7 Potential involvement of σ receptors in the mechanisms of METH-induced
neurotoxicity
Mechanistically, the neurotoxic effects of METH seem to involve the activation of certain
events such as dopamine and 5-HT release, oxidative stress, ER stress and mitochondrial
death cascades, excitotoxicity, microglial activation, and hyperthermia (Krasnova and Cadet,
2009). In addition, compelling evidence in the literature indicates that apart from being a direct
target of METH, σ receptors play an important role in the modulation of other neurotransmitter
systems and downstream events involved in METH-induced neurotoxicity. Systematic
mechanistic studies, however, have not been conducted in the context of METH. Below are
mentioned some of the mechanisms involved in the neurotoxic effects of METH and the
potential role that σ receptors can play based on evidence from independent studies in the
literature. In those instances where the role of an individual subtype of σ receptor is known,
the subtype is specified. Otherwise, the term σ receptor, with no subtype designation, is used.
Figure 1.4 shows various pathways of METH’s neurotoxicity and the steps at which σ
receptors could potentially act.
1.7.1

Dopamine and 5-HT release: METH acts through DAT, SERT and VMAT2 to cause

excessive release of dopamine and 5-HT into the cytoplasm and synapse (Stephans and
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Yamamoto, 1994; Riddle et al., 2006), which is thought to be one of the initiating factors in
METH’s neurotoxic cascade.
σ Receptors are found in the dopaminergic nerve terminals and cell bodies in the brain
(Gundlach et al., 1986) and stimulate dopamine synthesis and release (Booth and
Baldessarini, 1991; Bastianetto et al., 1995; Weiser et al., 1995). σ Receptor agonists have
been shown to facilitate dopamine release, through both σ-1/2 receptors (Booth and
Baldessarini, 1991; Bastianetto et al., 1995; Weiser et al., 1995; Derbez et al., 2002). σ-2
Receptors modulate DAT and the release of dopamine via protein kinase C (PKC) and Ca2+calmodulin systems (Derbez et al., 2002).
σ Receptors are also present on 5-HT neurons and have been shown to modulate them
(Campbell et al., 1989; Shirayama et al., 1993; Hashimoto et al., 1997).
1.7.2

Glutamate, NMDA and excitotoxicity: Glutamate release and excitotoxic mechanisms

have also been implicated in METH-induced neurotoxicity (Krasnova and Cadet, 2009). σ
Receptors have an important role in modulating the glutamatergic NMDA system and display
neuroprotective effects against excitotoxic mechanisms in ischemic stroke models, midbrain
and cortical dopaminergic neurons, and retinal ganglion cells (DeCoster et al., 1995; Shimazu
et al., 2000; Dun et al., 2007; Shen et al., 2008).
1.7.3

Reactive oxygen and nitrogen species: After excessive dopamine release, auto-

oxidation reactions lead to the formation of harmful ROS, including dopamine quinones,
superoxide radicals, hydroxyl radicals, and hydrogen peroxide (Krasnova and Cadet, 2009).
Additionally, excessive NMDA receptor stimulation by glutamate causes production of
superoxide and nitric oxide (NO) production by activation of neuronal nitric oxide synthase
(nNOS) (Lafon-Cazal et al., 1993a; Lafon-Cazal et al., 1993b; Gunasekar et al., 1995).
These ROS can injure neurons and surrounding cells via oxidative damage to cellular
components such as lipids, proteins, and DNA (Krasnova and Cadet, 2009). Excess 5-HT also
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leads to the generation of ROS (Wrona et al., 1997; Jiang et al., 1999) and cause similar
damage.
σ-2 Receptor activation has been shown to cause the release of ROS in tumor cells
(Ostenfeld et al., 2005; Hornick et al., 2010). In contrast, σ receptor antagonism affords
protection in brain ischemia, a condition in which ROS are generated (Schetz et al., 2007). In
addition, recent studies suggest that σ receptors can modulate nNOS activity in animal
models of stroke (Yang et al., 2010). These studies indicate a potential connection between σ
receptors and oxidative/nitrosative stress mechanisms of METH-induced neurotoxicity.
1.7.4

ER stress, calcium and mitochondrial death cascades: METH causes ER stress and

activation of mitochondrial death cascades partly due to increases in oxidative stress in the
cell (Jayanthi et al., 2004). ER stress causes disturbances in cellular calcium homeostasis
(Gorlach et al., 2006). ER stress and calcium dysregulation contributes to cell death observed
due to METH (Jayanthi et al., 2004). Sustained ER stress and excessive calcium efflux in turn
can contribute to METH-induced apoptosis via mitochondrial pore permeabilization (Jayanthi
et al., 2004; Kroemer et al., 2007).
σ Receptors are located on the ER and mitochondria (Guitart et al., 2004; Zeng et al.,
2007). σ-1 Receptors have been shown to function as chaperones at the mitochondrialassociated ER membrane (MAM). At MAM, σ-1 receptors play an important role in regulating
calcium levels via IP3 receptors and maintaining homeostasis in the cell against oxidative
stress and perturbations in calcium (Hayashi and Su, 2007). On the other hand, σ-2 receptor
activation has been shown to cause a biphasic flux of calcium from the ER and mitochondrial
stores which leads to apoptotic cell death (Vilner and Bowen, 2000; Cassano et al., 2009).
1.7.5

Apoptotic factors: METH causes apoptotic cell death in certain brain areas including

the striatum, cortex, and hippocampus (Deng et al., 2001). The apoptotic process can be
either caspase-dependent or independent (Jayanthi et al., 2004).
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σ-2 Receptor activation has been shown to cause apoptosis in tumor cells via
caspase-dependent and independent processes, depending on the cell type (Bowen, 2000;
Crawford and Bowen, 2002). σ-2 Receptor activation has also been shown to cause apoptotic
cell death in tumor cells via alterations in cellular sphingolipid levels (Crawford et al., 2002). In
contrast, σ-1 receptor agonists have been shown to have neuroprotective effects by regulating
intracellular calcium levels and preventing activation of pro-apoptotic genes in retinal ganglion
cells (Tchedre and Yorio, 2008). σ-1 Receptor agonists have also been reported to preserve
protective genes like bcl-2 in a cerebral focal ischemia model (Yang et al., 2007). σ Receptor
ligands have been shown to cause cytotoxicity and apoptotic cell death in various cell lines,
including rat C6 glioma cells, NG108-15 neuroblastoma-glioma, SK-N-SH neuroblastoma, SHSY5Y neuroblastoma, PC12 pheochromocytoma and COS-7 (Crawford and Bowen, 2002;
Crawford et al., 2002).
1.7.6

Microglial activation: Recent studies have underscored the role of accessory cells like

microglia in METH-induced neurotoxicity (Thomas et al., 2004; Sekine et al., 2008). Microglial
activation has been observed in areas of the brain that have been damaged by METH
(Thomas et al., 2004; Sekine et al., 2008). Drugs that attenuate neurotoxic effects also
suppress microglial activation (Krasnova and Cadet, 2009). However, the mechanisms by
which microglia influence METH’s neurotoxic effects are still not very clear. Release of
cytokines and ROS/RNS have been suggested as possible contributing mechanisms
(Krasnova and Cadet, 2009).
σ Receptors are found on microglia and can modulate microglial activation, membrane
ruffling and migration (Hall et al., 2009). The subtype of sigma receptors involved in this effect
is not clear and additional experiments will need to be performed to address this issue.
1.7.7

Hyperthermia: METH increases body temperature, which is known to exacerbate

neurotoxic effects (Bowyer et al., 1994). The production of ROS and release of cytokines like
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IL1β have been implicated in the generation of METH’s hyperthermia (Bowyer et al., 1994;
Imam et al., 1999; Riedel and Maulik, 1999; Yamashita et al., 2000; Fukami et al., 2004).
Moreover, dopaminergic and serotonergic systems are likewise implicated in METH-induced
body temperature alterations (Numachi et al., 2007). σ Receptor ligands, with their ability to
modulate these neurotransmitter systems, cytokines, as well as ROS, can attenuate
elevations in body temperature (Campbell et al., 1989; Bastianetto et al., 1995; Derbez et al.,
2002; Schetz et al., 2007; Matsumoto et al., 2008). Additionally, σ receptors are located in the
hypothalamic brain region and have previously been shown to modulate body temperature
(Gundlach et al., 1986; Rawls et al., 2002). A combination of all these factors may explain how
σ receptors can regulate METH-induced hyperthermia.
1.7.8

Other mechanisms:

1.7.8.1 Cytoskeleton: METH-induced nerve terminal damage involves the cleavage of
cytoskeletal proteins (Wallace et al., 2003). σ-1 Receptors are found in association
with ankyrin, which is a cytoskeletal adaptor protein (Hayashi and Su, 2001).
1.7.8.2 Neurotrophic factors: σ Receptors can play a role in signal amplification in several
systems especially that of neuotrophins, which are involved in the survival and
differentiation of neurons (Cass et al., 2006). σ-1 Receptor activation enhances BDNF
signaling which has a protective role against METH-induced neurotoxicity (Matsuzaki
et al., 2004; Yagasaki et al., 2006).
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Figure 1.4: Potential involvement of σ receptors in the mechanisms of METH-induced
neurotoxicity

ROS
/RNS

MICROGLIA

METH
Dopamine

Glutamate release

σ

DAT

σ

NMDA

σ

Microglial activation

Inflammatory cytokines

Terminal degeneration
(Lipid peroxidation
Protein and DNA oxidation)
VMAT2

RNS

Dopamine

NOS

ROS/
RNS

Mitochondrial death
cascade activation

σ

Calcium

ER Stress

σ
NEURON
Apoptosis

16

1.8 AC927, CM156 and SN79

N

AC927 (N-phenethylpiperidine oxalate)

CM156 (3-(4-(4-cyclohexylpiperazin-1-yl)butyl)benzo[d] thiazole-2(3H)-thione)

SN79 (6-acetyl-3-(4-(4-(4-florophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one)

AC927

(N-phenethylpiperidine

oxalate),

CM156

(3-(4-(4-cyclohexylpiperazin-1-

yl)butyl)benzo[d] thiazole-2(3H)-thione) and SN79 (6-acetyl-3-(4-(4-(4-florophenyl)piperazin-1yl)butyl)benzo[d]oxazol-2(3H)-one) were synthesized to have high affinity and selectivity for σ
receptors over other non-σ sites (Maeda et al., 2002; Mesangeau et al., 2008; Kaushal et al.,
2011a). The affinities of AC927, CM156 and SN79 for σ-1/2 receptors, as well as other
receptors, transporters, ion channels and binding sites are listed in Table 1.2. All these
compounds have been previously tested against the behavioral effects of cocaine and were
found to function as antagonists at σ receptors (Xu et al., 2010; Kaushal et al., 2011a;
Matsumoto et al., 2011).
1.8.1

Receptor binding assays: The affinity of the novel compounds for σ receptors and

other non-σ binding sites was determined by conducting competition binding assays in
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tissues or cells that were heavily concentrated with the respective proteins of interest. This
assay is based on the principle of competition between a radiolabelled ligand (specific for that
site) and an unlabelled ligand for binding to a receptor or transporter.
Table 1.2 shows the results obtained from radioligand binding studies for AC927,
CM156 and SN79. AC927 has nanomolar affinity for σ-1/2 receptors and micromolar to
negligible affinity for the other sites tested. CM156 has high affinity for both σ-1/2 receptors in
the nanomolar and subnanomolar range. Compared to its high affinity for σ receptors, CM156
had >1000-fold weaker affinity for other non-σ binding sites tested. SN79 has high nanomolar
affinity for σ-1/2 receptors. However, SN79 also exhibits moderate affinity for 5-HT2 receptors,
SERT and norepinephrine transporters (NET), as well as some affinity for DAT. For all other
sites listed in Table 1.2, SN79 displayed negligible affinity (>10,000 nM affinity or >1,000-fold
selectivity compared to σ binding).
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Table 1.2: Binding affinity of AC927, CM156 and SN79 for σ and non-σ sites
Binding Site
Sigma receptors:

Radioligand

Nonspecific binding

Tissue
AC927

3

5 nM [ H](+)σ1
pentazocine
3
3 nM [ H]di-oσ2
tolylguanidine
Monoamine transporters:
3
0.5 nM [ H]WIN
Dopamine
35,428
0.2 nM
Serotonin
3
[ H]paroxetine
0.5 nM
Norepinephrine
3
[ H]nisoxetine
Other neurotransmitter receptors:
3
Adenosine
4.0 nM [ H]NECA
125
Adrenergic, beta1 0.04 nM [ I]()iodocyanopindolol

10 µM
haloperidol
10 µM
haloperidol

Rat brain
Rat brain

50 µM cocaine
1.5 µM
imipramine
4 µM
desipramine

Rat brainstem
Rat cerebral
cortex

1 µM NECA
3 µM alprenolol

3

Cannabinoid, CB1

0.5 nM [ H]CP
55940

Cannabinoid, CB2

0.5 nM [ H]CP
55940

Dopamine D2

5 nM [ H](-)sulpiride

Rat striatum

1 µM HU-210

3

1 µM HU-210

Bovine striatum
Human
Neuroepithelioma
Human
recombinant
HEK293 cells
Human
recombinant
CHO cells

30 ± 2
138 ±18

Ki
CM156
1.3 ± 0.4

SN79
27 + 2

0.6 ± 0.1 7 + 0.09

2939 ± 452 1175 ±100 2610 + 57
>10,000

1402±152

8828±1197

>10,000

> 10,000

> 10,000

>10,000

159 + 15
177 + 14
>10,000

> 10,000

>10,000

>10,000

>10,000

ND

>10,000

>10,000

>10,000

1041 ± 9

>10,000

>10,000

>10,000

>10,000

ND

>10,000

>10,000

ND

>10,000

>10,000

ND

>10,000

>10,000

ND

>10,000

>10,000

>10,000

>10,000

Rat cortex/hippoc

ND

>10,000

>10,000

Rat forebrain

ND

>10,000

>10,000

Rat brain

ND

>10,000

>10,000

Rat cerebellum

ND

>10,000

>10,000

Rat brain

ND

>10,000

>10,000

ND

>10,000

>10,000

ND

2570

>10,000

>10,000

3080

>10,000

>10,000

2155

>10,000

ND

3

GABA A, agonist
site
GABA A, BDZ
alpha 1
GABA-B
Glutamate, AMPA
Glutamate, kainite

5 nM [ H]GABA

1 µM GABA

Bovine
cerebellum

1 nM
3
[ H]flunitrazepam
3
1 nM [ H]CGP
54626A
3
5 nM [ H]AMPA
3
10 nM [ H]kainic
acid
3
2 nM [ H]CGP
39653
3
4 nM [ H]MDL105,519

0.5 µM
flumazenil

Bovine cortex

3

Glutamate, NMDA
agonist
Glutamate, NMDA
glycine
Glutamate,
3
10 nM [ H]TCP
NMDA/PCP
3

5 nM [ H]TCP
Glutamate,
mGluR1
Glutamate,
mGluR5
Glycine,strychnine
Histamine H2

20 nM
3
[ H]quisqualic acid
3

100 µM baclofen
100 µM AMPA

Rat cerebral
cortex
Rat forebrain

10 µM kainic acid Rat forebrain
300 µM NMDA
3 µM MDL105,519
100 µM (+)MK801
10 µM
cyclazocine
1 mM Lglutamate

Rat forebrain

10 nM [ H]MPEP

10 µM MPEP

16 nM
3
[ H]strychnine
0.1 nM
125
[ I]aminopotentidin
e

100 µM
Rat spinal cord
strychnine nitrate

3

Muscarinic, central 0.15 nM [ H]QNB
Muscarinic,
peripheral

1 µM haloperidol Rat brain

3

0.3 nM [ H]QNB

3 µM tiotidine

Guinea pig
striatum

Rat cerebral
cortex
Guinea pig
0.1 µM atropine
bladder
0.1 µM atropine
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>10,000

Muscarinic M1

3

0.5 nM [ H]N-methyl
scopolamine
3

Muscarinic M2

0.5 nM [ H]N-methyl
scopolamine
125

1 nM [ I]αbungarotoxin
0.05 nM
Nicotinic, neuronal 3
[ H]epibatidine
Opioid, non0.5 nM
3
selective
[ H]bremazocine
3
1 nM [ H]naloxone
Nicotinic, muscle

5-HT2

3

2 nM [ H]ketanserin

Hormone, peptide, steroid receptors:
125
1
0.06 nM [ I](Sar Angiotensin II, AT1
8
Ile )angiotensin
125
4
0.1 nM [ I]Tyr Angiotensin II, AT2
angiotensin II
0.2 nM
Bradykinin, BK2
3
[ H]bradykinin
Cholecystokinin,
125
0.02 nM [ I]CCK-8
CCKA
Cholecystokinin,
125
0.02 nM [ I]CCK-8
CCKB
125
0
CRF, non0.1 nM [ I]Tyr selective
Ocrf
0.033 nM
Endothelin, ETA
125
[ I]endothelin-1
0.025 nM
Endothelin, ETB
125
[ I]endothelin-1
125
0.1 nM [ I]3,7βEstrogen
estradiol
Galanin, non125
0.07 nM [ I]galanin
selective
1 nM
Glucocorticoid
3
[ H]dexamethasone
1.4 nM
Neurokinin, NK1
3
[ H]substance P
0.1 nM
Neurokinin, NK2
125
[ I]neurokinin A

1 µM ()scopolamine

Human
recombinant
CHO cells
1 µM
Human
methylscopolami recombinant
ne
CHO cells
Human TE671
10 µM nicotine
cells
20 nM
Human SK-N-F1
epibatidine
cells
10 µM
Rat brain
levallorphan
Rat forebrain
1 µM naloxone
1 µM mianserin

Rat brain

1 µM angiotensin Human KAN-TS
II
cells
0.05 µM
Bovine
angiotensin II
cerebellum
100 nM
Guinea pig ileum
bradykinin TFA

ND

>10,000

>10,000

ND

1210

>10,000

ND

>10,000

>10,000

ND

>10,000

>10,000

>10,000
>10,000

>10,000
>10,000

>10,000
>10,000

1376 ±159

321 + 16

ND

>10,000

>10,000

ND

>10,000

>10,000

ND

>10,000

>10,000

>10,000

1 µM CCK-8

Mouse pancreas

ND

>10,000

>10,000

1 µM CCK-8

Mouse forebrain

ND

>10,000

>10,000

ND

>10,000

>10,000

ND

>10,000

>10,000

ND

>10,000

>10,000

ND

>10,000

>10,000

ND

>10,000

>10,000

ND

>10,000

>10,000

ND

>10,000

>10,000

ND

1510

>10,000

ND

>10,000

>10,000

ND

>10,000

0

1 µM Tyr -oCRF
0.1 µM
endothelin-1
0.1 µM
endothelin-1
10 nM 17βestadiol
100 nM galanin
(porcine)
10 µM
triamcinolone
1 µM substance
P
1 µM neurokinin
A

Rat cerebral
cortex
Human
neuroblastoma
Human
astrocytoma
Human breast
cancer
Rat brain
Human
recombinant
Rat submaxillary
gland
Human
recombinant
CHO cells
Rat cerebral
cortex

Neurokinin, NK3
(NKB)

0.1 nM
125
[ I]eledoisin

Oxytocin

1 nM [ H]oxytocin

1 µM oxytocin

Testosterone,
cytosolic

0.5 nM
3
[ H]methyltrienolone
2 nM
3
2
[ H](3MeHis )TRH

0.7 µM
Human LnCAP
methyltrienolone cells

ND

>10,000

10 µM TRH

Rat forebrain

ND

>10,000

1 µM VIP

Rat forebrain

ND

>10,000

ND

>10,000

>10,000

>10,000

1710

>10,000

TRH

3

VIP, non-selective 0.05 nM [
Vasopressin 1
Ion channels:
Calcium, type L
(DHP)

125

I]VIP

1 µM eledoisin

Rat uterus

0.5 nM
3
[ H]phenylalanyl3,4,5-v

1 µM Arg vasopressin

Rat liver

0.2 nM
3
[ H]nitrendipine

1 µM nifedipine

Rat cerebral
cortex

>10,000
>10,000
>10,000
>10,000

8
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125

0.01 nM [ I]ωconotoxin GVIA
Potassium, ATP- 0.2 nM
3
sensitive
[ H]glibenclamide
2+
Potassium, Ca
0.05 nM
125
act VI
[ I]apamin
Enzymes and other miscellaneous:
0.3 mM
Acetylcholine
3
[ H]acethylthiocholi
esterase
ne
14
Choline
0.2 nM [ C]acetyl
acetyltransferase coenzyme
14
Glutamic acid
4 µM [ C]Ldecarboxylase
glutamic acid
Leukotriene, LTB4 0.48 nM
3
(BLT)
[ H]leukotriene B4
Leukotriene, LTD4 0.2 nM
3
(CysLT1)
[ H]leukotriene D4
MAO-A oxidase,
14
50 µM [ C]5-HT
peripheral
10 µM
MAO-B oxidase,
14
[ C]phenylethylami
peripheral
ne
3
Nitric oxide, NOS 5 nM [ H]NOARG
1.7 nM
Platelet activating 3
[ H]hexadecylfactor
acetyl-PAF
3
Thromboxane,
2
nM
[ H]SQ
TXA2
29,548
Calcium, type N

0.1 µM ωconotoxin GVIA
0.1 µM
glibenclamide

Rat cerebral
cortex
Rat cerebral
cortex

100 nM apamin

100 µM
physostigmine

>10,000

>10,000

>10,000

>10,000

>10,000

>10,000

Rat forebrain

ND

>10,000

>10,000

Human
recombinant

ND

>10,000

>10,000

ND

>10,000

>10,000

ND

>10,000

>10,000

ND

>10,000

>10,000

ND

>10,000

>10,000

ND

>10,000

>10,000

ND

>10,000

>10,000

0.1 µM Ro 41Rat cerebral
1049
cortex
100 µM aminooxy
Rat striatum
acetic acid
500 nM
Guinea pig
leukotriene B4
spleen
1 µM leukotriene
Guinea pig lung
D4
Rat liver
1 µM Ro 41-1049
mitochondria
10 µM Ro 166491

Rat liver
mitochondria

100 µM NOARG Rat brain

ND

1 µM C16-PAF

ND

Rabbit platelets

10 µM pinaneHuman platelets
thromboxane

ND

1220
>10,000
>10,000

>10,000
>10,000
>10,000

Affinities (Ki in nM) were determined in tissue or cell homogenates. The values in this table represent
the mean + S.E.M. from replicate assays. Values of >10,000 signify that there was less than 30%
displacement of the radioligand at that concentration.
releasing

factor;

DHA=dihydroalprenolol;

BTZ=benzothiazepine; CRF=corticotrophin

DHP=dihydropyridine;

GABA=γ-aminobutyric

acid;

LSD=lysergic acid diethylamide; MAO=monoamine oxidase; MPEP=2-methyl-6-(phenylethynyl)pyridine;
G

NECA=5’-N-ethylcarboxamidoadenosine; NOARG=L-N -nitro-arginine; PAF=platelet activating factor;
QNB=quinuclidinyl

benzilate;

TBOB=t-butylbicycloorthobenzoate;

TBPS=t-

butylbicyclophosphorothionate; TCP=1-[1-)2-thienyl)cyclohexyl]piperidine; TRH=thyrotropin releasing
hormone; VIP=vasoactive intestinal peptide.
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1.8.2

Pharmacokinetic studies: Pharmacokinetic studies were conducted for SN79 and

CM156, but not for AC927 as it displayed toxicity at supratherapeutic doses deeming it not
suitable as a drug candidate.
1.8.2.1

In vitro liver microsomal assays: The metabolic stability of CM156 was

evaluated through the NIDA Medications Development Program in liver microsomes prepared
from rat, monkey and human (Table 1.3). Using a Tecan Liquid Handling System (Tecan,
Research Triangle Park, NC), CM156 (5 µM) was incubated at 37° C with the reaction
mixture. At designated time points (0, 15, 30 and 60 min) the supernatants were collected and
analyzed using LC/MS.
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Table 1.3 Metabolic stability of CM156 in rat, monkey, and human liver microsomes
Species Incubati Cofactor Area Percent Loss Percent
on Time (+/-)
Ratio Of Substrate Remaining
(min)
Rat
0
+
143
0.0%
100%
15
+
12.7
91.2%
8.8%
30
+
12.2
91.5%
8.5%
60
+
11.5
92.0%
8.0%
0
148
0.0%
100%
60
148
0.0%
100%

HalfLife
(min)
4.62

Clearance
(ml/min/kg)
270

Monkey

0
15
30
60
0
60

+
+
+
+
-

140
3.17
2.11
1.81
146
144

0.0%
97.7%
98.5%
98.7%
0.0%
1.4%

100%
2.3%
1.5%
1.3%
100%
98.6%

2.8

184

Human

0
15
30
60
0
60

+
+
+
+
-

133
51.4
15.4
7.35
138
142

0.0%
61.3%
88.4%
94.5%
0.0%
No loss

100%
38.7%
11.6%
5.5%
100%
103%

10.6

58.8

Values are the mean of triplicate determinations, except for the zero cofactor values that are the mean
of duplicate determinations. CM156 was tested at a concentration of 5 µM. Protein concentration was
set at 1.0 mg protein/ml.
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1.8.2.2

In vivo pharmacokinetic studies:

Plasma pharmacokinetic parameters

associated with oral dosing of SN79 are summarized in Table 1.4.

In this study, blood

concentration of orally administered SN79 (20 mg/kg) was determined in Sprague Dawley rats
at different time intervals using ultra performance liquid chromatography. CM156 showed
short half life in in vitro microsomal assays due to which it was not tested in in vivo
pharmacokinetic studies.

Table 1.4: Mean plasma pharmacokinetic parameters of SN79 after oral administration
in Sprague-Dawley rats
AUC
117.34 g-hr/ml
T1/2
7.51 hr
Cmax
0.205 g/ml
MRT
9.87 hr
Vd
115.10 l/kg
CLss/F
0.18 l/hr/kg
Tmax
1.5 hr
Cmax, maximum concentration; T max, time to reach maximum concentration; AUC, area under the curve
concentration; Vd, volume of distribution; MRT, mean residence time; CLss/F, apparent oral clearance at
steady state.
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1.8.3

Cytochrome P450 Interactions: Since, SN79 was the most druggable compound out

of AC927 and CM156 (it did not display any toxicity like AC927 and had long half life unlike
CM156), it was the only compound to be moved forward in the cytochrome P450 studies. The
effect of SN79 on a number of human cytochrome P450 enzymes was assessed by
NovaScreen CYP Screen (Caliper Life Sciences, Hopkinton, MA). The specific cytochrome
P450 enzymes selected were those most likely to cause problematic drug-drug interactions.
Table 1.5 provides a synopsis of the assay conditions, with NADPH (nicotinamide adenine
dinucleotide phosphate) added to the substrate to catalyze the reaction. SN79 was evaluated
at a single screening concentration of 10 µM, with 50% used as the criterion for significant
inhibition at this concentration.

Table 1.5 Human cytochrome P450 inhibition studies
Cytochrome P450
1A2
2A6
2C19
2C9*1
2D6
3A4

Substrate
5 µM 7-ethoxy-3-cyanocoumarin
3 µM coumarin
2.5 µM 7-ethoxy-3-cyanocoumarin
37.5 µM 7-methoxy-4-trifluouromethylcoumarin
0.5 µM AMMC
0.5 µM dibenzyl fluorescein

% Inhibition by SN79
17.8%
-10.4%
34.8%
15.3%
-1.7%
29.0%

Duplicate assays were conducted for the inhibition of human recombinant cytochrome P450 enzymes
expressed in SF9 cells by SN79. NADPH was added to the substrate to catalyze the reaction. SN79
was evaluated at a single screening concentration of 10 µM, with 50% used as the criterion for
significant inhibition at this concentration. Negative values represent slight induction. SN79 did not
significantly inhibit or induce the major cytochrome P450 enzymes tested.
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1.9 In vivo model: Male, Swiss Webster mice
This strain of mice was used for the studies in this dissertation because they are
capable of exhibiting the behavioral and neurotoxic effects of METH, and have been widely
used to study σ and non-σ compounds (Itzhak and Ali, 1996; Ali and Itzhak, 1998; Callahan
and Ricaurte, 1998; Itzhak et al., 1998; Itzhak et al., 2003; Nguyen et al., 2005; Matsumoto et
al., 2008). Their continued use will facilitate comparisons to data already in the literature. Mice
were preferred over rats for these studies because the novel compounds are produced in
small amounts, and the smaller size of the mice will help in optimizing their use. Male mice
were used in this study because of varying levels of progesterone in the system of female
mice during estrous cycle (Kosaka et al., 1988). Progesterone is considered an endogeneous
σ ligand and can therefore interfere with the binding of the drugs and interpretation of the
results (Su, 1991).

1.10 In vitro model: NG108-15 cells
In order to elucidate the cellular mechanisms of METH-induced toxicity at which σ
receptors may intervene, a neuronal cell culture model (neuroblastoma×glioma hybridoma,
NG108-15 cells) was used. A cell culture model also provides a system where the
temperature can be maintained constant and the mechanistic basis of the neuroprotective
effects of σ antagonists can be studied under more controlled conditions compared to in vivo.
NG108-15 cells when differentiated display neurite outgrowth, electrical excitability and
express proteins with neuronal and glial properties (Ma et al., 1998). These cells have been
used extensively as a sensitive cell line to study toxic effects of various drugs and chemicals
(Canete and Diogene, 2008). Additionally, NG108-15 cells have been commonly used in the
literature to study the functioning of σ receptors, thus making it a suitable model for these
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studies (McLawhon et al., 1981; Georg and Friedl, 1991; Vilner et al., 1995b; Hayashi and Su,
2003a; Peeters et al., 2004).

1.11 Specific Aims
The future chapters will describe the studies conducted using sigma receptor antagonists:
AC927, CM156 and SN79 in in vivo and in vitro models. The aims of this dissertation are as
follows:
Specific Aim 1: To determine if antagonism of σ receptors (using AC927, CM156 and
SN79) can attenuate METH-induced neurotoxicity in vivo: The following studies were
performed:
1. To determine if σ receptor antagonists (AC927, CM156 and SN79) can attenuate
METH-induced neurotoxicity in vivo. Male, Swiss Webster mice were pretreated with
AC927, CM156 or SN79 to determine if METH-induced dopaminergic and serotonergic
neurotoxicity can be attenuated. The markers studied were: striatal dopamine and 5HT levels, striatal DAT and SERT expression levels. This study had been included in
chapter 2.
2. To determine if the σ receptor antagonists can attenuate the hyperthermic effects of
METH. Male, Swiss Webster mice were pretreated with AC927, CM156 or SN79 to
determine if METH-induced hyperthermia can be attenuated. This study has been
included in Chapter 3.
3. To determine if hyperthermia is associated with neurotoxicity of METH. Correlation
between the body temperature of the mice and striatal dopamine and serotonin levels
was determined. This study has been included in Chapter 3.

27

Specific Aim 2: To determine the mechanisms of neuroprotective effects of sigma
receptor antagonists against METH-induced neurotoxicity in vitro: The following studies
were performed:
1. Identification of the mechanisms of METH-induced neurotoxicity in differentiated
NG108-15 cells that can be prevented by sigma receptor antagonists (AC927 and
SN79). Differentiated NG108-15 cells were used as a model system to identify the
mechanisms of METH-induced neurotoxicity that can be attenuated by sigma receptor
antagonists. The neurotoxic end points and mediators detected were: apoptosis,
necrosis, caspase-3, -9, -8 activation, ROS/RNS generation and dopamine release.
The results from this study have been included in chapter 4 and 5.
2. Effect of elevated temperature on METH-induced neurotoxicity in differentiated NG10815 cells: Differentiated NG108-15 cells were used to study the effect of METH
treatment at 37 °C and elevated temperature (40 °C). The ability of SN79 to attenuate
METH and elevated temperature-induced toxicity was also determined. The results
from this study have been included in Chapter 5.
Specific Aim 3: To determine if antagonism of σ-2 receptors can attenuate METHinduced neurotoxicity in vitro: A series of potential σ 2 receptor selective compounds were
synthesized and screened using radioligand binding assay for their high affinity and selectivity
for σ2 receptors over σ1 receptors and other non- σ sites. Sigma-2 receptor antagonist,
CM398 was tested to determine its ability to attenuate METH-induced apoptotic and necrotic
end points. The results from this study have been included in Chapter 6.
It is expected that this study will help us understand the role of σ receptors especially σ 2
receptor subtype in the neurotoxic effects of METH. The work is significant because of the
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impact it will have not only on the understanding of the functioning of σ receptors but also on
the potential development of medications to treat METH-induced neurotoxicity.

1.12 Contributions: The compounds CM156 and SN79 were synthesized by Dr. Christophe
Mésangeau and Dr. Sanju Narayanan in Dr. Christopher R. McCurdy’s lab at University of
Mississippi. AC927 was obtained from Dr. Andrew Coop’s laboratory at University of
Maryland, Baltimore.
The radioligand binding studies for SN79 were performed by Dr. Jamaluddin Shaikh,
Michael Seminerio and Dr. Yan-tong Xu at the University of Mississippi and West Virginia
University. The radioligand binding studies for CM156 and AC927 were performed by Dr.
Jamaluddin Shaikh at the University of Mississippi. The NOVAScreen for all the three
compounds were performed by Calipers Life Sciences (Hanover, MD).
The in vivo pharmacokinetic studies for SN79 were performed by Dr. Harsha
Vinnakota in Dr. Bonnie A. Avery’s lab at University of Mississippi.
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CHAPTER 2
EVALUATION OF SIGMA RECEPTOR ANTAGONISTS AGAINST
METH-INDUCED NEUROTOXICITY: IN VIVO STUDIES
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2.1 Introduction
High or repeated METH administration results in hyperthermia and neurotoxicity
(Cruickshank and Dyer, 2009). At high doses, neurotoxic cascades are activated due to
excessive dopamine and 5-HT release into the cytoplasm and synapse (Baldwin et al., 1993;
Kuczenski et al., 1995; Gough et al., 2002). Neuroimaging and postmortem studies in human
METH users, as well as studies performed using animal models, have shown damage to
dopaminergic and serotonergic neurons measured as reductions in DAT, SERT, dopamine
and 5-HT levels in several brain regions (Krasnova and Cadet, 2009). Recent studies have
indicated an association between neurotoxicity and several neuropsychiatric disorders
including psychosis, motor and cognitive deficits (Walsh and Wagner, 1992; Cruickshank and
Dyer, 2009), conferring additional urgency to the development of effective pharmacotherapies
against the effects of METH.
In the present study, the role of σ receptors in METH-induced neurotoxicity was evaluated.
We focused on σ receptors for several reasons. First, METH binds to σ receptors at
physiologically relevant concentrations (Nguyen et al., 2005). Second, σ receptors are present
on dopamine and 5-HT neurons, which are damaged by neurotoxic doses of METH, and can
modulate their function (Campbell et al., 1989; Bastianetto et al., 1995; Derbez et al., 2002).
Third, σ receptors participate in cell death pathways in tumor cells (Bowen, 2000), suggesting
their possible contribution in METH-induced neurotoxic cascades. Fourth, targeting σ
receptors can attenuate chronic disabilities like cognitive deficits, psychosis, and depression,
which are also caused by METH’s neurotoxicity (Cruickshank and Dyer, 2009).
Therefore, in this study three sigma receptor antagonists (AC927, CM156 and SN79)
were tested to determine if they can attenuate METH-induced neurotoxicity in vivo. All these
compounds have previously been tested against the behavioral and toxic effects of cocaine,
and were found to function as antagonists at σ receptors (Xu et al., 2010; Kaushal et al.,
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2011a; Matsumoto et al., 2011). The effect of pretreatment of AC927, CM156 and SN79 was
determined on the striatal dopaminergic and serotonergic neurotoxicity caused by METH. The
markers used were: striatal dopamine and 5-HT levels, striatal DAT and SERT expression.

2.2 Materials and Methods
2.2.1. Animals: Male, Swiss Webster mice (18-28 g; Harlan, Indianapolis, IN) were used for
the in vivo studies. They were housed in groups of five with a 12:12h light/dark cycle with food
and water available ad libitum. Naïve mice were randomly assigned to different treatment
groups. All procedures involving animals were performed as approved by the Institutional
Animal Care and Use Committee at the West Virginia University.
2.2.2. Drugs: CM156 and SN79 were obtained from Dr. Christopher McCurdy’s laboratory
(University of Mississippi, University, MS). AC927 was provided by Dr. Andrew Coop
(University of Maryland, Baltimore, MD). METH hydrochloride was obtained from Research
Biochemicals International (Natick, MA).
2.2.3. METH neurotoxic schedule: As shown in Figure 2.1 male, Swiss Webster mice were
randomly divided into four experimental groups: 1) Saline/Saline, 2) Saline/METH (1.25, 2.5,
5, 10 mg/kg) 3) Antagonist (AC927: 5, 10, 20 mg/kg; CM156: 5, 10, 20 mg/kg or SN79: 1, 3,
10 mg/kg)/Saline, 4) Antagonist (AC927: 5, 10, 20 mg/kg, i.p.; CM156: 5, 10, 20 mg/kg, i.p. or
SN79: 1, 3, 10 mg/kg, i.p.)/METH (5, 10 mg/kg, I.p.). These doses of AC927, CM156 and
SN79 were selected as these were effective in attenuating the behavioral and toxic effects of
cocaine, another sigma receptor agonist (Xu et al., 2010; Kaushal et al., 2011a; Matsumoto et
al., 2011). The first drug was administered 15 min prior to the second drug. Each group of
mice received their treatment a total of four times at two hour intervals. One hour after each
treatment, the body temperature of the mice was recorded. To allow sufficient time for the
METH-induced degeneration of nerve terminals to occur, the animals were sacrificed and their
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brains removed one week following treatment (Cappon et al., 2000). The detailed procedure
for each of the end points is provided below.

Figure 2.1 Neurotoxic schedule of METH

AC927/SN79/CM156

METH

Day

1

2

2h

2h

2h

2h

BT1

BT2

BT3

BT4

3

4

Animals monitored

5

6

7

Animals sacrificed
•DA, 5HT ELISA
•DAT, SERT IHC

2.2.3.1. Dopamine assay: The mice (n = 5-9/group) were randomly assigned to one of
the following treatments: (1) Saline + Saline; (2) Saline + METH (1.25, 2.5, or 5 mg/kg, i.p.);
(3) AC927 (5, 10, 20 mg/kg, i.p.)/CM156 (5, 10, or 20 mg/kg, i.p.)/SN79 (1, 3, 10 mg/kg, i.p.) +
Saline; (4) AC927 (5, 10, 20 mg/kg, i.p.)/CM156 (5, 10, or 20 mg/kg, i.p.)/SN79 (1, 3, 10
mg/kg, i.p.) + METH (5 mg/kg, i.p.). The striatum and cerebellum were dissected from each
treated mice and then frozen in liquid nitrogen. The tissues were stored at -80 oC for later
analysis of dopamine content. One week after the treatment schedule, the mice were
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sacrificed and the striatum and cerebellum were dissected from each treated mice and then
frozen in liquid nitrogen. The tissues were stored at -80 °C for later analysis of dopamine
content. Using a dopamine research enzyme immunoassay kit and protocols provided by the
manufacturer (Rocky Mountain Diagnostics, Colorado Springs, CO), mouse brain striatal and
cerebellar dopamine were quantified. Brain tissues were homogenized in 0.01 N HCl and
dopamine was extracted and then acylated to N-acyldopamine using the buffer and reagents
provided by the ELISA kit. Acylated dopamine from the tissue samples was incubated with
solid phase bound dopamine, dopamine antiserum, and antiserum buffer to compete for a
fixed number of antiserum binding sites. Free antigen and free antigen-antiserum complexes
were removed via the wash buffer. The antibody bound to the solid phase dopamine was
detected

using

an

anti-rabbit

IgG-peroxidase

conjugate

with

TMB

(3,3’,5,5”-

tetramethylbenzidine) as the substrate. The amount of antibody bound to the solid phase
dopamine was measured by monitoring the reaction at 450 nm. The solid phase dopamine
measured is inversely proportional to the dopamine concentration of the tissue sample and is
quantified relative to a standard curve of known concentrations.
2.2.3.2. 5-HT assays: The mice (n = 5-10/group) were randomly assigned to one of the
following treatments: (1) Saline + Saline; (2) Saline + METH (1.25, 2.5, 5 or 10 mg/kg, i.p.); (3)
AC927 (5, 10, 20 mg/kg, i.p.)/CM156 (5, 10, or 20 mg/kg, i.p.)/SN79 (1, 3, 10 mg/kg, i.p.) +
Saline; (4) AC927 (5, 10, 20 mg/kg, i.p.)/CM156 (5, 10, or 20 mg/kg, i.p.)/SN79 (1, 3, 10
mg/kg, i.p.) + METH (5, 10 mg/kg, i.p.). One week following the treatments, striatum and
cerebellum were dissected from each treated mice and then frozen in liquid nitrogen. The
tissues were stored at -80 oC for later analysis of 5-HT content. The protocol was the same as
described above for dopamine, with the exception that brain tissues were homogenized in 0.2
M perchloric acid, followed by centrifugation at 3,000 rpm for 10 min at 4 ºC. The supernatants
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were collected and evaluated for 5-HT levels using 5-HT research enzyme immunoassay kits
(Rocky Mountain Diagnostics, Colorado Springs, CO).
2.2.3.3. DAT Immunohistochemistry: Striatal sections were assessed for DAT
expression. The mice (n = 4/group) were randomly assigned to one of the following treatment
groups: (1) Saline + Saline; (2) Saline + METH (5 mg/kg, i.p.); (3) AC927 (10 mg/kg,
i.p.)/CM156 (10 mg/kg, i.p.)/SN79 (3 mg/kg, i.p.) + METH (5 mg/kg, i.p.); (4) AC927 (10
mg/kg, i.p.)/CM156 (10 mg/kg, i.p.)/SN79 (3 mg/kg, i.p.) + Saline. Striatal sections were
assessed for DAT expression. One week following treatment, the mice were perfused
transcardially

with 0.1

M phosphate buffered saline (pH

7.4), followed by 4%

paraformaldehyde. The brains were further fixed overnight in 4% paraformaldehyde. Coronal
sections (50 µm) of the fixed tissue were made throughout the rostral-caudal extent of the
striatum using a cryostat, and processed in a free-floating state in 0.1 M Tris-HCl buffered
saline (TBS, pH 7.5). The sections were treated with 0.3% in H2O2 in TBS for 30 min at room
temperature. The sections were then treated with TBS containing 0.2% Triton X-100 and 1.5%
normal goat serum for 30 min at room temperature. Incubation of the sections with anti-rat
DAT antibody (Chemicon International, Temecula, CA; MAB369, dilution 1:10,000) were then
performed for 36 h at 4 ºC. The labeled sections were washed twice in TBS and processed
using Vectastain Elite ABC (Vector Laboratories, Burlingame, CA). Sections were incubated
with biotinylated secondary anti-rat antisera (diluted 1:200) in TBS-NBS for 60 min. This was
followed by incubation of the sections with avidin-biotinylated peroxidase substrate in TBS for
60 min. The staining was visualized by reacting 3,3’-diaminobendine containing 0.01% H2O2
for 5 min.
The stained sections were mounted onto gelatin-coated slides and dried. The
sections were dehydrated, cleared, and coverslipped. The images were captured digitally
using a Leica DMIL microscope (Leica Microsystems, Bannockburn, IL) and optical density
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readings quantified in anterior regions of the striatum using ImageJ software (National
Institutes of Health, Bethesda, MD). To obtain the data point for a given animal, at least two
sections per mouse brain were processed and the optical density readings from both the
striatal regions of each section averaged.
2.2.3.4. SERT Immunohistochemistry: To confirm that depletion in 5-HT levels is due to
METH-induced damage to serotonin nerve terminals, the striatal sections were assessed for
SERT expression. This experiment was performed after relocation of the lab to a different
building, with a slightly higher ambient temperature (SERT expression: 23-23.5 ˚C) than the
earlier lab (5-HT levels: 21-22 °C). Since serotonin neurotoxicity is sensitive to changes in
ambient room temperature (Malberg and Seiden, 1998), a dose response validation for
serotonin neurotoxicity was conducted in the first part of the study. Moreover, higher mortality
was observed in the 10 mg/kg METH group, therefore in the second part of the studyCM156
was evaluated against the 5 mg/kg dose of METH. The mice (n = 4/group) were randomly
assigned to one of the following treatment groups: (1) Saline + Saline; (2) Saline + METH (5,
10 mg/kg, i.p.); (3) AC927 (10 mg/kg, i.p.)/CM156 (20 mg/kg, i.p.)/SN79 (3 mg/kg, i.p.) +
METH (5, 10 mg/kg, i.p.); (4) AC927 (10 mg/kg, i.p.)/CM156 (20 mg/kg, i.p.)/SN79 (3 mg/kg,
i.p.) + Saline.

The protocol was the same as for DAT immunohistochemistry with the

exception of incubating with rabbit anti-mouse SERT antibody (Millipore, Temecula, CA;
AB9726, dilution 1:5,000) for 36 h at 4 ºC. The labeled sections were washed thrice in TBS
and processed with Histostain-Plus kit (DAB, Broad Spectrum) (Invitrogen, Camarillo, CA).
Briefly, the labeled sections were incubated in 100 µl of DAB substrate for 4 min. The sections
were then washed in 5 ml of distilled water. The stained sections were mounted on the slides
and analysed in the same way as for DAT immunohistochemistry.
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2.2.4. Statistical analysis: The data from the dopamine and 5-HT assays, and DAT and
SERT immunohistochemical studies were evaluated using one-way analysis of variance
(ANOVA). Post-hoc analyses were performed with Dunnett’s test for comparisons to controls
or Tukey’s tests for pairwise comparisons. For all statistical analyses, p < 0.05 was considered
statistically significant.

2.3

Results

2.3.1. Dopamine assays: One-way ANOVA showed that METH produced a dose dependent
reduction of dopamine levels in the striatum (Figure 2.2A., F(3,27) = 7.26, p < 0.0005). Posthoc Dunnett’s tests revealed that the striatal changes produced by the following doses of
METH differed significantly from the saline control group: 2.5 mg/kg (q = 2.55, p < 0.05), 5
mg/kg (q = 4.61, p < 0.01). However, no significant changes in dopamine concentration
following doses of METH, were observed in the cerebellum (F(3,27) = 0.20, n.s.).
Administration of AC927 in the absence of METH had no significant effects on
dopamine levels in the striatum and cerebellum of the mouse brain (Figure 2.2B). ANOVA
confirmed that there were no significant differences between the treatment groups in either the
striatum (F[3,16]=1.10, n.s.) or the cerebellum (F[3,16]=0.14, n.s.). One-way ANOVA showed
that AC927 pretreatment significantly protected against the striatal dopamine depletions
produced by METH (F(4,23) = 6.26, p < 0.005). Post-hoc Tukey’s multiple comparison tests
showed that METH caused a siginificant decrease in dopamine levels (q = 5.96, p < 0.001)
and AC927 (10 mg/kg) significantly attenuated the striatal (q = 5.58, p < 0.01) dopamine
depletions caused by METH.
When the selective σ receptor antagonist CM156 was administered in the absence of
METH, one-way ANOVA showed that there were no significant changes in striatal and
cerebellar dopamine levels (F(3,16) = 0.36, n.s.; F(3,16) = 0.37, n.s. respectively).
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Nevertheless, in the presence of METH (5 mg/kg), pretreatment with CM156 significantly
protected against the neurotoxic dopamine depletions produced by METH in the striatum
(Figure 2.2C, F(4,24) = 12.32, p < 0.0001). Post-hoc Tukey’s tests show that METH treatment
caused a significant decrease in dopamine levels (q = 7.50, p < 0.001) and that pretreatment
with the following doses of CM156 differed significantly protected against METH-induced
striatal dopamine depletions: 10 mg/kg (q = 7.60, p < 0.001) and 20 mg/kg (q = 7.36, p <
0.001).
When SN79 was administered in the absence of METH, one-way ANOVA showed that
there were no significant changes in striatal and cerebellar dopamine levels (Figure 2.2D,
F(3,19) = 1.53, ns; F(3,19) = 1.30, ns). One-way ANOVA showed that SN79 pretreatment
significantly attenuated METH-induced dopamine depletion (F(4,24) = 31.61, p < 0.0001).
Post-hoc Tukey’s test show that METH treatment caused a significant decrease in dopamine
levels when compared with saline treatment (q = 10.68, p < 0.001) and that SN79
pretreatment is able to significantly prevent METH induced decrease in dopamine levels
(SN79 dose: 1 mg/kg, q = 11.70, p < 0.001; 3 mg/kg, q = 12.24, p < 0.001; 10 mg/kg q =
14.28, p < 0.001).

38

A

B
125

100

*

75

DA level (% control)

DA level (% control)

125

***
***

50
25

100
75
50

0

25

1.25

2.5

0

5

C
###

100
75

***
50
25

125

-METH
+METH

10

20

D

###
###

DA Level (% control)

###

5

AC927 Pretreatment Dose (mg/kg, i.p.)

METH (mg/kg, i.p.)

.

DA Level (% control)

**

0

0

125

-METH
+METH

##

###

-METH
+METH

100
75
50

***

25
0

0
0

5

10

0

20

1

3

10

SN79 Pretreatment Dose (mg/kg, i.p.)

CM156 Pretreatment Dose (mg/kg, i.p.)

Figure 2.2 Dopamine assays: A. Dose response of METH. B, C and D. Effect of AC927, CM156
and SN79 pretreatment on METH-induced striatal dopamine depletion. (A) Dose response effects
of METH on dopamine (DA) levels in the striatum. Male, Swiss Webster mice (n = 5-9 per group) were
injected (i.p.) with METH (1.25-5.0 mg/kg, i.p.) or saline (0 mg/kg, i.p.) at 2 h intervals for a total of four
times. DA levels in the striatum were measured one week later. (B, C, D) Effects of CM156 on METHinduced depletion of dopamine (DA) levels in striatum of mouse brain tissue. Male, Swiss Webster mice
(n = 5 per group) were pretreated with saline or AC927 (5, 10, 20 mg/kg, i.p.) or CM156 (5, 10, 20
mg/kg, i.p.) or SN79 (1, 3, 10 mg/kg, i.p.). Mice were then treated with saline (-METH 0 mg/kg, i.p.) or
METH (+METH 5 mg/kg, i.p.) after 15min. This treatment regimen was repeated at 2 h intervals for a
total of four times. Tissue samples from mouse striatum were collected and DA concentration was
measured one week later. Data was reported as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 vs.
saline, ##p < 0.01, ###p < 0.001 vs. METH.
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2.3.2. 5-HT assays: Figure 2.3A illustrates striatal 5-HT levels following administration of
METH. A one-way ANOVA showed a significant reduction in 5-HT levels in the mouse
striatum (F(4,35) = 2.93, p < 0.05). Post-hoc Dunnett’s tests confirmed that 5-HT levels were
significantly reduced relative to the saline control following injection of 10 mg/kg, i.p. of METH
(q = 3.38, p < 0.01). However, in the cerebellum, METH did not produce significant 5-HT
depletions (F(4,35) = 2.33, n.s.).
Figure 2.3B shows the effects of the σ receptor antagonist AC927 (0-20 mg/kg, i.p.) on
METH-induced 5-HT depletions in the striatum of mice. To determine the effects of AC927
against METH-induced 5-HT depletions, a one-way ANOVA followed by a post-hoc Tukey’s
multiple comparison was run. Pretreatment with AC927 (5, 10 or 20 mg/kg, i.p.) significantly
attenuated the ability of METH to produce its neurotoxic effects in the striatum (F(7,32) = 4.49,
p < 0.005). Post-hoc Tukey’s multiple comparisons tests confirmed that pretreatment with the
10 mg/kg dose of AC927 significantly attenuated the striatal (q = 6.17, p < 0.01) 5-HT
depletions caused by METH.
As the one-way ANOVA showed, administration of CM156 alone produced no significant
changes in striatal and cerebellar 5-HT levels (F(3,21) = 2.37, n.s.; and F(3,21) = 0.49, n.s.,
respectively). However, similar to that seen with dopamine, a one-way ANOVA showed that
pretreatment with CM156 protected against METH-induced 5-HT depletions in the striatum
(Figure 2.3C; F(4,34) = 11.14, p < 0.0001). Post-hoc Tukey’s tests confirmed that METH
treatment caused a significant depletion in striatal 5-HT levels (q = 8.93, p < 0.01) and that
pretreatment with CM156 (20 mg/kg) significantly attenuated METH (10 mg/kg, i.p.)-induced
striatal 5-HT depletions (q = 4.92, p < 0.05) when compared to pretreatment with saline.
One-way ANOVA showed that administration of SN79 alone produced no significant
changes in 5-HT levels in cerebellum and striatum (2.3D, F(3,19) = 0.24, ns and F(3,38) =
0.72, ns respectively). When SN79 is given as a pretreatment prior to METH treatment, two40

way ANOVA showed a significant effect of METH treatment (F(1,71) = 9.60, p < 0.005), SN79
pretreatment (F(3,71) = 5.26, p < 0.005) and SN79 pretreatment × METH treatment interaction
(F(3,71) = 3.29, p < 0.05). Post-hoc Tukey’s test showed that METH treatment caused a
significant decrease in striatal 5-HT levels (q = 5.86, p < 0.01) and that SN79 pretreatment is
able to significantly prevent the METH-induced decrease in 5-HT levels (SN79 dose: 1 mg/kg,
q = 4.95, p < 05; 3 mg/kg, q = 5.29, p < 0.01 and 10 mg/kg, q = 6.88, p < 0.001).
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Figure 2.3 5-HT assays: A. Dose response of METH. B,C and D. Effect of AC927, CM156 and
SN79 pretreatment on METH-induced striatal 5-HT depletion. (A) Dose response effects of METH
on 5-HT levels in the striatum. Male, Swiss Webster mice (n = 5-10 per group) were injected with saline
or METH (1.25-10.0 mg/kg, i.p.) or saline (0 mg/kg, i.p.) at 2 h intervals for a total of four times. Striatal
tissue samples were collected one week later and measured for 5-HT concentration. (B, C, D) Effect of
AC927, CM156 and SN79 pretreatment on METH-induced alteration of 5-HT levels in the striatum of
mouse brain. Male, Swiss Webster mice (n = 5-10 per group) were pretreated with saline or AC927 (5,
10, 20 mg/kg, i.p.) or CM156 (5, 10, 20 mg/kg, i.p.) or SN79 (1, 3, 10 mg/kg, i.p.), and 15 min later, the
mice were treated with saline (-METH 0 mg/kg, i.p.) or METH (+METH 10 mg/kg, i.p.). These treatment
combinations were repeated at 2 h intervals a total of four times. One week later, mouse striatum were
collected and 5-HT concentration was measured. Data was reported as mean ± SEM. **p < 0.01vs.
saline, #p < 0.05, ##p < 0.01, ###p < 0.001 vs. METH.
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2.2.5. DAT immunohistochemistry: Figure 2.4A illustrates the effects of METH and AC927
on DAT immunoreactivity in the mouse striatum. ANOVA revealed a significant difference
between the treatment groups (F(3,12) = 43.76, p < 0.0001). Post-hoc Tukey’s multiple
comparison

tests

confirmed

that

METH

caused

a

significant

reduction

in

DAT

immunoreactivity (q = 14.26, p < 0.001). Pretreatment with AC927 significantly attenuated the
METH-induced neurotoxicity (q = 13.63, p < 0.001), whereas treatment with AC927 alone had
no significant effects on DAT expression (q = 3.56, n.s.).
Immunohistochemical analysis of striatal DAT expression confirmed that the METHinduced reductions in striatal dopamine levels were linked to degeneration of dopaminergic
nerve terminals. Figure 2.4B depicts the effects of METH and CM156 on DAT
immunoreactivity in the mouse striatum, with a significant difference between the treatment
groups (F(3,34) = 14.89, p < 0.0001). Post-hoc Tukey’s multiple comparisons tests confirmed
that METH caused a significant reduction in DAT immunoreactivity relative to treatment with
saline alone (q = 7.70, p < 0.001). Pretreatment with CM156 (10 mg/kg) significantly
attenuated METH-induced neurotoxicity (q = 7.90, p < 0.001), whereas treatment with CM156
alone had no significant effects on DAT expression (q = 0.75, n.s.).
Figure 2.4C illustrates the effects of METH and SN79 on DAT immunoreactivity in the
mouse striatum. ANOVA revealed a significant difference between the treatment groups
(F(3,71) = 162.90, p < 0.0001). Post-hoc Tukey’s multiple comparison tests confirmed that
METH caused a significant reduction in DAT immunoreactivity (q = 28.66, p < 0.001).
Pretreatment with SN79 significantly attenuated the METH-induced neurotoxicity (q = 24.66, p
< 0.001), whereas treatment with SN79 alone had no significant effects on DAT expression (q
= 1.81, n.s.).
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Figure 2.4 DAT Immunohistochemistry: Effect of (A) AC927, (B) CM156 and (C) SN79
pretreatment on METH-induced decrease in striatal DAT levels. Male, Swiss Webster mice (n = 4
per group) were pretreated with saline (SAL) or AC927 (AC, 10 mg/kg, i.p.) or CM156 (CM, 10 mg/kg,
i.p.) or SN79 (SN, 3 mg/kg, i.p.). After 15 min, the mice were then treated with saline (SAL) or METH (5
mg/kg, i.p.). This treatment schedule was repeated 4 times at 2 h intervals. One week later, the brain
was removed and stained for DAT immunoreactivity. A representative section from each treatment
group is shown, along with average optical density readings (mean ± SEM). ***p < 0.001 vs. saline,
###p < 0001 vs. METH.
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2.2.6. SERT immunohistochemistry: Immunohistochemical analysis revealed that METH
induced reductions in striatal SERT expression. One-way ANOVA showed that METH caused
a significant decrease in SERT expression in the striatum of the mice (Figure 2.5A; F(2,20) =
56.67, p < 0.0001). Post-hoc Dunnett’s tests showed that both 5 and 10 mg/kg doses of
METH significantly reduced striatal SERT expression (q = 9.27, p < 0.01 and q = 8.41, p <
0.01, respectively).
The effects of METH and AC927 on SERT immunoreactivity in the mouse striatum
were explored in order to confirm that 5-HT depletions were a result of nerve terminal damage
(Figure 2.5B). Significant difference between the treatment groups (F(5,47) = 50.85, p <
0.0001) were revealed using a one-way ANOVA. Post-hoc Tukey’s multiple comparisons tests
confirmed that METH (5 and 10 mg/kg) caused a significant reduction in SERT
immunoreactivity relative to treatment with saline alone (q = 15.90, p < 0.001 and q = 14.43, p
< 0.001 respectively). Pretreatment with AC927 (10 mg/kg) significantly attenuated METH (5
and 10 mg/kg)-induced neurotoxicity (q = 12.98, p < 0.001 and q = 11.85, p < 0.001
respectively), whereas treatment with AC927 alone had no significant effects on SERT
expression (q = 0.87, n.s.).
Immunohistochemical analysis of striatal SERT expression confirmed that the METHinduced reductions in striatal 5-HT levels were linked to degeneration of serotonergic nerve
terminals. Figure 2.5C depicts the effects of METH and CM156 on SERT immunoreactivity in
the mouse striatum, with a significant difference between the treatment groups (F(5,44) =
45.42, p < 0.0001). Post-hoc Tukey’s multiple comparisons tests confirmed that METH (5 and
10 mg/kg) caused a significant reduction in SERT immunoreactivity relative to treatment with
saline alone (q = 15.07, p < 0.001 and q = 13.67, p < 0.001 respectively). Pretreatment with
CM156 (20 mg/kg) significantly attenuated METH (5 and 10 mg/kg)-induced neurotoxicity (q =
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13.17, p < 0.001 and q = 8.10, p < 0.001), whereas treatment with CM156 alone had no
significant effects on SERT expression (q = 0.4, n.s.).
Figure 2.5D illustrates the effects of METH and SN79 on SERT immunoreactivity in the
mouse striatum. ANOVA revealed a significant difference between the treatment groups
(F(3,54) = 53.73, p < 0.0001). Post-hoc Tukey’s multiple comparison tests confirmed that
METH caused a significant reduction in SERT immunoreactivity (q = 15.07, p < 0.001).
Pretreatment with SN79 significantly attenuated the METH-induced neurotoxicity (q = 14.81, p
< 0.001), whereas treatment with SN79 alone had no significant effects on SERT expression
(q = 2.91, n.s.).
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Figure 2.5 SERT Immunohistochemistry: Effect of (A) AC927, (B) CM156 and (C) SN79
pretreatment on METH-induced decrease in striatal SERT levels. Male, Swiss Webster mice (n = 4
per group) were injected with METH (5, 10 mg/kg, i.p.) or saline at 2 h intervals for a total of four times.
One week later, the brain was removed and stained for SERT immunoreactivity. (B, C, D) Male, Swiss
Webster mice (n = 4 per group) were pretreated with saline (SAL) or AC927 (AC, 10 mg/kg, i.p.) or
CM156 (CM, 20 mg/kg, i.p.) or SN79 (SN, 3 mg/kg, i.p.). After 15 min, the mice were then treated with
saline (SAL) or METH (5 mg/kg, i.p.). This treatment schedule was repeated 4 times at 2 h
intervals. One week later, the brain was removed and stained for SERT immunoreactivity. A
representative section from each treatment group is shown, along with average optical density readings
(mean ± SEM). ***p < 0.001 vs. saline, ###p < 0001 vs. METH.
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2.3 Discussion
The current study demonstrates that pretreatment with AC927, CM156 and SN79 can
mitigate METH-induced decreases in striatal dopamine and 5-HT levels and DAT and SERT
expression levels. These protective effects likely involve modulation through both σ1 and σ2
receptors. The implications of the results are discussed below.
Consistent with the literature, high subchronic dose administration of METH leads to
dopaminergic and serotonergic neurotoxicity (Krasnova and Cadet, 2009). The striatal and
cerebellar brain regions were evaluated for the neurotoxic effects of METH. Since METH is
retained for a longer time in the striatum as compared to the control cerebellum brain region,
this explains why no significant neurotoxicity was seen in the cerebellum (Fowler et al., 2007).
The damage to 5-HT neurons was observed at comparatively higher doses than dopamine
neurons, most likely because METH has higher affinity for DAT than SERT (Han and Gu,
2006). In addition, METH causes greater release of dopamine than 5-HT in the striatum
(Gough et al., 2002), providing an opportunity for increased oxidative damage to dopaminergic
neurons. For the striatal 5-HT neurotoxicity studies, SERT immnunohistochemistry and 5-HT
depletion experiments were performed in different buildings with slightly different ambient
temperatures (5-HT: 21-22 °C, SERT: 23-23.5 ˚C). Since 5-HT neurotoxicity is sensitive to
changes in ambient room temperature (Malberg and Seiden, 1997; Malberg and Seiden,
1998), this may explain the difference in dose response between the two experiments
In this study, AC927, CM156 and SN79 pretreatment protected against two markers of
METH-induced striatal dopamine and serotonin nerve terminal degeneration (dopamine and
5-HT depletion and reductions in DAT and SERT expression levels), thus providing evidence
of neuroprotection.
Although the mechanisms of METH-induced neurotoxicity are not very well understood,
there are some evidences in the literature suggesting the involvement of the following
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cascades of events: excessive release of monoamines like dopamine and 5-HT, autooxidation
of monoamines leading to reactive oxygen species generation, ER stress and activation of
mitochondrial death cascades as well as glutamatergic/NMDA-mediated excitotoxic
mechanisms (Kaushal and Matsumoto, 2011). AC927, CM156 and SN79 can provide
neuroprotection by acting through σ receptors and competitively or non-competitively
intervening at the previously described METH’s downstream mechanisms (Kaushal and
Matsumoto, 2011). First, σ receptors are located on dopamine and 5-HT neurons, and can
modulate the release of these neurotransmitters (Campbell et al., 1989; Bastianetto et al.,
1995; Derbez et al., 2002). Second, σ receptors have been implicated in protective effects
against ROS-related dysfunctions such as brain ischemia (Schetz et al., 2007). Third,
presence of σ receptors at the ER and mitochondria and its function as a chaperone between
these organelles can help regulate the ER stress and mitochondrial death cascades (Tsai et
al., 2009; Su et al., 2010). Fourth, σ receptors can modulate NMDA receptor function, and
have been shown to protect against excitotoxic mechanisms in ischemic stroke models,
midbrain and cortical dopaminergic neurons, and retinal ganglion cells (DeCoster et al., 1995;
Shimazu et al., 2000; Shen et al., 2008). Taking all these observations from the literature and
the results obtained from this study into consideration, the neuroprotective effects of σ
receptor antagonists may be due to their ability to modulate various steps in METH’s
neurotoxic cascade.
σ Receptors, due to their properties of intracellular translocation, protein-protein interaction
and chaperone activity can help normalize a disordered system (Tsai et al., 2009). Therefore,
in addition to mitigating METH-induced neurotoxicity, targeting σ receptors has also been
reported to effectively attenuate neurotoxicity in several other models including β-amyloid,
carbon monoxide, and excitotoxicity (Marrazzo et al., 2005; Meunier et al., 2006; Shen et al.,
2008). Additionally, σ receptors may play a role in animal models of neuropsychiatric
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complications like depression, psychosis, cognitive and motor deficits (Guitart et al., 2004;
Mishina et al., 2005), which are also observed in METH users and have been associated with
the neurotoxic effects of METH (Cruickshank and Dyer, 2009).
In conclusion, pretreatment with AC927, CM156 and SN79 significantly protects against
METH’s dopamine and 5-HT neurotoxicity. Together with other studies, the data suggest an
important role of σ receptors in various METH-induced complications, and suggest a
mechanistic-based strategy for mitigating these adverse effects. Future studies will be
conducted to provide a more complete understanding of the underlying mechanisms through
which σ ligands convey neuroprotective actions.

2.4

Contributions: Nidhi Kaushal conducted the Dopamine ELISA studies for SN79; 5-HT

ELISA studies for CM156 and SN79; DAT immunohistochemistry studies for SN79 and SERT
immunohistochemistry studies for AC927, CM156 and SN79.
Dr. Jamaluddin Shaikh performed the DAT immunohistochemistry studies for AC927 and
CM156; Dopamine ELISA studies for AC927 and CM156; and 5-HT ELISA studies for AC927.
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CHAPTER 3
EVALUATION OF AC927, CM156 AND SN79 AGAINST METHINDUCED HYPERTHERMIA
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3.1. Introduction

Methamphetamine is a highly abused drug which produces neurotoxic effects
and psychiatric complications (Davidson et al., 2001; Cadet et al., 2003). High or
repeated METH administration also causes an elevation in body temperature (Fukumura et
al., 1998; Numachi et al., 2007). Previous clinical reports and animal studies suggest the

lethality produced by METH is closely related with hyperthermia, which may be the
primary cause of death (Bowyer et al., 1994; Davidson et al., 2001).Earlier studies have
shown that hyperthermia potentiates METH-induced dopamine and 5-HT depletions and
exacerbates oxidative stress in the brain (Bowyer et al., 1994; Hirata et al., 1995; Fukumura et
al., 1998), whereas hypothermia protects against these effects (Bowyer et al., 1994).
Therefore, the hyperthermic effect of METH is an essential factor for the neurotoxic effects of
METH. It is critical to verify if the neuroprotective effects of these σ receptor antagonists is
dependent on their ability to decrease the hyperthermic effects of METH.

Recent evidence has shown that METH produces some of its physiological and
behavioral effects through σ receptors (Nguyen et al., 2005). σ Receptors can be
found on monoaminergic neurons (Booth and Baldessarini, 1991; Bastianetto et al.,
1995) and modulate the release of neurotransmitters such as dopamine and
serotontin, which have been linked to changes in body temperature (Lee et al., 1985;
Gonzalez et al., 1986; Lipton and Clark, 1986; Schwartz et al., 1995; Salmi and
Ahlenius, 1998). In addition, σ receptor ligands can modulate thermoregulation (Rawls
et al., 2002), likely mediated through an association between thermosensitive neurons
and σ receptors in the hypothalamus (Bouchard and Quirion, 1997).
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The present study investigated whether METH-induced hyperthermia could be
prevented using the σ receptor antagonists AC927, CM156 and SN79. Two wellknown markers of neurotoxicity were also evaluated; striatal dopamine and serotonin
levels, results of which have been shown in Chapter 2. Striatal tissue was used in the
present investigation because it contains the terminals of monoaminergic neurons and
is the region primarily affected by METH-induced neurotoxicity (Brunswick et al., 1992;
Kovachich et al., 1989; Ricaurte et al., 1980; Seiden et al., 1988). Using correlation
analysis, it was also determined if the body temperatures of mice in each of the
treatment groups can be correlated with striatal dopamine and serotonin levels.

3.2 Methods
3.2.1. Animals: Male, Swiss Webster mice (18-28 g; Harlan, Indianapolis, IN) were used for
the in vivo studies. They were housed in groups of five with a 12:12h light/dark cycle with food
and water available ad libitum. Naïve mice were randomly assigned to different treatment
groups. All procedures involving animals were performed as approved by the Institutional
Animal Care and Use Committee at the West Virginia University.
3.2.2. Drugs: CM156 and SN79 were obtained from Dr. Christopher McCurdy’s laboratory
(University of Mississippi, University, MS). AC927 was provided by Dr. Andrew Coop
(University of Maryland, Baltimore, MD). METH hydrochloride was obtained from Research
Biochemicals International (Natick, MA).
3.2.3 Experimental schedule: As shown in Figure 3.1 male, Swiss Webster mice (n = 510/group) were randomly divided into four experimental groups: 1) Saline/Saline, 2)
Saline/METH (1.25, 2.5, 5, 10 mg/kg) 3) Antagonist (AC927: 5, 10, 20 mg/kg; CM156: 5, 10,
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20 mg/kg or SN79: 1, 3, 10 mg/kg)/Saline, 4) Antagonist (AC927: 5, 10, 20 mg/kg, i.p.;
CM156: 5, 10, 20 mg/kg, i.p. or SN79: 1, 3, 10 mg/kg, i.p.)/METH (5, 10 mg/kg, I.p.). The first
drug was administered 15 min prior to the second drug. Each group of mice received their
treatment a total of four times at two hour intervals. Core body temperature was measured 1 h
following each of the four treatment injections with a Thermalert TH-S monitor (Physitemp
Instruments Inc., Clifton, NJ). During the temperature measurements, mice were gently held at
the base of the tail and a probe (RET-3) was inserted approximately 2.5 cm past the rectum
into the colon for 8-10 s until a rectal temperature was maintained for 3-4 seconds. All
procedures involving animals were performed as approved by the Institutional Animal Care
and Use Committee at the University of Mississippi and West Virginia University.
3.2.4 Statistical analysis: The body temperature readings were evaluated using one-way
analysis of variance (ANOVA). Post-hoc analyses were performed with Dunnett’s test for
comparisons to controls and Tukey’s tests for pairwise comparisons. The body temperature of
the mice from each group was correlated with the striatal dopamine and 5-HT levels obtained
a week later. Results from studies in Chapter 2 measuring striatal dopamine and 5-HT levels
have been used for the correlation studies. For all statistical analyses, p < 0.05 was
considered statistically significant.
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Figure 3.1 Neurotoxic schedule of METH
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3.3 Results
3.3.1 Body temperature: The hyperthermic effects of METH are represented in Figure
3.2. One-way ANOVA demonstrated that METH produces a dose dependent increase in core
body temperature after the first injection (F(4,81) = 7.29, p < 0.0001), second injection
(F(4,81) = 12.70, p < 0.0001), third injection (F(4,81) = 29.21, p < 0.0001), and fourth injection
(F(4,81) = 52.72, p < 0.0001). Post-hoc Dunnett’s tests confirmed that compared to saline, the
following doses of METH significantly increased body temperature under the specified
conditions: after the first injection with METH 2.5 mg/kg (q = 2.53, p < 0.05), 5 mg/kg (q =
3.62, p < 0.01), and 10 mg/kg (q = 4.99, p < 0.01); after the second injection with METH 1.25
mg/kg (q = 4.46, p < 0.01), 2.5 mg/kg (q = 4.05, p < 0.01), 5 mg/kg (q = 6.01, p < 0.01), and
10 mg/kg (q = 5.52, p < 0.01); after the third injection with METH 1.25 mg/kg (q = 4.53, p <
0.01), 2.5 mg/kg (q = 4.91, p < 0.01), 5 mg/kg (q = 9.01, p < 0.01), and 10 mg/kg (q = 8.95, p
< 0.01); and after the fourth injection with METH 1.25 mg/kg (q = 3.91, p < 0.01), 2.5 mg/kg (q
= 5.30, p < 0.01), 5 mg/kg (q = 9.46, p < 0.01) and 10 mg/kg (q = 13.57, p < 0.01).
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Figure 3.2 Dose response of METH-induced hyperthermia Dose response effects of METH on core
body temperature. Male, Swiss Webster mice (n = 5-10 per group) were injected with saline or METH
(1.25-10 mg/kg, i.p.) at 2 h intervals for a total of four times. Core body temperature was measured via
rectal thermometer 1 h after each injection and data was reported as mean ± SEM. *p < 0.05, **p <
0.01, ***p < 0.001 vs. saline.
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AC927, on the other hand, did not significantly change core body temperature after the
first injection (Figure 3.3A, F(3,19) = 1.29, ns), second injection (F(3,19) = 1.02, ns), third
injection (F(3,19) = 1.25, ns) and fourth injection (F(3,19) = 1.44, ns). However, pretreatment
with AC927 significantly attenuated the ability of METH to produce its hyperthermic effects
(Figure 3.3B; after 2nd injection, F(4,20) = 5.86, p < 0.005 and 3rd injection, F(4,20) = 9.12, p
< 0.0005).
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Figure 3.3 Effect of AC927 on basal body temperature, and METH-induced hyperthermia in mice.
Effect of (A) AC927 (5, 10, 20 mg/kg, i.p.) alone on core body temperature, (B) Saline or AC927 (5, 10,
20 mg/kg, i.p.) pretreatment on METH (5 mg/kg, i.p.)-induced hyperthermia. Male, Swiss Webster mice
(n = 5-10 per group) were pretreated with saline or AC927 (5, 10, 20 mg/kg, i.p.), and after 15 min, the
mice were treated with saline or METH (5 mg/kg, i.p.). Core body temperature was measured 1 h after
each injection combination. This regimen was repeated four times at 2 h intervals. Data was reported
as mean ± SEM. ###p < 0.001 vs. METH.
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The effects of CM156 alone on body temperature are depicted in Figure 3.4A. One-way
ANOVA showed that CM156 alone had no significant effects on body temperature after the
first (F(3,36) = 0.05, n.s.), second (F(3,36) = 1.81, n.s.), third (F(3,36) = 1.37, n.s.), or fourth
(F(3,36) = 1.68, n.s.) injection. Pretreatment with CM156 attenuated METH (5 mg/kg, i.p.)induced hyperthermia after all but the first injection (Figure 3.4B): first (F(3,51) = 0.99, n.s.);
second (F(3,51) = 7.56, p < 0.0005); third (F(3,51) = 10.44, p < 0.0001); fourth (F(3,51) =
15.79, p < 0.0001). Post-hoc Dunnett’s tests showed that the following changes were
significant from the second injection onwards: after the second injection, CM156 (20 mg/kg,
i.p.), when compared to saline-pretreatment, significantly mitigated the hyperthermia effects of
METH (q = 4.47, p < 0.01); after third injection, CM156 (5, 10 and 20 mg/kg, i.p.) attenuated
the hyperthermic effects of METH (q = 2.51, p < 0.05; q = 3.71, p < 0.01 and q = 5.09, p <
0.01 respectively); after the fourth injection, CM156 (10 and 20 mg/kg, i.p.) attenuated the
hyperthermic effects of METH (q = 3.82, p < 0.01 and q = 6.59, p < 0.01 respectively).
Figure 3.4C shows the effects of pretreatment w
against the hyperthermia produced by a high (10 mg/kg, i.p.) dose of METH. One-way
ANOVA showed a significant attenuation of METH-induced hyperthermia after the fourth
injection (first: F(3,21) = 1.20, n.s.; second: F(3,21) = 1.29, n.s.; third: F(3,21) = 2.57, n.s.;
fourth: F(3,21) = 21.18, p < 0.0001). Post-hoc Tukey’s tests revealed that pretreatment with
CM156 (10 and 20 mg/kg, i.p.) attenuated the hyperthermic effects of METH after the fourth
injection (q = 3.68, p < 0.01; q = 7.86, p < 0.01 respectively).
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Figure 3.4 Effect of CM156 on basal body temperature and METH (5 and 10 mg/kg)-induced
hyperthermia in mice Effects of CM156 on (A) basal body temperature, (B) METH (5 mg/kg, i.p.) or
(C) METH (10 mg/kg, i.p.) induced hyperthermia. Male, Swiss Webster mice (n = 5-10 per group) were
pretreated with saline or CM156 (5, 10, 20 mg/kg, i.p.), and after 15 min, the mice were treated with
saline or METH (5, 10 mg/kg, i.p.). Core body temperature was measured 1 h after each injection
combination. This regimen was repeated four times at 2 h intervals. Data was reported as mean ±
SEM. *p < 0.05, **p < 0.05 vs. METH.
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One-way ANOVA showed that SN79 treatment significantly reduced body temperature
(Figure 3.5 A) when compared with saline treated mice after the first injection (F(3,59) =
21.77, p < 0.0001), second injection (F(3,59) = 20.12, p < 0.0001), third injection (F(3,59) =
11.34, p < 0.0001) and fourth injection (F(3,59) = 18.01, p < 0.0001). Post-hoc Dunnetts test
revealed that SN79 (10 mg/kg) significantly decreased the basal body temperature after first
injection (q = 6.54, p < 0.001), second injection (q = 5.98, p < 0.001), third injection (q = 4.36,
p < 0.001) and fourth injection (q = 5.58, p < 0.001).
One-way ANOVA showed that SN79 pretreatment is able to significantly attenuate the
hyperthermic effects of METH (Figure 3.5B and C) after the first injection (F(11,123) = 24.04,
p < 0.0001), second injection (F(11,123) = 15.40, p < 0.0001), third injection (F(11,123) =
18.25) and fourth injection (F(11,123) = 18.21). Post-hoc Tukey’s test revealed that the
following doses of SN79 attenuated the hyperthermic effects of METH (5 mg/kg) after the first
injection (3 mg/kg: q = 4.84, p < 0.05; 10 mg/kg: q = 9.26, p < 0.001), second injection (3
mg/kg: q = 5.51, p < 0.01; 10 mg/kg: q = 6.86, p < 0.001), third injection (1 mg/kg: q = 4.80, p
< 0.05; 3 mg/kg: q = 8.41, p < 0.001; 10 mg/kg: q = 7.76, p < 0.001) and fourth injection (1
mg/kg: q = 5.85, p < 0.01; 3 mg/kg: q = 7.85, p < 0.001; 10 mg/kg: q = 9.63, p < 0.001). Posthoc Tukey’s test also revealed that the following doses of SN79 attenuated the hyperthermic
effects of METH (10 mg/kg) after the first injection (3 mg/kg: q = 5.71, p < 0.01; 10 mg/kg: q =
13.34, p < 0.001), second injection (1 mg/kg: q = 5.91, p < 0.01; 3 mg/kg: q = 9.59, p < 0.001;
10 mg/kg: q = 10.39, p < 0.001), third injection (1 mg/kg: q = 5.18, p < 0.05; 3 mg/kg: q = 7.39,
p < 0.001; 10 mg/kg: q = 10.20, p < 0.001) and fourth injection (3 mg/kg: q = 6.94, p < 0.001;
10 mg/kg: q = 9.84, p < 0.001).
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Figure 3.5 Effect of SN79 treatment on basal body temperature and METH (5 and 10 mg/kg)induced hyperthermia in mice. Effects of SN79 on (A) basal body temperature, (B) METH (5 mg/kg,
i.p.) or (C) METH (10 mg/kg, i.p.) induced hyperthermia. Male, Swiss Webster mice (n = 5-10 per
group) were pretreated with saline or SN79 (1, 3, 10 mg/kg, i.p.), and after 15 min, the mice were
treated with saline or METH (5, 10 mg/kg, i.p.). Core body temperature was measured 1 h after each
injection combination. This regimen was repeated four times at 2 h intervals. Data was reported as
mean ± SEM. ###p < 0.001 vs. Saline; *p < 0.05, **p < 0.05, ***p < 0.001 vs. METH.
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3.3.2 Correlation: Table 3.1-3.3 summarizes the mean + S.E.M. for each of the groups, with
the statistical results shown at the bottom. The numbers in the parentheses of the treatment
group column represent doses (in mg/kg, i.p.) of AC927, CM156, SN79 or METH. The
correlation plot for each experiment is shown above the table.
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Figure 3.6 and Table 3.1 Correlation of body temperature and striatal (A) dopamine
(DA) and (B) 5-HT levels of mice pretreated with saline or AC927(5-20 mg/kg) prior to
saline or METH (5 mg/kg)
A

Body Temperature (C)

42

BT1
BT2
BT3
BT4

40
38
36
34
0

50

100

150

DA Level (% Saline Control)

Treatment Group
Sal/Sal
Sal/Meth(5)

DA (% Saline
Control)
100 ± 4.83
48.21 ± 4.45

BT1

BT2

BT3

BT4

37.4 ± 0.16
37.76 ± 0.23

37.3 ± 0.18
38.8 ± 0.30

37.38 ± 0.21
39.52 ± 0.40

37.24 ± 0.21
39 ± 0.26

AC927(5)/Meth(5)

67.19 ± 11.28

37.64 ± 0.31

37.52 ± 0.23

37.74 ± 0.26

38.16 ± 0.47

AC927(10)/Meth(5)

96.64 ± 11.69

37.26 ± 0.36

37.56 ± 0.24

37.42 ± 0.26

37.36 ± 0.33

AC927(20)/Meth(5)

69.08 ± 9.24

37.85 ± 0.42

37.53 ± 0.33

37.28 ± 0.26

37.43 ± 0.42

AC927(5)/Sal

97.16 ± 0.82

37.52 ± 0.22

37.14 ± 0.17

37.68 ± 0.18

37.54 ± 0.26

AC927(10)/Sal

91.27 ± 4.46

37.64 ± 0.25

37.66 ± 0.11

37.72 ± 0.09

37.36 ± 0.19

AC927(20)/Sal

81.47 ± 7.78

37.02 ± 0.30

37.02 ± 0.44

37.34 ± 0.20

36.94 ± 0.16

P

<0.05

<0.01

<0.05

< 0.05

Pearson r

-0.3219

-0.4313

-0.3899

-0.3672

r²

0.1036

0.186

0.152

0.1348

The values from individual mice were used to calculate the correlation between core body temperature
at each of the four time points and striatal dopamine levels measured one week later. The table
summarizes the mean + S.E.M. for each of the groups, with the statistical results shown at the bottom.
The numbers in the parentheses of the treatment group column represent doses (in mg/kg, i.p.) of
AC927 or methamphetamine (METH).
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B

Body Temperature (C)

42

BT1
BT2
BT3
BT4

40
38
36
34
0

50

100

150

5-HT Level (% Saline Control)

Treatment Group

5-HT (% Saline
Control)

BT1

BT2

BT3

BT4

Sal/Sal

100 ± 6.71

37.1 ± 0.07

37.18 ± 0.16

37.3 ± 0.11

37.38 ± 0.12

Sal/METH(5)

55.35 ± 4.99

38.24 ± 0.18

39.2 ± 0.28

39.42 ± 0.24

39.22 ± 0.23

AC927(5)/METH(5)

67.85 ± 4.16

37.52 ± 0.22

37.5 ± 0.16

37.5 ± 0.13

37.8 ± 0.27

AC927(10)/METH(5)

109.55 ± 12.86

37.32 ± 0.20

37.3 ± 0.16

37.4 ± 0.14

37.28 ± 0.23

AC927(20)/METH(5)

82.71 ± 16.50

37.5 ± 0.23

37.5 ± 0.14

37.82 ± 0.28

37.9 ± 0.12

AC927(5)/Sal

90.77 ± 6.37

37.34 ± 0.18

37.2 ± 0.19

37.62 ± 0.13

37.34 ± 0.26

AC927(10)/Sal

102.24 ± 6.23

37.34 ± 0.10

37.4 ± 0.08

37.46 ± 0.06

37.54 ± 0.13

AC927(20)/Sal

98.30 ± 3.67

37.16 ± 0.29

37.3 ± 0.22

37.48 ± 0.12

37.28 ± 0.14

P

< 0.01

< 0.005

< 0.0005

< 0.005

Pearson r

-0.4042

-0.481

-0.5693

-0.4707

r²

0.1634

0.2314

0.3241

0.2216

The values from individual mice were used to calculate the correlation between core body temperature
at each of the four time points and striatal serotonin levels measured one week later.

The table

summarizes the mean + S.E.M. for each of the groups, with the statistical results shown at the bottom.
The numbers in the parentheses of the treatment group column represent doses (in mg/kg, i.p.) of
AC927 or methamphetamine (METH).
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Figure 3.7 and Table 3.2 Correlation of body temperature and striatal (A) dopamine
(DA) and (B) 5-HT levels of mice pretreated with saline or CM156 (5-20 mg/kg) prior to
saline or METH (5 and 10 mg/kg)
A

Body Temperature (°C)

42

BT1
BT2
BT3
BT4

40
38
36
34
32
0

50

100

150

DA Level (% Saline Control)

Treatment Group

DA (% Saline
Control)

BT1

BT2

BT3

BT4

Sal/Sal

100 ± 7.15

37.06 ± 0.10

36.62 ± 0.20

36.72 ± 0.09

36.7 ± 0.25

Sal/Meth(5)

51.06 ± 4.96

37.98 ± 0.30

38.22 ± 0.20

38.36 ± 0.25

38.5 ± 0.21

CM156(5)/Meth(5)

69.20 ± 8.17

37.58 ± 0.28

37.64 ± 0.23

37.28 ± 0.31

37.86 ± 0.49

CM156(10)/Meth(5)

101.71 ± 5.52

37.08 ± 0.48

37.12 ± 0.12

37.08 ± 0.25

37.04 ± 0.25

CM156(20)/Meth(5)

99.07 ± 6.33

36.76 ± 0.07

36.44 ± 0.07

36.76 ± 0.19

36.62 ± 0.15

CM156(5)/Sal

96.34 ± 7.94

37.04 ± 0.05

36.88 ± 0.21

36.8 ± 0.12

36.98 ± 0.07

CM156(10)/Sal

106.87 ± 7.80

37.1 ± 0.21

37.08 ± 0.12

36.76 ± 0.18

36.66 ± 0.22

CM156(20)/Sal
P
Pearson r
2
r

100.74 ± 6.07

37.06 ± 0.14
<0.0005
-0.5581
0.3114

37.06 ±0.13
<0.0001
-0.6725
0.4523

37.08 ± 0.23
<0.0001
-0.6793
0.4614

36.98 ± 0.12
<0.0001
-0.6923
0.4793

The values from individual mice were used to calculate the correlation between core body temperature
at each of the four time points and striatal dopamine levels measured one week later. The table
summarizes the mean + S.E.M. for each of the groups, with the statistical results shown at the bottom.
The numbers in the parentheses of the treatment group column represent doses (in mg/kg, i.p.) of
CM156 or methamphetamine (METH).
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B
Body Temperature (°C)

42

BT1
BT2
BT3
BT4

40
38
36
34
32
0

50

100

150

5-HT Level (% Saline Control)

Treatment Group

5-HT (%
Saline
Control)

BT1

BT2

BT3

BT4

Sal/Sal

100 ± 8.16

36.84 ± 0.10

36.32 ± 0.07

36.5 ± 0.09

36.66 ± 0.12

Sal/Meth(10)

58.35 ± 5.91

38.48 ± 0.20

38.36 ± 0.17

38.99 ± 0.19

40.15 ± 0.33

CM156(5)/Meth(10)

76.44 ± 4.76

38 ± 0.23

37.96 ± 0.18

38.46 ± 0.23

39.14 ± 0.29

CM156(10)/Meth(10)

66.80 ± 5.42

38.6 ± 0.10

38.76 ± 0.56

38.36 ± 0.61

37.86 ± 0.79

CM156(20)/Meth(10)

86.45 ± 3.88

38.34 ± 0.25

37.72 ± 0.63

37.66 ± 0.49

36.54 ± 0.32

CM156(5)/Sal

102.04 ± 4.10

37.38 ± 0.14

37.28 ±0.06

36.94 ± 0.07

37.4 ± 0.10

CM156(10)/Sal

96.09 ± 6.11

37.38 ± 0.19

37.42 ± 0.19

36.88 ± 0.17

37 ± 0.14

CM156(20)/Sal
P
Pearson r
2
r

98.74 ± 6.07

37.34 ± 0.13
< 0.0001
-0.5978
0.3573

37.48 ± 0.17
<0.0005
-0.5170
0.2673

37.06 ± 0.14
< 0.0001
-0.7484
0.5601

36.58 ± 0.17
< 0.0001
-0.6552
0.4293

The values from individual mice were used to calculate the correlation between core body temperature
at each of the four time points and striatal serotonin levels measured one week later.

The table

summarizes the mean + S.E.M. for each of the groups, with the statistical results shown at the bottom.
The numbers in the parentheses of the treatment group column represent doses (in mg/kg, i.p.) of
CM156 or methamphetamine (METH).
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Figure 3.8 and Table 3.3 Correlation of body temperature and striatal (A) dopamine
(DA) and (B) 5-HT levels of mice pretreated with saline or SN79 (1-10 mg/kg) prior to
saline or METH (5 and 10 mg/kg)

A
Body Temperature (°C)

42

BT1
BT2
BT3
BT4

40
38
36
34
32
0

50

100

150

DA Level (% Saline Control)

Treatment Group

DA (% Saline
Control)

BT1

BT2

BT3

BT4

Sal/Sal

100 ± 6.9

37.86 ± 0.24

37.24 ± 0.29

37.06 ± 0.29

36.8 ± 0.30

SN79(1)/Saline

112.39 ± 4.55

37.76 ± 0.17

37.16 ± 0.14

36.92 ± 0.19

36.9 ± 0.26

SN79(3)/Saline

112.04 ± 4.75

37.06 ± 0.33

36.78 ± 0.31

36.78 ± 0.41

36.8 ± 0.26

SN79(10)/Saline

111.87 ± 4.7

35.2 ± 0.48

35.42 ± 0.41

35.54 ± 0.35

35.6 ± 0.33

Saline/Meth(5)

41.95 ± 6.59

37.96 ± 0.23

38.14 ± 0.19

38.86 ± 0.34

39.62 ±0.32

SN79(1)/Meth(5)

105.58 ± 3.70

37.32 ± 0.26

37.14 ± 0.23

37.24 ± 0.39

37.52 ± 0.24

SN79(3)/Meth(5)

108.48 ± 4.53

36.38 ± 0.36

36.26 ± 0.36

36.02 ± 0.32

36.8 ± 0.35

SN79(10)/Meth(5)

119.58 ± 4.76

34.94 ± 0.32

35.8 ± 0.38

36.24 ± 0.32

36.16 ± 0.35

P
Pearson r
2

r

<0.01

<0.0005

<0.0001

<0.0001

-0.4164

-0.5291

-0.5819

-0.7555

0.1734

0.28

0.3386

0.5708

The values from individual mice were used to calculate the correlation between core body temperature
at each of the four time points and striatal dopamine levels measured one week later. The table
summarizes the mean + S.E.M. for each of the groups, with the statistical results shown at the bottom.
The numbers in the parentheses of the treatment group column represent doses (in mg/kg, i.p.) of
SN79 or methamphetamine (METH).
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B
Body Temperature (°C)

42

BT1
BT2
BT3
BT4

40
38
36
34
32
0

50

100

150

200

5HT Level (% Saline Control)

.
Treatment Group

5-HT (% Saline
Control)

BT1

BT2

BT3

BT4

Sal/Sal

100 ± 6.86

37.14 ± 0.19

36.82 ± 0.15

36.65 ± 0.20

37 ± 0.19

SN79(1)/Saline

115.59 ± 7.95

37.32 ± 0.20

37.12 ± 0.20

36.99 ± 0.16

37.24 ± 0.12

SN79(3)/Saline

107.58 ± 6.70

37.4 ± 0.15

37.11 ± 0.13

36.94 ± 0.14

37.14 ± 0.13

SN79(10)/Saline

99.51 ± 11.80

35.85 ± 0.31

35.46 ± 0.36

35.72 ± 0.36

35.6 ± 0.34

Saline/Meth(10)

55.76 ± 6.14

38.78 ± 0.22

38.45 ± 0.20

39.17 ± 0.18

38.83 ± 0.34

SN79(1)/Meth(10)

93.18 ± 5.63

38.56 ± 0.14

37.37 ± 0.22

37.9 ± 0.27

38.16 ± 0.31

SN79(3)/Meth(10)

95.81 ± 6.91

37.31 ± 0.27

36.43 ± 0.34

37.27 ± 0.34

37.53 ± 0.33

SN79(10)/Meth(10)

108.08 ± 8.83

35.88 ± 0.26

36.33 ± 0.24

36.71 ± 0.18

36.63 ± 0.17

<0.01

<0.005

<0.001

<0.05

-0.3025

-0.3208

-0.3735

-0.2875

0.09152

0.1029

0.1395

0.08267

P
Pearson r
2

r

The values from individual mice were used to calculate the correlation between core body temperature
at each of the four time points and striatal serotonin levels measured one week later.

The table

summarizes the mean + S.E.M. for each of the groups, with the statistical results shown at the bottom.
The numbers in the parentheses of the treatment group column represent doses (in mg/kg, i.p.) of
SN79 or methamphetamine (METH).
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3.4 Discussion
σ Receptor antagonists, AC927, CM156 and SN79 can attenuate the hyperthermic effects
of METH. Mechanistically, dopaminergic and serotonergic systems are implicated in METHinduced body temperature alterations (Numachi et al., 2007). In addition, the production of
ROS and release of cytokines like IL1β have been implicated in the generation of METH’s
hyperthermia (Bowyer et al., 1994; Imam et al., 1999; Riedel and Maulik, 1999; Yamashita et
al., 2000; Fukami et al., 2004).. Moreover, σ Receptor ligands, with their ability to modulate
these neurotransmitter systems, cytokines, as well as ROS, can attenuate elevations in body
temperature (Campbell et al., 1989; Bastianetto et al., 1995; Derbez et al., 2002; Schetz et al.,
2007; Matsumoto et al., 2008). Additionally, σ receptors are located in the hypothalamic brain
region and have previously been shown to modulate body temperature (Gundlach et al., 1986;
Rawls et al., 2002). A combination of all these factors may explain how AC927, CM156 and
SN79 can prevent METH-induced hyperthermia.
When body temperature of the mice was correlated with the striatal dopamine and 5-HT
levels a week later, a significant correlation was observed. This indicates that the METHinduced neurotoxicity is related to the body temperature of the mice during treatment. In
addition, the ability of AC927, CM156 and SN79 to attenuate the depletions in dopamine and
5-HT levels may be related to their ability to decrease the hyperthermic effects of METH.
However, correlation does not always mean causation. As discussed earlier, sigma receptors
may be able to attenuate the hyperthermic effects of METH through various mechanisms; they
may also be able to prevent METH-induced neurotoxicity at a cellular level independent of
temperature influence. However, the separation of these effects in an in vivo system may not
be possible or very difficult to interpret.
Certain animal studies can be performed to determine if the σ antagonists can attenuate
the neurotoxicity independent of decreases in body temperature. It involves maintaining the
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mice at elevated ambient temperatures (under a 37 ºC heating lamp) and then conducting the
experiment. This would prevent the decrease in body temperature observed by pretreatment
with σ receptor antagonists. However, the limitation of this study is that the positive control
METH treated mice all die (Miller and O'Callaghan, 1994; Miller and O'Callaghan, 2003;
Seminerio et al., 2011). Nevertheless, this study was conducted with AC927 which
significantly decreased the METH-induced mortality. However, the neurotoxicity data was
difficult to interpret because of the lack of a positive control (Seminerio et al., 2011).
In order to clearly differentiate between the ability of σ receptor antagonists to attenuate
the neurotoxic effects of METH independent of temperature modulation, an experimental
model is needed where temperature component can be controlled and separated the effects
of METH alone. Therefore, in the next chapter, a neuronal cell culture model was used to
begin identifying the mechanisms of METH’s neurotoxicity and the pathways where σ
receptors may mediate neuroprotection.

3.5 Contributions: Nidhi Kaushal conducted the body temperature experiments for CM156
(serotonin depletion experiment) and SN79 (dopamine and 5-HT depletion experiment).
Dr. Jamaluddin Shaikh performed the body temperature experiments for AC927
(dopamine and 5-HT depletion experiments) and CM156 (dopamine depletion experiment).
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CHAPTER 4
EVALUATION OF AC927 AGAINST METH-INDUCED
NEUROTOXICITY: IN VITRO STUDIES
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4.1. Introduction
Methamphetamine (METH) is a highly abused psychostimulant drug that results in
neurotoxicity at high or repeated drug administration (Krasnova and Cadet, 2009).

This

neurotoxicity is seen as dopamine nerve terminal degeneration and apoptosis in several brain
regions (Krasnova and Cadet, 2009), the mechanism of which is not completely understood.
However, some of the neurotoxic cascades involved are excessive release of dopamine,
oxidative/nitrosative stress, endoplasmic reticulum (ER) stress, and activation of mitochondrial
death cascades (Cadet and Brannock, 1998; Krasnova and Cadet, 2009).
Among its various targets, METH interacts with sigma (σ) receptors at physiologically
relevant micromolar concentrations (Nguyen et al., 2005; Han and Gu, 2006). Two subtypes
of σ receptors, σ1 and σ2, are expressed in almost all types of mammalian cells (Guitart et al.,
2004). σ1 Receptors are highly conserved 223 amino acid membrane bound proteins (Kekuda
et al., 1996). They function as chaperones at the mitochondrial-ER membrane and regulate
Ca2+ signaling via inositol trisphosphate (IP3) receptors (Hayashi and Su, 2007). Additionally,
σ1 receptors can undergo protein-protein interactions with several other cellular proteins such
as binding immunoglobulin protein (BiP), ankyrin-B, IP3 receptors, and dopamine D1 receptors
(Hayashi and Su, 2001; Hayashi and Su, 2007; Navarro et al., 2010; Su et al., 2010). σ1
Receptors are also capable of translocation to different subcellular compartments upon
stimulation through ligand binding and changes in intracellular conditions (Hayashi and Su,
2003a). In contrast, σ2 receptors are less well characterized. However, they are elevated in
immortalized cell lines and tumor cells (Vilner et al., 1995b), where they have been implicated
in the control of cell cycle functions (Wheeler et al., 2000), alterations in cellular Ca2+ levels
(Vilner and Bowen, 2000), and cell death signaling involving sphingolipid products (Crawford
et al., 2002).
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Previous

in

vivo

studies

have

shown

that

pretreatment

with

AC927

(N-

phenethylpiperidine oxalate), a σ receptor ligand, attenuates the neurotoxic effects of METH in
male, Swiss Webster mice (Matsumoto et al., 2008; Seminerio et al., 2011). The ability of
AC927 to mitigate neurotoxic cascades is consistent with the location of σ receptors in various
subcellular organelles like ER, mitochondria, lysosomes, cell membrane, and nucleus
(McCann et al., 1994; Zeng et al., 2007) as well as the functional roles of σ receptors in cells
a
drugs of abuse like METH remains unclear due to various limitations, including the lack of a
suitable in vitro model system. Previous studies to understand the mechanisms of METHinduced toxicity employed either primary neuronal cultures or immortalized cell lines of
neuronal origin (Cadet et al., 1997; Choi et al., 2002; Deng et al., 2002; Kanthasamy et al.,
2006; Wu et al., 2007). In order to induce cell death/damage, millimolar concentrations of
METH were required, which are rarely achieved in vivo (Segal and Kuczenski, 2006; Melega
et al., 2008). Therefore, a model system suitable for identifying potential mechanisms leading
to neurotoxicity is needed.
In order to elucidate the cellular mechanisms of METH-induced neurotoxicity at which AC927
may intervene via σ receptors, a neuronal/glial cell culture model (neuroblastoma × glioma
hybridoma, NG108-15 cells) was used in the present study. NG108-15 cells when
differentiated display neurite outgrowth, electrical excitability, and express proteins with
neuronal and glial properties (Ma et al., 1998). These cells have been used extensively as a
sensitive cell line to study the toxic effects of various drugs and chemicals (Canete and
Diogene, 2008). Additionally, NG108-15 cells have been commonly used in the literature to
study the functions of σ receptors (Hayashi and Su, 2003a). In the current study, the end
points measured were reactive oxygen and nitrogen species (ROS/RNS) generation,
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dopamine release, apoptosis, and necrosis. Finally, AC927 was tested against these cytotoxic
endpoints and mediators to gain insight into the mechanisms of σ-mediated neuroprotection.

4.2 Materials and Methods
4.2.1 Cell line and culture
4.2.1.1. Cell growth: The neuroblastoma x glioma, hybridoma cell line NG108-15
(Hamprecht et al., 1985) were obtained from ATCC (Rockville, MD). Cells were maintained in
25 cm2 (T25) or 75 cm2 (T75) culture flasks (Corning-Costar, Lowell, MA) in hi-glucose (4.5
g/L) DMEM (Dulbecco’s modified Eagle’s medium) supplemented with 10% FBS (fetal bovine
serum), penicillin, streptomycin, and HAT (hypoxanthine-aminopterin-thymidine) at 37⁰C in a
humidified incubator in 5% CO2.
4.2.1.2. Cell differentiation: Culture medium was replaced with differentiation medium
(DMEM with 0.5% FBS, penicillin, streptomycin, HAT and 1% DMSO) and the cells allowed to
grow for a further 3-4 days.

4.2.2 Reactive oxygen/nitrogen species: Cells grown in complete or differentiation medium
were used for assay when 60-70% confluent. The culture medium was replaced phenol red
free medium containing 0.5% FBS and 5 µM fluorigenic, oxidizable, dye CM-H2DCFDA (5(and-6)-chloromethyl-2’,7’-dichlorodihydrofluorescein diacetate) and returned to the incubator
at 37 ⁰C for 45-60 min. Cells were treated with appropriate concentrations of METH or AC927.
Exogenously added 100 µM H2O2 and Na2Cr2O7 served as a positive control in this assay. All
compounds were added in replicates of 4 or 8 and the plates are returned to the incubator. In
the assay, AC927 (0-300 µM), N-acetylcysteine (NAC, 10 mM), catalase (10000 units per ml),
L-NMMA (200 µM) were added 15 min prior to the addition of METH (0.1-3000 µM), H2O2 (100
µM) or Na2Cr2O7 (100 µM). At specified time points, plates were read in a Fluostar Optima
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fluorescence plate reader fitted with a 485/520 nm excitation/emission filter set (BMG Labtech
GmbH, Offenberg, Germany).
4.2.3 Dopamine release: NG108-15 cells grown and differentiated in T75 flasks were
harvested by replacing the medium with Ca++, Mg++ free DPBS (Dulbecco’s PhosphateBuffered Saline), centrifuged, re-suspended in differentiation medium with reduced glucose
(1.5 g/l) at 3 x 105 cells per ml and seeded in 24-well CellBind tissue culture plates (CorningCostar, Lowell, MA) at 0.5 ml per well. After 4 hr, various concentrations of METH (0.3-300
µM) were added to sets of wells. KCl (50 mM) was used as a positive control for maximum
dopamine release. In one set of wells, AC927 was added 15 min prior to the addition of METH
or KCl. After 5 min of exposure to KCl or METH, supernatants were harvested (450 µl),
centrifuged to remove cells, acidified with the addition of 1/10 volume of buffer (0.1 N HCl, 10
mM EDTA and 40 mM Na2S2O5) and samples were stored at -20 ⁰C. Dopamine was
quantitated in an enzyme-linked immunosorbent assay (ELISA) employing a kit from Rocky
Mountain Diagnostics (Denver, CO) and manufacturer’s protocols. Briefly, dopamine was
extracted from the culture supernatants by binding to an affinity gel matrix, acetylated, eluted
and then measured in a competitive inhibition ELISA, using a standard curve of known
concentrations of dopamine.
4.2.4 Hoechst and propidium iodide staining: NG108-15 cells were grown and
differentiated in 96-well culture plates and exposed to various concentrations of METH (0-10
mM), AC927 (0.3-30 µM), AC927 (0.3-30 µM)+METH (0-1 mM) for 24 hrs at 37 °C. Hoechst
stain (20 µg/ml final concentration) and propidium iodide stain (20 µg/ml final concentration)
were added to each well and incubated at room temperature for 10 min. Three images are
taken/well using an UV light microscope. Cells with brightly stained and fragmented nuclei
were counted as apoptotic and cells that were red were counted as necrotic. The percentage
of apoptotic and necrotic cells were counted with the help of Image J cell counter (NIH).
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4.2.5 Statistical analysis: Statistical analysis of data was performed using ANOVA with
appropriate post-hoc tests employing GraphPad Prism 4 (GraphPad Software, San Diego,
CA).

4.3. Results
4.3.1. Reactive oxygen/nitrogen species: As shown in Figure 4.1, CM-H2DCFDA detected
exogenously added H2O2 within 10 min (168.91 ± 6.95 % of untreated control) and up to 60
min (176.69 ± 7.1 % of control). Low levels of ROS were also induced in NG108-15 cells by
Na2Cr2O7 starting at 10 min; ROS in this sample increased dramatically 4 hr after treatment
(140.1 ± 8.6 % of control) and continued to increase up to 24 hr reaching 223.70 ± 21.92 % of
that in untreated control cells. These controls established that the assay contained sufficient
and stable reagents to continuously detect oxidizing radicals from within 10 min of initiation
and up to 24 hr. All tested concentrations of METH except the lowest (0.1 µM) induced the
production of ROS capable of oxidizing CM-H2DCFDA significantly above background levels
within 10 min of exposure, with 3 µM inducing the highest levels (201.97 ± 9.97 % of control).
The difference between METH-induced ROS and basal ROS in NG108-15 cells diminished
beyond 60 min, while ROS continued to accumulate in cells treated with Na2Cr2O7 up to 24 hr.
Statistical analysis of the data obtained from 10 to 60 min employing two-way repeated
measures ANOVA showed a significant effect of METH concentration (F(10,1364) = 54.41, p
< 0.0001), time (F(3,1364) = 21.14, p < 0.0001) and METH treatment × time interaction
(F(30,1364) = 1.84, p < 0.005). Bonferroni’s post-hoc tests further established that the
following concentrations of METH and positive control are capable of reproducibly inducing
the strongest and sustained ROS responses: 0.3 µM (10 min: t = 4.7, p < 0.001; 20 min: t =
3.46, p < 0.01; 30 min: t = 2.95, p < 0.05 and 60 min: t = 2.63, p < 0.05), 1 µM (10 min: t =
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6.88, p < 0.001; 20 min: t = 5.46, p < 0.001; 30 min: t = 4.58, p < 0.001 and 60 min: t = 3.82, p
< 0.001), 3 µM (10 min: t = 11.46, p < 0.001; 20 min: t = 8.69, p < 0.001; 30 min: t = 7.60, p <
0.001 and 60 min: t = 5.33, p < 0.001), 10 µM (10 min: t = 3.50, p < 0.01), 30 µM (t = 3.81, p <
0.001), 100 µM (10 min: t = 6.30, p < 0.001; 20 min: t = 3.41, p < 0.01 and 30 min: t = 3.06, p
< 0.01), 300 µM (10 min: t = 8.58, p < 0.001; 20 min: t = 5.23, p < 0.001; 30 min: t = 5.78, p <
0.001 and 60 min: t = 3.71, p < 0.001), H2O2 (10 min: t = 7.74, p < 0.001; 20 min: t = 7.46, p <
0.001; 30 min: t = 7.27, p < 0.001 and 60 min: t = 8.63, p < 0.001) and Cr (10 min: t = 3.42, p
< 0.01; 20 min: t = 2.62, p < 0.05; 30 min: t = 3.20, p < 0.01 and 60 min: t = 3.63, p < 0.01).
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Figure 4.1 Dose response and time course of METH-induced ROS/RNS generation. The
production of ROS capable of oxidizing CM-H2DCFDA was conducted as described in the materials and
methods in NG108-15 cells following exposure to 100 µM H2O2, 100 µM Na2Cr2O7 (Cr), or 0 to 300 µM
METH. Relative fluorescence units from five separate experiments obtained at each indicated time
point are shown; data were normalized to the mean rfu for untreated cells to obtain percent control
values (n = 8/experiment) ± SEM.
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As shown in Figure 4.2A, ROS detectable by CM-H2DCFDA induced in NG108-15
cells by METH was completely inhibited in the presence of the common antioxidant and
radical scavenger NAC as seen within 20 min of addition of the drug, confirming that the
assay was indeed detecting ROS. Two-way ANOVA showed significant effect of NAC
treatment (F(1,80) = 962.7, p < 0.0001), METH and H2O2 treatment (F(5,80) = 10.64, p <
0.0001) and NAC treatment × METH and H2O2 treatment interaction (F(5,80) = 8.83, p <
0.0001). Bonferroni’s post-hoc tests showed that NAC significantly decreased ROS for all
tested concentrations of METH (0.1 µM: t = 11.66, p < 0.001; 0.3 µM: t = 12.86, p < 0.001; 1
µM: t = 12.91, p < 0.001 and 3 µM: t = 13.29, p < 0.001) and H2O2 (t = 18.39, p < 0.001).
Significant inhibition of radical generation persisted up to 4 hr after addition of METH, at which
time the experiment was terminated. Interestingly, NAC also reduced the ROS detectable in
untreated control cells (t = 7.97, p < 0.001) at 20 min, indicating that differentiated NG108-15
cells produce significant amounts of basal ROS.
The presence of catalase in the assay medium inhibited ROS induced by METH within
20 min of addition of the drug (Figure 4.2B). Two-way ANOVA confirmed significant effect of
catalase treatment (F(1,80) = 42.85, p < 0.0001), METH and H2O2 treatment (F(5,80) = 3.79, p
< 0.005) and catalase treatment × METH and H2O2 treatment (F(5,80) = 3.71, p < 0.005).
Bonferroni’s post-hoc tests confirmed significant differences for 1 µM and 3 µM METH
concentration (t = 3.17, p < 0.05 and t = 3.20, p < 0.05) and H2O2 treatment (t = 6.03, p <
0.001), suggesting that H2O2 was a small but significant product of reactive species induced
by these concentrations of the drug.
Finally, the increase in ROS in NG108-15 cells induced by METH was also
significantly inhibited in the presence of L-NMMA (Figure 4.2C). Two-way ANOVA showed a
significant effect of L-NMMA treatment (F(1,60) = 26.89, p < 0.0001), METH and H2O2
treatment (F(5,60) = 57.36, p < 0.0001) and L-NMMA treatment × METH and H2O2 treatment
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(F(5,60) = 5.85, p < 0.0005). Bonferroni’s post-hoc tests confirmed that L-NMMA inhibited the
ROS/RNS generated by 1 and 3 µM METH (t = 4.47, p < 0.001 and t = 5.09, p < 0.001
respectively), suggesting that the generation of some of the reactive species detected by CMH2DCFDA in these test groups must proceed through intermediates requiring the synthesis of
nitric oxide radicals.
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Figure 4.2 Effect of antioxidants (A) NAC, (B) catalase, (C) L-NMMA on METH-induced ROS/RNS
generation. Inhibition of ROS production in NG108-15 cells by N-acetylcysteine (NAC), catalase and LG

N -monomethyl arginine (L-NMMA). Inhibition of ROS following exposure to 0 to 3 µM
methamphetamine (METH) or 100 µM H2O2 was determined in the absence (solid bars) or presence
(gray bars) of 10 mM NAC (A), 10,000 units catalase (B) or 20 mM L-NMMA (C) 20 min following
exposure to METH. Data represent averages of relative fluorescence units from two separate
experiments (n = 4/experiment) ± SEM. Significant differences are noted, *p < 0.05, **p < 0.01 (control
vs. METH treated) and #p < 0.05, ###p < 0.001 (METH alone vs. METH with ROS inhibitor).
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As shown in Figure 4.3, CM-H2DCFDA detected exogenously added H2O2 within 10
min (146.69 ± 4.97 % of control) and ROS generated by Na2Cr2O7 in NG108-15 cells, which
peaked at 24 hr (242.06 ± 11.56 % of control). In contrast, all tested concentrations of AC927
from 0 to 300 µM failed to induce ROS significantly higher than that in untreated control cells.
Statistical analyses of the data employing two-way repeated measures ANOVA showed a
significant effect of AC927 and positive control treatment (F(9,900) = 75.37, p < 0.0001), time
(F(6,900) = 28.36, p < 0.0001) and AC927 and positive control treatment × time interaction
(F(54,900) = 60.50, p < 0.0001). Bonferroni’s post-hoc tests revealed that none of the tested
concentrations of AC927 were able to induce elevation of ROS above background levels,
while ROS was detected in cells treated with H2O2 (10 min: t = 11.26, p < 0.001; 20 min: t =
14.14, p < 0.001; 30 min: t = 14.50, p < 0.001; 60 min: t = 11.47, p < 0.001; 240 min: t = 3.03,
p < 0.05 and 480 min: t = 3.00, p < 0.05) and Na2Cr2O7 (240 min: t = 7.01, p < 0.001; 480 min:
t = 16.52, p < 0.001 and 1440 min: t = 34.24, p < 0.001). Interestingly, AC927 at 0.3 µM led to
a reduction in basal ROS in NG108-15 cells, the reduction becoming statistically significant at
240 min (t = 3.78, p < 0.01), 480 min (t = 2.87, p < 0.05) and up to 1440 min (t = 4.38, p <
0.001).
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Figure 4.3 Dose response and time course of AC927-induced ROS/RNS generation. The
production of ROS capable of oxidizing CM-H2DCFDA was conducted as described in the materials and
methods in NG108-15 cells following exposure to 100 µM H2O2, 100 µM Na2Cr2O7 (Cr), or 0 to 300 µM
AC927. Relative fluorescence units from two separate experiments obtained at each indicated time
point are shown; data were normalized to the mean rfu for untreated cells to obtain percent control
values (n = 8/experiment) ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control treatment.
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As shown in Figure 4.4, 0.3 µM AC927 attenuated the production of reactive radicals
induced by METH, reducing them to levels observed in untreated control cells for all tested
concentrations of METH except the highest (300 µM); data shown here were obtained 20 min
following stimulation with METH. Two-way ANOVA showed a significant effect of AC927
pretreatment (F(1,138) = 98.44, p < 0.0001), METH or positive control treatment (F(10,138) =
15.63, p < 0.0001) and AC927 pretreatment × METH or positive control treatment interaction
(F(10,138) = 2.39, p < 0.05). Bonferroni’s post-hoc tests showed that the AC927 attenuated
ROS/RNS generated by following METH concentrations: 0.1 µM (t = 3.28, p < 0.05), 0.3 µM (t
= 3.16, p < 0.05), 1 µM (t = 3.52, p < 0.01), 3 µM (t = 7.16, p < 0.001), 10 µM (t = 3.99, p <
0.01), 30 µM (t = 3.14, p < 0.05), 100 µM (t = 3.39, p < 0.05) and 300 µM (t = 3.84, p < 0.01).
As expected, AC927 did not inhibit the oxidation of the dye by exogenously added H2O2 (t =
1.39, ns). It also failed to significantly inhibit the small amount of ROS generated by Na2Cr2O7
at this time point (t = 0.99, ns). However, at later time points, AC927 inhibited ROS induction
by Na2Cr2O7 as seen at 4 hr (t = 4.05, p < 0.001) and 24 hr (t = 7.73, p < 0.001).
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Figure 4.4 Effect of AC927 pretreatment on METH-induced ROS/RNS generation.
Inhibition of methamphetamine (METH)-induced ROS generation in NG108-15 cells by AC927. The
production of ROS capable of oxidizing CM-H2DCFDA was assessed in differentiated NG108-15 cells in
the presence of 0 to 300 µM METH, 100 µM H2O2 or 100 µM Na2Cr2O7 (Cr) in the absence (solid bars)
or presence (gray bars) of 0.3 µM AC927 as described in the methods. Data represent averages of
relative fluorescence units from two different experiments (n = 8/experiment) obtained 20 min after
addition of drug ± SEM. Significant differences are noted as **p < 0.01 (control vs. METH treated) and
#p < 0.05, ##p < 0.01, ###p < 0.001 (METH alone vs. METH with AC927).
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4.3.2. Dopamine release assay: As shown in Figure 4.5, in untreated cells, 0.0-41.85 pg of
dopamine was detected. In contrast, when cells were treated with KCl, 268.30-389.62 pg of
dopamine was detected in the culture supernatant 5 min following exposure.
Dopamine secretion was induced by all four concentrations of METH ranging from 0.3
to 300 µM, with 3 µM METH inducing maximum secretion with 204.75-413.12 pg per 1.5 x 105
cells, compared to that in untreated control cells. One-way ANOVA showed a significant effect
of METH treatment (F(5,23) = 8.87, p < 0.001). Post-hoc Dunnett’s tests show that the 0.3 and
3 µM of METH caused a significant increase in dopamine release (q = 2.77, p < 0.05 and q =
5.32, p < 0.01). KCl (50 µM) also caused a significant increase in dopamine release (q = 5.78,
p < 0.01).
In cells exposed to 0.3 µM AC927 for 5 min, dopamine levels were not significantly
different from those in untreated controls (F(5,18) = 0.20, ns). Two-way ANOVA showed a
significant effect of METH and KCl treatment (F(5,30) = 19.39, p < 0.0001), AC927
pretreatment (F(1,30) = 32.21, p < 0.0001) and AC927 pretreatment × METH and KCl
treatment interaction (F(5,30) = 4.86, p < 0.005). Bonferroni’s post-hoc tests confirm that
AC927 pretreatment attenuates dopamine release caused by 0.3 and 3 µM METH (t = 3.19, p
< 0.05 and t = 5.58, p < 0.001 respectively). Pretreatment of cells with AC927 did not
however, block the release of dopamine in cells treated with KCl (t = 0.23, p < 0.05).
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Figure 4.5 Effect of AC927 pretreatment on METH-induced dopamine release. Release of
dopamine in response to methamphetamine (METH) from NG108-15 cells. Supernatants harvested
from NG108-15 cells cultured in the presence or absence of METH and/or AC927 (x-axis) and
quantitated as described in the materials and methods are represented as pg dopamine per 1.5 x 10

5

cells in 500 µl of medium. Data represent means from four (METH or KCl alone) or three (METH with
AC927) independent experiments ± SEM. Significant differences are noted as follows, *p < 0.05, **p <
0.01 (control vs. METH or KCl treated) and #p < 0.05, ###p < 0.001 (METH alone vs. METH with
AC927).
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4.3.3. Hoechst and propidium iodide staining: The apoptotic effects of various
concentrations of METH (0-1 mM) on NG108-15 cells over a period of 24 hr are shown in
Figure 4.6A. One-way ANOVA showed that METH caused a significant and concentration
dependent increase in the percentage of apoptotic cells (F(7,187) = 37.21, p < 0.0001). Posthoc analysis employing Dunnett’s tests showed that the following concentrations of METH
caused significant increases in apoptosis when compared with controls: 3 µM (q = 2.87, p <
0.05), 10 µM (q = 3.74, p < 0.01), 100 µM (q = 5.99, p < 0.001), 300 µM (q = 7.73, p < 0.001),
and 1000 µM (q = 13.68, p < 0.001).
AC927 pretreatment significantly attenuated the apoptotic effects of METH. Two-way
ANOVA showed a significant effect of METH treatment (F(6,392) = 37.82, p < 0.0001), AC927
pretreatment (F(3,392) = 55.94, p < 0.0001) and METH treatment × AC927 pretreatment
interaction (F(18,392) = 5.41, p < 0.0001). Post-hoc Bonferroni’s tests showed that AC927
(0.3, 3 and 30 µM) attenuated the apoptotic effects of METH. AC927 (0.3 µM) attenuated the
apoptotic effects of the following concentrations of METH: 3 µM (t = 3.34, p < 0.01), 10 µM (t =
3.70, p < 0.01), 100 µM (t = 5.05, p < 0.001), 300 µM (t = 5.85, p < 0.001), and 1000 µM (t =
9.80, p < 0.001). AC927 (3 µM) prevented the apoptotic effects of the following concentrations
of METH: 10 µM (t = 3.52, p < 0.01), 100 µM (t = 3.45, p < 0.01), 300 µM (t = 5.67, p < 0.001),
and 1000 µM (t = 8.84, p < 0.001). AC927 (30 µM) attenuated the apoptotic effects of the
following concentrations of METH: 100 µM (t = 3.20, p < 0.05), 300 µM (t = 3.00, p < 0.05),
and 1000 µM (t = 7.82, p < 0.001).
The necrotic effects of various concentrations of METH (0-1 mM) on NG108-15 cells
over a period of 24 hr are shown in Figure 4.6B. One-way ANOVA showed that METH caused
a significant and concentration dependent increase in the percentage of necrotic cells
(F(7,187) = 7.35, p < 0.0001). Post-hoc analysis employing Dunnett’s tests showed that the
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following concentrations of METH caused significant increases in necrosis when compared
with no treatment controls: 300 µM (q = 3.82, p < 0.01) and 1000 µM (q = 5.88, p < 0.01).
AC927 pretreatment significantly attenuated the necrotic effects of METH. Two-way
ANOVA showed a significant effect of METH treatment (F[6,392] = 8.32, p < 0.0001) and
AC927 pretreatment (F(3,392) = 17.14, p < 0.0001). Post-hoc Bonferroni’s tests showed that
the following concentrations of AC927 attenuated the necrotic effects of METH (300 and 1000
µM): 0.3 µM, t = 4.33, p < 0.001 and t = 4.26, p < 0.001; 3 µM, t = 3.30, p < 0.01 and t = 3.91,
p < 0.001; 30 µM, t = 3.29, p < 0.01 and t = 2.87, p < 0.05.
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Figure 4.6 Effect of AC927 pretreatment on METH-induced (A) apoptosis and (B)
necrosis. AC927 protects against methamphetamine (METH)-induced apoptosis (A) and necrosis (B).
NG108-15 cells were pretreated with AC927 (0-30 µM) prior to exposure to METH (0-1 mM) for 24 hr.
After 24 hr, the wells were incubated with Hoechst 33342 and propidium iodide stains (20 µg/ml each)
to obtain percentages of apoptotic and necrotic cells. Data represent means from two separate
experiments (n = 3/experiment) ± SEM. Significant differences are indicated by *p < 0.05, **p < 0.01,
***p < 0.001 (control vs. METH treated); #p < 0.05, ##p < 0.01, ###p < 0.001 (METH alone vs. METH
with AC927).
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4.4 Discussion
This study showed that METH causes apoptosis in differentiated NG108-15 cells at
physiologically relevant micromolar concentrations and can cause necrosis at higher
concentrations. At earlier time points, ROS/RNS generation and release of dopamine were
also observed. AC927, a σ receptor ligand, attenuated the apoptotic and necrotic cell death as
well as the neurotoxicity mediators. The implications of these findings are further discussed
below.
One of the key mediators of METH’s neurotoxicity is ROS/RNS generation, which can
occur through multiple mechanisms including excessive dopamine release, microglial
activation, glutamate release, and mitochondrial dysfunction (Krasnova and Cadet, 2009).
Excessive generation of ROS/RNS can injure neurons and surrounding cells via direct
oxidative damage to cellular components such as lipids, proteins, and DNA, or by causing ER
stress and activation of mitochondrial death cascades, ultimately leading to nerve terminal
degeneration or cell death (Krasnova and Cadet, 2009). This study demonstrated that METH
generates ROS/RNS in the NG108-15 model system. All tested concentrations of METH
ranging from 0.1 to 300 µM induced the production of ROS/RNS within 10 min of exposure.
High and stable ROS/RNS levels were detected at 20 min and up to 60 min after exposure of
NG108-15 cells to METH. After the first hour, the levels of ROS/RNS decreased, indicating
that the cells may shift to the production of radicals not detected by CM-H2DCFDA.
Alternately, in METH-treated cells, endogenous peroxidases as well as antioxidants such as
glutathione may be rapidly recruited after the first hour to scavenge H2O2 and ·ONOOradicals.
At the early time point (20 min) that gave consistent and robust ROS/RNS signals
following METH administration, the antioxidant NAC reduced the signal indicating that the
fluorescent probe CM-H2DCFDA was detecting ROS/RNS. In addition, catalase and L-NMMA
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also decreased the METH-induced signal indicating that H2O2 and NO species were being
generated. This result is consistent with the ability of METH to generate H2O2 and NO species
from various sources including dopamine oxidation and glutamate-induced NOS activation
(Krasnova and Cadet, 2009). It is also interesting to note that the dose response of METHinduced reactive species generation did not follow a classical sigmoidal pattern, displaying
highest radical generation at the 3 µM concentration. This pattern of results is most likely due
to multiple mechanisms and sources of METH’s ROS/RNS generation (Krasnova and Cadet,
2009).
AC927 pretreatment attenuated the ROS/RNS generated by METH. This effect of
AC927 does not seem to be a general antioxidant effect because AC927 did not prevent the
H2O2-mediated ROS signal or reduce the basal cellular ROS/RNS signal. However, at the 4 hr
time point onwards, AC927 (0.3 µM) attenuated the basal cellular ROS/RNS levels as well as
the ROS signal produced by Na2Cr2O7. Na2Cr2O7 generates ·O2-, H2O2 and .OH- in the cell
(Azad et al., 2008). In combination with NO, ·O2- can produce ·ONOO- in the cell. The ability of
AC927 to attenuate the ROS signal produced by Na2Cr2O7 and not H2O2 is most likely due to
increased levels of cellular antioxidant/antioxidant enzymes like superoxide dismutase which
can reduce superoxide levels in the cell, or decreased levels of enzymes like NOS which can
generate NO leading to the production of ·ONOO-. Since this effect of AC927 is observed after
4 hr and not before, it suggests the induction of cellular antioxidants or a decrease in prooxidant/nitrosative stress enzymes, rather than the effect of generalized intrinsic antioxidant
activity.
Corroborating with this interpretation, several studies in the literature demonstrate the
ability of σ receptors to modulate cellular ROS/RNS generation and antioxidant systems.
Previous studies in tumor cells have shown that σ2 receptor activation causes ROS generation
(Ostenfeld et al., 2005). σ1 Receptors are also involved in oxidative stress-mediated toxicities
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like ischemic stroke and have been shown to provide protective effects (Schetz et al., 2007). σ
Receptors also play a regulatory role in the redox state of the cell, and can modulate cellular
NOS enzyme activity (Vagnerova et al., 2006; Tsai et al., 2009; Yang et al., 2010). In addition
to modulating the cellular redox system, σ receptors can also regulate other systems that are
involved in ROS/RNS generation by METH. First, σ receptors can regulate glutamate release
through NMDA receptors which in turn causes nNOS activation and nitrosative stress
(DeCoster et al., 1995). Second, σ receptors can modulate microglial activation through Ca2+
dependent mechanisms, which can contribute to the release of inflammatory cytokines and
ROS/RNS generation (Hall et al., 2009). Third, σ receptors can regulate the release of
dopamine which in turn undergoes autooxidation and is a major cause of METH’s ROS
generation (Gonzalez-Alvear and Werling, 1994; Derbez et al., 2002).
Although additional studies are needed to identify the specific mechanism(s) through
which AC927 reduces the generation of METH-induced ROS/RNS, the studies conducted
herein suggest that the modulation of dopamine release may be an important contributor.
AC927 attenuates METH-induced dopamine release from the NG108-15 cells, with peak
release observed at the 3 µM concentration of METH which is consistent with the peak
observed in the ROS assay. Moreover, AC927 pretreatment prevented the dopamine release
caused by METH, but not the non-specific dopamine release caused by K+-mediated
hyperpolarization. This is consistent with the role of σ receptors in regulating DAT function and
dopamine release in several in vivo and in vitro studies, including the involvement of Ca2+dependent and protein kinase C-mediated mechanisms (Booth and Baldessarini, 1991;
Derbez et al., 2002).
METH also caused apoptosis and necrosis in NG108-15 cells. Oxidative and
nitrosative stress in the cell can lead to the activation of pro death pathways like mitochondrial
release of cytochrome c, and/or caspase 3 activation which ultimately leads to apoptotic or
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necrotic cell death (Higuchi et al., 1998). AC927 significantly attenuated both the apoptotic
and necrotic cell death which is consistent with the role of σ receptors in cell death
mechanisms (Bowen, 2000; Marrazzo et al., 2011). Furthermore, the protective effects of
AC927 observed in NG108-15 cells is complementary and consistent with the neuroprotection
observed in earlier in vivo studies (Matsumoto et al., 2008; Seminerio et al., 2011). Moreover,
in tumor cells, AC927 has been shown to prevent apoptosis caused by σ2 receptor agonists,
further underscoring an important role of σ receptors in cell death mechanisms (Marrazzo et
al., 2011).
Apart from σ receptors, D1 receptor antagonism can also protect against the apoptotic
effects of METH (Jayanthi et al., 2005). Recent studies have shown that σ1 and D1 receptors
heteromerize in cells, which has implications for the downstream effects of psychostimulants
including the activation of adenyl cyclase and MAPK pathways (Navarro et al., 2010).
Therefore, AC927 may potentially modulate the σ1 and D1 interaction and mitigate the toxic
effects of METH.
In summary, the data in this chapter demonstrates that METH can cause apoptosis
and necrosis in an in vitro system representative of a differentiated neuronal cell, which
mechanistically involves dopamine release and induction of reactive oxygen/nitrogen radicals.
Additionally, a synthetic σ ligand, AC927, can attenuate the cytotoxic effects of METH and
contributing neurotoxic mechanisms. Future studies will be directed towards the elucidation of
the downstream neurotoxic pathways activated after ROS/RNS generation in differentiated
NG108-15 cells. Also, the individual contributions of the two subtypes of σ receptors will have
to be discerned, as better tools are developed.

4.5 Contributions: Nidhi Kaushal conducted the apoptosis and necrosis assays. Dr. Meenal
Elliott performed the dopamine release assay and the ROS assay.
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CHAPTER 5
EVALUATION OF SN79 AGAINST METH AND ELEVATED
TEMPERATURE-INDUCED NEUROTOXICITY: IN VITRO STUDIES
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5.1 Introduction
METH is known to cause cell death in various brain regions as well as in vitro cell culture
system (Krasnova and Cadet, 2009). Previous in vivo studies have shown that pretreatment of
σ receptor antagonists attenuated the neurotoxic effects of METH in male, Swiss Webster
mice (Matsumoto et al., 2007; Kaushal et al., 2011b; Seminerio et al., 2011). Nevertheless,
the role of σ-receptors in neurotoxicity resulting from drugs of abuse like METH remained
unclear due to various limitations, including the lack of a suitable in vitro model system. In
chapter 4, differentiated NG108-15 cells were used to identify some of the most well studied
mechanisms of METH-induced neurotoxicity: ROS/RNS generation and dopamine release.
Notably, the concentrations of METH used to cause apoptosis and the activation of these
neurotoxicity mediators were within the physiologically relevant micromolar concentrations.
AC927, a sigma receptor antagonist attenuated METH-induced neurotoxicity (apoptosis and
necrosis), and its mediators like ROS/RNS generation and dopamine release. In that study,
AC927 was the only compound to be tested. In order to confirm that the protective effects
observed were mediated through sigma receptors, another sigma receptor antagonist needed
to be tested. SN79, with its long half-life and low propensity for toxicity is a better drug
candidate than AC927. In this study, SN79 was therefore tested against METH-induced cell
death (apoptosis and necrosis) and its mediators like ROS/RNS generation to confirm the
pattern of results obtained with AC927. If a sigma receptor antagonist attenuates the
neurotoxic effects of METH, the agonist is expected to enhance the toxicity. With this
hypothesis, DTG (a sigma receptor agonist) was tested against METH-induced cell death and
shifts in dose response curve of METH-induced cell death were evaluated. In addition to
testing SN79 against METH-induced cell death and ROS/RNS generation; in this study
additional mechanisms of METH-induced apoptotic cell death in differentiated NG108-15 cells
were identified. The mechanisms looked into were caspase dependence or independence
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(caspase-3 activation), as well as activation of intrinsic (caspase-9 activation) or extrinsic
apoptotic pathway (caspase-8 activation).
In addition to identifying the sigma receptor sensitive mechanisms of METH-induced
neurotoxicity, it is also important to evaluate the contribution of elevated temperature as
observed during METH administration during in vivo studies. Although the exact mechanism
of hyperthermic effects of METH is not clear, release of inflammatory cytokines like IL-1β from
microglial cells, ROS/RNS generation are thought to be contributing factors (Bowyer et al.,
1994; Imam et al., 1999; Riedel and Maulik, 1999; Yamashita et al., 2000; Fukami et al.,
2004). This increase in body temperature in turn can potentially exacerbate the neurotoxic
effects of METH by altering blood brain barrier permeability, increasing DAT function and
ROS/RNS production (Fleckenstein et al., 1997; Xie et al., 2000; Kiyatkin et al., 2007;
Numachi et al., 2007; Sharma et al., 2007).
However, it is very difficult to identify the individual contribution of METH and hyperthermia,
and their interaction at the cellular level in the brain in a complex in vivo system. This also
translates to the difficulty in identifying the mechanism of action of neuroprotective
pharmacological strategies in vivo. Therefore, in this study a differentiated NG108-15 model
system was maintained at 37 and 40 °C and then treated with METH to provide information
about the contribution of hyperthermia and METH separately and also their interaction
towards cell death (apoptosis and necrosis). In addition, sigma receptor antagonist, SN79 was
given as a pretreatment to understand which of these components can be modulated.

5.2 Materials and Methods
5.2.1. Cell line and culture
5.2.1.1. Cell growth: The neuroblastoma x glioma, hybridoma cell line NG108-15
(Hamprecht et al., 1985) were obtained from ATCC (Rockville, MD). Cells were maintained in
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25 cm2 (T25) or 75 cm2 (T75) culture flasks (Corning-Costar, Lowell, MA) in hi-glucose (4.5
g/L) DMEM (Dulbecco’s modified Eagle’s medium) supplemented with 10% FBS (fetal bovine
serum), penicillin, streptomycin, and HAT (hypoxanthine-aminopterin-thymidine) at 37⁰C in a
humidified incubator in 5% CO2.
5.2.1.2. Cell differentiation: Culture medium was replaced with differentiation medium
(DMEM with 0.5% FBS, penicillin, streptomycin, HAT and 1% DMSO) and the cells allowed to
grow for a further 3-4 days.
5.2.2 Hoechst and propidium iodide staining: NG108-15 cells were grown and
differentiated in 96-well culture plates and four types of experiments were conducted: 1) SN79
and METH: Cells were exposed to various concentrations of METH (0-1 mM), SN79 (1-100
nM), SN79 (1-100 nM)+METH (0-1 mM) for 24 hrs at 37 °C. 2) DTG and METH: Cells were
exposed to various concentrations of METH (0-1 mM), DTG (0.1 nM-10 µM), DTG (0.1 nM-10
µM) + METH (0-1 mM) for 24 hrs at 37 °C. 3) METH treatment at 37 or 40 °C: Cells were
exposed to various concentrations of METH (0-1 mM) at either 37 or 40 °C. 4) SN79 and
METH: Cells were exposed to various concentrations of METH (0-1 mM), SN79 (1-100 nM),
SN79 (1-100 nM)+METH (0-1 mM) for 24 hrs at 40 °C. Hoechst stain (20 µg/ml final
concentration) and propidium iodide stain (20 µg/ml final concentration) were added to each
well and incubated at room temperature for 10 min. Three images are taken/well using an UV
light microscope. Cells with brightly stained and fragmented nuclei were counted as apoptotic
and cells that were red were counted as necrotic. The percentage of apoptotic and necrotic
cells were counted with the help of Image J cell counter (NIH). The sum of percentage of
apoptotic and necrotic cells was referred to as “total cell death”.
5.2.3 MTT assay: NG108-15 cells grown and differentiated in 96-well culture plates were
exposed to various concentrations of METH (0-10 mM), SN79 (0.1 -300 nM) or SN79 (0.1 –
300 nM) + METH (1 mM) for 24 hrs. After incubation at 37 ⁰C for the specified times, 10 µl
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MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) freshly prepared in PBS
was added to the wells at a final concentration of 50 µg/ml and the plates were incubated at
37 ⁰C for a further 4 hr. 100 µl of solubilization solution (10% SDS in 0.1N HCl) was then
added to each well and the plates incubated overnight. Absorbance was read at 570 nm with
a reference wavelength of 690 nm. Percent cell viability was computed by dividing average
absorbance values for experimental wells to average absorbance values for cells in untreated
control wells.
5.2.4 Trypan blue exclusion assay: Cells were grown and differentiated in 6-well plates. On
the day of the experiment, the differentiation media was changed to phenol red free
differentiation media with various concentrations of METH (0-3 mM), SN79 (1 -30 nM) or
SN79 (1 – 30 nM)+METH (1 mM) for 24 hrs. The media was removed and the cells detached
using Trypsin-EDTA and then mixed with media. 10 µl of trypan blue dye and 10 µl of cell
mixture were mixed and the number of total, live and dead cells was counted using a
Countess Automated Cell Counter (Invitrogen, Carlsbad, CA).
5.2.5 Caspase-3, -9 and -8 assay: NG108-15 cells were grown and differentiated in 96-well
culture plates and time course and inhibition studies were conducted: 1) Time course: Cells
were exposed to various concentrations of METH (0-1 mM) for 1.5, 3, 6, 9, 12, 18 and 24 hrs.
2) Inhibition: The cells were treated with either METH (0-1 mM), SN79 (1-100 nM) or SN79 (1100 nM)+METH (0-1 mM) for the time point at which a peak response was observed for
caspase-3, -9 or -8 activation. At appropriate time points for the time course or inhibition
studies, reagents from the Caspase-Glo luminescence assay kit for caspase 3/7, -9, -8
(Invitrogen, Carlsbad, CA) were added to the wells and incubated for 2 hrs. The plate was
read using a luminescence plate reader. The no cell blank readings were subtracted from all
the treatment readings. The results were expressed as % untreated control cells at that time
point.
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5.2.6 Reactive oxygen/nitrogen species: Cells grown and differentiated in 96 well plate (104
cells per well). The culture medium was replaced phenol red free medium containing 0.5%
FBS and 5 µM fluorigenic, oxidizable, dye CM-H2DCFDA (5-(and-6)-chloromethyl-2’,7’dichlorodihydrofluorescein diacetate) and returned to the incubator at 37 ⁰C for 45-60 min.
Cells were treated with appropriate concentrations of METH or SN79. Exogenously added 100
µM H2O2 and Na2Cr2O7 served as a positive control in this assay. All compounds were added
in replicates of 4 or 8 and the plates are returned to the incubator. In the assay, SN79 (1-100
nM), N-acetylcysteine (NAC, 10 mM), catalase (10000 units per ml), L-NMMA (200 µM) were
added 15 min prior to the addition of METH (0.1-3000 µM), H2O2 (100 µM) or Na2Cr2O7 (100
µM). At specified time points, plates were read in a Fluostar Optima fluorescence plate reader
fitted with a 485/520 nm excitation/emission filter set (BMG Labtech GmbH, Offenberg,
Germany).
5.2.7 Statistical analysis: Statistical analysis of data was performed using ANOVA with
appropriate post-hoc tests employing GraphPad Prism 4 (GraphPad Software, San Diego,
CA).

5.3 Results
5.3.1 Apoptosis/Necrosis:
5.3.1.1. SN79 and METH:
Apoptosis: One-way ANOVA showed that METH treatment caused a significant
increase in the percentage of apoptotic cells (F(7,192) = 22.14, p < 0.0001). Post-hoc
Dunnett’s tests confirmed that the following concentrations of METH caused a significant
increase in the percentage of apoptotic cells: 10 µM (q = 3.79, p < 0.01), 30 µM (q = 5.09, p <
0.001), 100 µM (q = 7.15, p < 0.01), 300 µM (q = 7.72, p < 0.01) and 1000 µM (q = 9.77, p <
0.01). SN79 pretreatment significantly attenuated the apoptotic effects of METH (Figure 5.1A).
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Two-way ANOVA showed a significant effect of METH treatment (F(7,538) = 14.63, p <
0.0001), SN79 pretreatment (F(3,538) = 100.90, p < 0.0001), and SN79 pretreatment × METH
treatment (F(21,538) = 6.47, p < 0.0001). Bonferroni’s post-hoc tests showed that SN79 (1, 10
and 100 nM) pretreatment is able to attenuate the apoptotic effects of the following
concentrations of METH: 3 µM (t = 2.80, p < 0.05 and t = 3.07, p < 0.05), 10 µM (t = 4.36, p <
0.001; t = 4.59, p < 0.001 and t = 4.61, p < 0.001 respectively), 30 µM (t = 5.78, p < 0.001; t =
5.32, p < 0.001 and t = 5.59, p < 0.001 respectively), 100 µM (t = 6.40, p < 0.001; t = 6.70, p <
0.001 and t = 8.21, p < 0.001 respectively), 300 µM (t = 5.48, p < 0.001; t = 7.30, p < 0.001
and t = 7.64, p < 0.001 respectively) and 1000 µM (t = 11.00, p < 0.001; t = 9.52, p < 0.001
and t = 10.52, p < 0.001 respectively).
Necrosis: One-way ANOVA showed that METH treatment caused a significant
increase in the percentage of necrotic cells (F(7,192) = 8.28, p < 0.0001). Post-hoc Dunnett’s
tests confirmed that 300 and 1000 µM METH caused a significant increase in the percentage
of necrotic cells (q = 4.45, p < 0.01 and q = 6.31, p < 0.01 respectively). SN79 pretreatment
significantly attenuated the necrotic effects of METH (Figure 5.1B). Two-way ANOVA showed
a significant effect of SN79 pretreatment (F(3,538) = 14.71, p < 0.0001), METH treatment
(F(7,538) = 6.98, p < 0.0001) and SN79 pretreatment × METH treatment interaction
(F(21,538) = 1.82, p < 0.05). Post-hoc Bonferroni’s test confirmed that the following
concentrations of SN79 attenuate the necrotic effects of 300 µM (1 nM: t = 3.12, p < 0.05; 10
nM: t = 3.57, p < 0.01; 100 nM: t = 2.98, p < 0.05) and 1000 µM METH (1 nM: t = 4.31, p <
0.001; 10 nM: t = 2.85, p < 0.05; 100 nM: t = 5.89, p < 0.001).
Total cell death: One-way ANOVA showed that METH treatment caused a significant
increase in the percentage of total cell death (F(7,192) = 29.26, p < 0.0001). Post-hoc
Dunnett’s tests confirmed that the following concentrations of METH caused a significant
increase in the percentage of total cell death: 10 µM (q = 3.63, p < 0.01), 30 µM (q = 5.55, p <
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0.01), 100 µM (q = 6.68, p < 0.01), 300 µM (q = 8.84, p < 0.01) and 1000 µM (q = 11.71, p <
0.01). SN79 pretreatment significantly attenuated METH-induced cell death (Figure 5.1C).
Two-way ANOVA showed a significant effect of SN79 pretreatment (F(3,539) = 73.49, p <
0.0001), METH treatment (F(7,539) = 15.85, p < 0.0001) and SN79 pretreatment × METH
treatment interaction (F(21,539) = 5.41, p < 0.0001). Post-hoc Bonferroni’s test confirmed that
the following concentrations of SN79 attenuate cell death caused by 10 µM (1 nM: t = 3.52, p
< 0.05; 10 nM: t = 3.67, p < 0.01; 100 nM: t = 3.60, p < 0.01), 30 µM (1 nM: t = 4.79, p <
0.0001; 10 nM: t = 5.08, p < 0.0001; 100 nM: t = 4.90, p < 0.0001), 100 µM (1 nM: t = 4.52, p <
0.001; 10 nM: t = 5.06, p < 0.0001; 100 nM: t = 6.65, p < 0.0001), 300 µM (1 nM: t = 5.47, p <
0.0001; 10 nM: t = 6.84, p < 0.0001; 100 nM: t = 6.59, p < 0.0001) and 1000 µM METH (1 nM:
t = 9.52, p < 0.0001; 10 nM: t = 7.58, p < 0.0001; 100 nM: t = 10.42, p < 0.0001).
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Figure 5.1 Effect of SN79 pretreatment on METH-induced (A) apoptosis, (B) necrosis
and (C) total cell death. SN79 protects against methamphetamine (METH)-induced apoptosis (A),
necrosis (B) and total cell death (C). Differentiated NG108-15 cells were pretreated with SN79 (0-100
nM) prior to exposure to METH (0-1 mM) for 24 hr. After 24 hr, the wells were incubated with Hoechst
33342 and propidium iodide stains (20 µg/ml each) to obtain percentages of apoptotic and necrotic
cells. Total cell death = Apoptotic cell death + Necrotic cell death. Data represent means from three
separate experiments (n = 3/experiment) ± SEM. Significant differences are indicated by **p < 0.01
(control vs. METH treated); #p < 0.05, ##p < 0.01, ###p < 0.001 (METH alone vs. METH with SN79).

103

5.3.1.2. DTG and METH:
Apoptosis: METH treatment on its own caused a significant increase in apoptotic cell
death in differentiated NG108-15 cells. One way ANOVA showed a significant effect of METH
treatment (F(6,244) = 22.51, p < 0.0001). Dunnett’s post-hoc tests confirmed that the following
concentrations of METH cause a significant increase in apoptosis: 10 µM (q = 3.29, p < 0.01),
100 µM (q = 6.94, p < 0.01) and 1000 µM (q = 9.85, p < 0.01).
Figure 5.2A shows that DTG pretreatment displayed a trend towards a shift in the dose
response curve of METH-induced apoptosis towards the left; however, the effect was not
significant. Two way ANOVA shows a significant effect of METH treatment (F(6,889) = 37.83,
p < 0.0001) and DTG pretreatment (F(6,889) = 7.49, p < 0.0001) but METH treatment×DTG
pretreatment interaction was not significant (F(36,889) = 0.68, n.s.). Bonferroni’s post-hoc
tests show that DTG pretreatment at 10 nM and 1 µM with METH 1 µM concentration was
significantly different than METH 1 µM treatment alone (t = 2.92, p < 0.05 and t = 2.88, p <
0.05 respectively).
Necrosis: METH treatment on its own caused a significant increase in necrotic cell
death in differentiated NG108-15 cells. One way ANOVA showed a significant effect of METH
treatment (F(6,249) = 48.59, p < 0.0001). Dunnett’s post-hoc tests confirmed that METH 1000
µM caused a significant increase in necrosis (q = 14.25, p < 0.01).
Figure 5.2B shows that DTG pretreatment at intermediate concentrations shifts the
dose response curve of METH towards the left, and at even higher concentrations shows an
upward and leftward shift in the dose response curve. Two way ANOVA showed a significant
effect of METH treatment (F(6,948) = 55.75, p < 0.0001), DTG pretreatment (F(6,948) =
77.15, p < 0.0001) and METH treatment × DTG pretreatment interaction (F(36,6) = 1.80, p <
0.005). Bonferroni’s post-hoc tests confirm that the following concentrations of DTG in
combination with METH are significantly different than METH treatment alone: DTG 10 nM (10
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µM: t = 3.07, p < 0.05 and 100 µM: t = 4.59, p < 0.001), DTG 100 nM (0.01 µM: t = 2.78, p <
0.05; 0.1 µM: t = 2.75, p < 0.05; 1 µM: t = 5.44, p < 0.001; 10 µM: t = 5.07, p < 0.001 and 100
µM: t = 7.01, p < 0.001), DTG 1 µM (0 µM: t = 2.85, p < 0.05; 1 µM: t = 7.39, p < 0.001; 10 µM:
t = 7.92, p < 0.001; 100 µM: t = 9.33, p < 0.001 and 1000 µM: t = 4.02, p < 0.001), DTG 10
µM (0 µM: t = 6.87, p < 0.001; 0.01 µM: t = 4.49, p < 0.001; 0.1 µM: t = 5.18, p < 0.001; 1 µM:
t = 7.07, p < 0.001; 10 µM: t = 8.31, p < 0.001; 100 µM: t = 10.08, p < 0.001 and 1000 µM: t =
5.21, p < 0.001).
Total cell death: METH treatment on its own caused a significant increase in cell death
in differentiated NG108-15 cells. One way ANOVA showed a significant effect of METH
treatment (F(6,249) = 62.50, p < 0.0001). Dunnett’s post-hoc tests confirmed that the following
concentrations of METH caused a significant increase in total cell death: 1 µM (q = 3.15, p <
0.05), 10 µM (q = 3.54, p < 0.01), 100 µM (q = 6.48, p < 0.01) and 1000 µM (q = 16.97, p <
0.01). Figure 5.2C shows that DTG pretreatment at intermediate concentrations shifted the
dose response curve of METH-induced cell death towards the left and at even higher
concentrations displayed an upward and leftward shift in the dose response curve. Two way
ANOVA showed a significant effect of METH treatment (F(6,948) = 88.73, p < 0.0001), DTG
pretreatment (F(6,948) = 46.62, p < 0.0001) and METH treatment × DTG pretreatment
interaction (F(36,946) = 1.69, p < 0.01). Bonferroni’s post-hoc tests confirm that the following
concentrations of DTG in combination with METH are significantly different than METH
treatment alone: DTG 10 nM (1 µM: t = 3.02, p < 0.05; 10 µM: t = 3.75, p < 0.01 and 100 µM: t
= 5.22, p < 0.001), DTG 100 nM (0.1 µM: t = 2.89, p < 0.05; 1 µM: t = 4.23, p < 0.001; 10 µM: t
= 5.52, p < 0.001 and 100 µM: t = 5.25, p < 0.001), DTG 1 µM (0 µM: t = 3.29, p < 0.01; 1 µM:
t = 7.07, p < 0.001; 10 µM: t = 6.14, p < 0.001; 100 µM: t = 7.63, p < 0.001 and 1000 µM: t =
3.35, p < 0.001), DTG 10 µM (0 µM: t = 5.76, p < 0.001; 0.01 µM: t = 3.30, p < 0.01; 0.1 µM: t
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= 3.44, p < 0.01; 1 µM: t = 5.75, p < 0.001; 10 µM: t = 7.23, p < 0.001; 100 µM: t = 7.62, p <
0.001 and 1000 µM: t = 5.27, p < 0.001).
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Figure 5.2 Effect of DTG pretreatment on METH-induced (A) apoptosis, (B) necrosis and (C) total
cell death. NG108-15 cells were exposed to DTG (0.1 nM-10 µM) and/or METH (0-1000 µM) for 24 hr.
After 24 hr, the wells were incubated with Hoechst 33342 and propidium iodide stains (20 µg/ml each)
to obtain percentages of apoptotic and necrotic cells. Total cell death = Apoptotic cell death + Necrotic
cell death. Data represent means from two separate experiments (n = 3/experiment) ± SEM. Significant
differences are indicated by *p < 0.05, **p < 0.01 (control vs. METH); ##p < 0.01, ###p < 0.001
(DTG+METH vs. METH).
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5.3.1.3. METH treatment at 37 and 40 °C
Apoptosis: METH treatment caused a significant increase in apoptotic cell death in
NG108-15 cells maintained at 37 °C. One way ANOVA showed a significant effect of METH
treatment (F(9,436) = 33.37, p < 0.0001). Dunnett’s post-hoc tests confirmed that the following
concentrations of METH caused a significant increase in apoptosis when compared to no
treatment control cells: 10 µM (q = 4.77, p < 0.01), 30 µM (q = 6.38, p < 0.01), 100 µM (q =
9.56, p < 0.01), 300 µM (q = 9.93, p < 0.01) and 1000 µM (q = 13.30, p < 0.01).
METH treatment at elevated temperature of 40 °C caused a significant increase in
apoptotic cell death when compared to control cells maintained at the same temperature. One
way ANOVA showed a significant effect of METH treatment (F(9,217) = 5.80, p < 0.0001).
Dunnett’s post-hoc tests confirmed that the following concentrations of METH caused a
significant increase in apoptosis when compared to control cells maintained at 40 °C: 10 µM
(q = 3.70, p < 0.01), 30 µM (q = 3.42, p < 0.01), 100 µM (q = 4.60, p < 0.01), 300 µM (q =
4.31, p < 0.01) and 1000 µM (q = 5.16, p < 0.01).
On comparing the METH treated NG108-15 cells at 37 and 40 °C, it was observed that cells
maintained at 40 °C had a higher percentage of apoptotic cells in the no treatment control as
well as METH treatment when compared with the cells maintained at 37 °C (Figure 5.3A). The
dose response of METH at 40 °C shows a parallel and upward shift in apoptotic cell death.
Two way ANOVA showed a significant effect of METH treatment (F(9,635) = 21.52, p <
0.0001) and temperature (F(1,635) = 31.49, p < 0.0001). Bonferroni’s post-hoc tests
confirmed that the following concentrations of METH caused a significant increase in
apoptosis when maintained at 37 and 40 °C: 1 µM (t = 2.92, p < 0.05), 10 µM (t = 4.47, p <
A 100 µM (t = 2.90, p < 0.05).
0.001) and
Necrosis: METH treatment caused a significant increase in necrotic cell death in
NG108-15 cells maintained at 37 °C. One way ANOVA showed a significant effect of METH
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treatment (F(9,428) = 32.93, p < 0.0001). Dunnett’s post-hoc tests confirmed that the following
concentrations of METH caused a significant increase in apoptosis when compared to no
treatment control cells: 300 µM (q = 6.75, p < 0.01) and 1000 µM (q = 14.02, p < 0.01).
METH treatment at an elevated temperature of 40 °C caused a significant increase in
apoptotic cell death when compared to control cells maintained at the same temperature. The
necrotic cell death was more sensitive to temperature, as lower concentrations of METH also
caused significant necrosis when maintained at 40 °C. One way ANOVA showed a significant
effect of METH treatment (F(9,205) = 9.63, p < 0.0001). Dunnett’s post-hoc tests confirmed
that the following concentrations of METH caused a significant increase in necrosis when
compared to control cells maintained at 40 °C: 1 µM (q = 2.86, p < 0.05), 3 µM (q = 2.89, p <
0.05), 10 µM (q = 3.24, p < 0.05), 30 µM (q = 2.75, p < 0.05), 100 µM (q = 7.10, p < 0.01), 300
µM (q = 4.20, p < 0.01) and 1000 µM (q = 7.33, p < 0.01).
On comparing the METH treated NG108-15 cells at 37 and 40 °C, it was observed that
cells maintained at 40 °C had a significantly higher percentage of necrotic cells in the no
treatment control as well as METH treatment when compared with the cells maintained at 37
°C (Figure 5.3B). The dose response of METH at 40 °C shows an up and leftward shift in
necrotic cell death. Two way ANOVA showed a significant effect of METH treatment (F(9,615)
= 19.76, p < 0.0001), temperature (F(1,615) = 600, p < 0.0001) and METH treatment ×
temperature interaction (F(9,615) = 8.81, p < 0.0001). Bonferroni’s post-hoc tests confirmed
that the following concentrations of METH caused a significant increase in apoptosis when
maintained at 40 versus 37 °C: 0 µM (t = 3.24, p < 0.05), 0.01 µM (t = 4.48, p < 0.001), 0.1 µM
(t = 5.17, p < 0.001), 1 µM (t = 8.79, p < 0.001), 3 µM (t = 7.02, p < 0.001), 10 µM (t = 9.45, p
< 0.001), 30 µM (t = 6.37, p < 0.001), 100 µM (t = 17.32, p < 0.001), 300 µM (t = 7.80, p <
0.001) and 1000 µM (t = 14.43, p < 0.001).
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Total cell death: METH treatment caused a significant increase in total cell death in
NG108-15 cells maintained at 37 °C. One way ANOVA showed a significant effect of METH
treatment (F(9,437) = 68.14, p < 0.0001). Dunnett’s post-hoc tests confirmed that the following
concentrations of METH caused a significant increase in apoptosis when compared to no
treatment control cells: 10 µM (q = 5.05, p < 0.01), 30 µM (q = 7.59, p < 0.01), 100 µM (q =
9.40, p < 0.01), 300 µM (q = 12.21, p < 0.01) and 1000 µM (q = 20.21, p < 0.01).
METH treatment at elevated temperature of 40 °C caused a significant increase in total
cell death when compared to control cells maintained at the same temperature. Similar to
necrotic cell death, the total cell death was sensitive to temperature as lower concentrations of
METH also caused cell death when maintained at 40 °C. One way ANOVA showed a
significant effect of METH treatment (F(9,208) = 13.78, p < 0.0001). Dunnett’s post-hoc tests
confirmed that the following concentrations of METH caused a significant increase in necrosis
when compared to control cells maintained at 40 °C: 1 µM (q = 2.91, p < 0.05), 3 µM (q =
3.00, p < 0.05), 10 µM (q = 3.99, p < 0.01), 30 µM (q = 3.58, p < 0.01), 100 µM (q = 8.17, p <
0.01), 300 µM (q = 5.31, p < 0.01) and 1000 µM (q = 8.57, p < 0.01).
On comparing the METH treated NG108-15 cells at 37 and 40 °C, it was observed that
cells maintained at 40 °C had a significantly higher percentage of cell death in no treatment
control as well as METH treatment when compared with the cells maintained at 37 °C (Figure
5.3C). The dose response of METH at 40 °C shows an up and leftward shift in total cell death.
Two way ANOVA showed a significant effect of METH treatment (F(9,627) = 36.68, p <
0.0001), temperature (F(1,627) = 652.3, p < 0.0001) and METH treatment × temperature
interaction (F(9,627) = 7.81, p < 0.0001). Bonferroni’s post-hoc tests confirmed that the
following concentrations of METH caused a significant increase in total cell death when
maintained at 40 versus 37 °C: 0 µM (t = 4.36, p < 0.001), 0.01 µM (t = 4.71, p < 0.001), 0.1
µM (t = 5.13, p < 0.001), 1 µM (t = 9.31, p < 0.001), 3 µM (t = 7.49, p < 0.001), 10 µM (t =
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10.74, p < 0.001), 30 µM (t = 6.56, p < 0.001), 100 µM (t = 17.67, p < 0.001), 300 µM (t = 7.81,
p < 0.001) and 1000 µM (t = 14.22, p < 0.001).
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Figure 5.3 Effect of temperature (37 versus 40 °C) on METH-induced (A) apoptosis, (B)
necrosis and (C) total cell death. NG108-15 cells were exposed to METH (0-1000 µM) for 24 hr at
37 or 40 °C. After 24 hr, the wells were incubated with Hoechst 33342 and propidium iodide stains (20
µg/ml each) to obtain percentages of apoptotic and necrotic cells. Total cell death = Apoptotic cell death
+ Necrotic cell death. Data represent means from two separate experiments (n = 3/experiment) ± SEM.
Significant differences are indicated by *p < 0.05, **p < 0.01 (control vs. METH treated at a particular
temperature); #p < 0.05, ###p < 0.001 (treatment at 37 °C vs.40 °C).
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5.3.1.4: SN79 and METH at 40 °C:
Apoptosis: SN79 treatment was able to significantly reduce the elevated apoptotic cell
death caused by increased temperature (40 °C). One way ANOVA showed a significant effect
of SN79 treatment (F(3,120) = 8.21, p < 0.0001). Dunnett’s post-hoc tests confirmed that the
following concentrations of SN79 significantly attenuated the apoptotic effect of elevated
temperature in control untreated cells: 1 nM (q = 4.14, p < 0.01), 10 nM (q = 4.32, p < 0.01)
and 10 nM (q = 3.16, p < 0.01).
SN79 also attenuated the combined apoptotic effect of elevated temperature and all
the concentrations of METH (Figure 5.4A). One way ANOVA showed a significant effect of
SN79 pretreatment prior to the following concentrations of METH treatment: 0.01 µM (F(3,40)
= 12.06, p < 0.0001), 0.1 µM (F(3,39) = 3.18, p < 0.05), 1 µM (F(3,114) = 20.05, p < 0.0001), 3
µM (F(3,65) = 7.63, p < 0.0005), 10 µM (F(3,108) = 30.55, p < 0.0001), 30 µM (F(3,74) =
23.44, p < 0.0001), 100 µM (F(3,115) = 31.41, p < 0.0001), 300 µM (F(3,73) = 15.99, p <
0.0001) and 1000 µM (F(3,110) = 13.29, p < 0.0001). Dunnett’s post-hoc tests confirmed that
SN79 pretreatment is able to attenuate the apoptotic effects of the following concentrations of
METH: 0.01 µM (1nM: q = 3.90, p < 0.01; 10 nM: q = 4.97, p < 0.01; 100 nM: q = 5.28, p <
0.01), 0.1 µM (100 nM: q = 2.96, p < 0.05), 1 µM (1 nM: q = 5.51, p < 0.01; 10 nM: q = 6.00, p
< 0.01; 100 nM: q = 7.00, p < 0.01), 3 µM (1 nM: q = 3.98, p < 0.01; 10 nM: q = 4.20, p < 0.01;
100 nM: q = 3.28, p < 0.01), 10 µM (1 nM: q = 8.05, p < 0.01; 10 nM: q = 8.29, p < 0.01; 100
nM: q = 6.64, p < 0.01), 30 µM (1 nM: q = 7.06, p < 0.01; 10 nM: q = 7.33, p < 0.01; 100 nM: q
= 6.30, p < 0.01), 100 µM (1 nM: q = 8.27, p < 0.01; 10 nM: q = 8.04, p < 0.01; 100 nM: q =
7.35, p < 0.01), 300 µM (1 nM: q = 5.72, p < 0.01; 10 nM: q = 6.07, p < 0.01; 100 nM: q = 5.50,
p < 0.01) and 1000 µM (1 nM: q = 5.01, p < 0.01; 10 nM: q = 4.58, p < 0.01; 100 nM: q = 5.64,
p < 0.01).
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Necrosis: SN79 treatment was able to significantly reduce the elevated necrotic cell
death caused by increased temperature (40 °C) in control untreated cells. One way ANOVA
showed a significant effect of SN79 treatment (F(3,120) = 12.57, p < 0.0001). Dunnett’s posthoc tests confirmed that the following concentrations of SN79 significantly attenuated the
apoptotic effect of elevated temperature: 1 nM (q = 4.82, p < 0.01), 10 nM (q = 4.95, p < 0.01)
and 10 nM (q = 5.04, p < 0.01).
SN79 also attenuated the combined necrotic effect of elevated temperature and all the
concentrations of METH (Figure 5.4B). One way ANOVA showed a significant effect of SN79
pretreatment prior to the following concentrations of METH treatment: 0.01 µM (F(3,40) =
11.98, p < 0.0001), 0.1 µM (F(3,70) = 36.99, p < 0.0001), 1 µM (F(3,114) = 18.84, p < 0.0001),
3 µM (F(3,65) = 29.95, p < 0.0001), 10 µM (F(3,108) = 10.09, p < 0.0001), 30 µM (F(3,74) =
15.68, p < 0.0001), 100 µM (F(3,115) = 24.65, p < 0.0001), 300 µM (F(3,73) = 17.50, p <
0.0001) and 1000 µM (F(3,110) = 24.19, p < 0.0001). Dunnett’s post-hoc tests confirmed that
SN79 pretreatment is able to attenuate the necrotic effects of the following concentrations of
METH: 0.01 µM (1nM: q = 5.19, p < 0.01; 10 nM: q = 5.06, p < 0.01; 100 nM: q = 3.82, p <
0.01), 0.1 µM (1 nM: q = 9.43, p < 0.01; 10 nM: q = 9.61, p < 0.01; 100 nM: q = 9.15, p <
0.01), 1 µM (1 nM: q = 5.84, p < 0.01; 10 nM: q = 6.65, p < 0.01; 100 nM: q = 5.58, p < 0.01),
3 µM (1 nM: q = 7.22, p < 0.01; 10 nM: q = 8.64, p < 0.01; 100 nM: q = 6.79, p < 0.01), 10 µM
(1 nM: q = 4.30, p < 0.01; 10 nM: q = 4.90, p < 0.01; 100 nM: q = 4.06, p < 0.01), 30 µM (1
nM: q = 4.35, p < 0.01; 10 nM: q = 5.34, p < 0.01; 100 nM: q = 6.47, p < 0.01), 100 µM (1 nM:
q = 7.34, p < 0.01; 10 nM: q = 6.68, p < 0.01; 100 nM: q = 6.98, p < 0.01), 300 µM (1 nM: q =
5.88, p < 0.01; 10 nM: q = 6.13, p < 0.01; 100 nM: q = 6.13, p < 0.01) and 1000 µM (1 nM: q =
6.46, p < 0.01; 10 nM: q = 6.75, p < 0.01; 100 nM: q = 7.47, p < 0.01).
Total cell death: SN79 treatment was able to significantly reduce the elevated cell
death caused by increased temperature (40 °C). One way ANOVA showed a significant effect
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of SN79 treatment (F(3,120) = 20.41, p < 0.0001). Dunnett’s post-hoc tests confirmed that the
following concentrations of SN79 significantly attenuated the cell death of elevated
temperature: 1 nM (q = 6.23, p < 0.01), 10 nM (q = 6.41, p < 0.01) and 10 nM (q = 6.24, p <
0.01).
SN79 also attenuated the combined effect elevated temperature and all the
concentrations of METH on cell death in differentiated NG108-15 cells (Figure 5.4C). One way
ANOVA showed a significant effect of SN79 pretreatment prior to the following concentrations
of METH treatment: 0.01 µM (F(3,40) = 27.03, p < 0.0001), 0.1 µM (F(3,39) = 20.74, p <
0.0001), 1 µM (F(3,114) = 28.69, p < 0.0001), 3 µM (F(3,65) = 42.27, p < 0.0001), 10 µM
(F(3,108) = 21.87, p < 0.0001), 30 µM (F(3,74) = 40.99, p < 0.0001), 100 µM (F(3,115) =
40.66, p < 0.0001), 300 µM (F(3,73) = 36.07, p < 0.0001) and 1000 µM (F(3,110) = 32.66, p <
0.0001). Dunnett’s post-hoc tests confirmed that SN79 pretreatment is able to attenuate the
cell death caused by the following concentrations of METH: 0.01 µM (1nM: q = 7.38, p < 0.01;
10 nM: q = 7.71, p < 0.01; 100 nM: q = 6.50, p < 0.01), 0.1 µM (1 nM: q = 6.43, p < 0.01; 10
nM: q = 6.59, p < 0.01; 100 nM: q = 6.62, p < 0.01), 1 µM (1 nM: q = 7.10, p < 0.01; 10 nM: q
= 8.00, p < 0.01; 100 nM: q = 7.35, p < 0.01), 3 µM (1 nM: q = 8.76, p < 0.01; 10 nM: q =
10.19, p < 0.01; 100 nM: q = 8.00, p < 0.01), 10 µM (1 nM: q = 6.53, p < 0.01; 10 nM: q = 7.14,
p < 0.01; 100 nM: q = 5.85, p < 0.01), 30 µM (1 nM: q = 8.06, p < 0.01; 10 nM: q = 9.22, p <
0.01; 100 nM: q = 9.89, p < 0.01), 100 µM (1 nM: q = 9.44, p < 0.01; 10 nM: q = 8.71, p < 0.01;
100 nM: q = 8.84, p < 0.01), 300 µM (1 nM: q = 8.50, p < 0.01; 10 nM: q = 8.90, p < 0.01; 100
nM: q = 8.65, p < 0.01) and 1000 µM (1 nM: q = 7.59, p < 0.01; 10 nM: q = 7.72, p < 0.01; 100
nM: q = 8.72, p < 0.01).
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Figure 5.4 Effect of SN79 pretreatment on METH-induced (A) apoptosis, (B) necrosis and (C)
total cell death at 40 °C. SN79 protects against methamphetamine (METH) and elevated temperature
(40 °C)-induced apoptosis (A), necrosis (B) and total cell death (C). NG108-15 cells were pretreated
with SN79 (1-100 nM) prior to exposure to METH (0-1000 µM) for 24 hr at 40 °C. After 24 hr, the wells
were incubated with Hoechst 33342 and propidium iodide stains (20 µg/ml each) to obtain percentages
of apoptotic and necrotic cells. Total cell death = Apoptotic cell death + Necrotic cell death. Data
represent means from two separate experiments (n = 3/experiment) ± SEM. Significant differences are
indicated by *p < 0.05, **p < 0.01 (control vs. METH treated); ##p < 0.01 (control/METH alone vs.
control/METH with SN79).
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5.3.2 MTT Assay: Figure 5.5A shows a dose response of METH-induced decrease in cell
viability. One-way ANOVA shows a significant effect of METH treatment (F(11,165) = 66.67, p
< 0.0001). Post-hoc Dunnett’s tests reveal a significant effect of the following concentrations
of METH: 1 mM (q = 8.13, p < 0.001), 3 mM (q = 17.24, p < 0.001) and 10 mM (q = 18.09, p <
0.001).
One-way ANOVA showed that SN79 (0.1-10000 nM) pretreatment significantly
attenuated the decrease in cell viability caused by METH (1 mM) (Figure 5.5B, F(12,269) =
13.94, p < 0.0001). Post-hoc Dunnett’s tests revealed that the following concentration of SN79
pretreatment were significantly different from METH treatment alone (0.1 nM: q = 3.59, p <
0.01; 0.3 nM: q = 3.48, p < 0.01; 1 nM: q = 7.26, p < 0.001; 3 nM: q = 4.97, p < 0.001; 10 nM:
q = 4.99, p < 0.001; 30 nM: q = 6.23, p < 0.001; 100 nM: q = 3.56, p < 0.01; 300 nM: q = 3.82,
p < 0.01; 1000 nM: q = 4.05, p < 0.001).
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Figure 5.5 MTT Assay: A. Dose response of METH-induced decrease in cell viability B. Effect of
SN79 pretreatment on METH (1000 µM)-induced decrease in cell viability. (A) Differentiated
NG108-15 cells were treated with METH (0-1000 µM). At 24 hour time point cell viability was
determined using MTT assay. METH 1-10 mM caused significant decrease in cell viability. (B)
Differentiated NG108-15 cells were pretreated with SN79 (0-10 µM), 15 min prior to adding METH (1
mM). SN79 attenuated the decrease in cell viability caused by METH at 1000 µM without significantly
altering the cell viability on its own (***P<0.001, ##P<0.01,###P<0.001; post hoc tests, * vs. no
treatment control, # vs. METH 1000 µM).
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5.3.3 Trypan blue exclusion assay:

METH treatment caused a significant decrease in

NG108 cell viability (Figure 5.6A). One-way ANOVA showed a significant effect of METH
treatment (F(10,38) = 9.64, p < 0.0001). Dunnett’s post-hoc tests confirmed that the following
doses of METH cause a significant decrease in cell viability (1 mM: q = 7.52, p < 0.01 and 3
mM: q = 6.66, p < 0.01). SN79 pretreatment attenuated METH (1 mM)-induced decrease in
cell viability (Figure 5.6B). Two-way ANOVA showed a significant effect of METH treatment
(F(1,54) = 5.83, p < 0.05), SN79 pretreatment (F(4,54) = 5.24, p < 0.005) and METH
treatment × SN79 pretreatment interaction (F(4,54) = 6.11, p < 0.0005). Bonferroni’s post-hoc
tests show that SN79 (1, 3, 10 and 30 nM) attenuate METH (1 mM)-induced decreases in cell
viability (t = 4.10, p < 0.001; t = 5.18, p < 0.001; t = 3.71, p < 0.01 and t = 3.73, p < 0.01
respectively).
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Figure 5.6 A. Dose response of METH-induced decrease in cell viability B. Effect of SN79
pretreatment on METH (1000 µM)-induced decrease in cell viability. (A) Differentiated NG108-15
cells were treated with METH (0-3000 µM) and at 24 hour time point cell viability was determined using
Trypan blue exclusion assay. METH 1-3000 µM caused significant decrease in cell viability. (B)
Differentiated NG108-15 cells were pretreated with SN79 (0-100 nM), 15 min prior to adding METH
(1000 µM). SN79 attenuated the decrease in cell viability caused by METH at 1000 µM without
significantly altering the cell viability on its own (**P<0.01, ##P<0.01,###P<0.001; post hoc tests, * vs.
no treatment control, # vs. METH 1000 µM).

5.3.4 Caspase-3, -8, -9 assay:
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5.3.4.1. Caspase-3 activation: METH treatment caused a significant increase in
caspase 3 activation in differentiated NG108-15 cells (Figure 5.7A). Two way ANOVA showed
a significant effect of METH treatment (F(3,104) = 16.78, p < 0.0001), time (F(4,104) = 47.59,
p < 0.0001) and METH treatment × time interaction (F(12,104) = 16.17, p < 0.0001).
Bonferroni’s multiple comparison post-hoc tests confirmed that 10, 100 and 1000 µM
concentrations of METH caused a significant increase in caspase-3 activation at the 24 hour
time point (t = 3.34, p < 0.05; t = 7.74, p <0.0001 and t = 19.27, p < 0.0001 respectively).
SN79 pretreatment is significantly able to attenuate METH-induced caspase-3
activation at the 24 hour time point (Figure 5.7B). Two way ANOVA showed a significant effect
of METH treatment (F(4,128) = 109.5, p < 0.0001), SN79 pretreatment (F(3,128) = 14.82, p <
0.0001) and METH × SN79 pretreatment interaction (F(12,128) = 4.73, p < 0.0001).
Bonferroni’s multiple comparison post-hoc tests showed that the following concentrations of
SN79 can attenuate caspase-3 activation caused by METH 100 µM (1 nM: t = 3.2, p < 0.05;
10 nM: t = 4.02, p < 0.01) and 1000 µM (1 nM: t = 5.33, p < 0.0001; 10 nM: t = 7.52, p <
0.0001; 100 nM: t = 5.32, p < 0.0001) treatment.
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Figure 5.7 A. Dose response and time course of METH treatment on Caspase-3 activation B.
Effect of SN79 pretreatment on METH-induced Caspase-3 activation at 24 hours. (A)
Differentiated NG108-15 cells were treated with METH (0-1000 µM) and caspase-3 activation
determined using Caspase-3/7 Glo Luminescence assay at 1.5, 3, 6, 12, 24 hour time points. At 24
hour time point, METH (10, 100 and 1000 µM) caused significant increase in caspase-3 activation. (B)
Differentiated NG108-15 cells were pretreated with SN79 (0-100 nM), 15 min prior to adding METH (1,
10, 100, 1000 µM). At 24 hour time point, SN79 attenuated the caspase-3 activation caused by METH
at 100 and 1000 µM without significantly altering the caspase-3 activation on its own (*p<0.05, ****p <
0.0001, #p < 0.05, ##P<0.01,####P<0.0001; post hoc tests, * vs. no treatment control, # vs. METH).
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5.3.4.2. Caspase-8 activation: METH treatment caused a significant increase in caspase-8
activation in differentiated NG108-15 cells (Figure 5.8A). Two way ANOVA showed a
significant effect of METH treatment (F(4,319) = 41.49, p < 0.0001), time (F(5,319) = 10.95, p
< 0.0001) and METH treatment × time interaction (F(20,319) = 3.13, p < 0.0001). Bonferroni’s
multiple comparison post-hoc tests confirmed that 1, 10, 100 and 1000 µM concentrations of
METH caused a significant increase in caspase-8 activation at the 9 hour time point (t = 3.56,
p < 0.05; t = 5.65, p <0.0001, t = 9.02, p < 0.0001 and q = 16.39, p < 0.0001 respectively).
METH (1000 µM concentration) also caused caspase-8 activation at the 1.5, 3, 6, 12, and 24
hour time points (t = 4.09, p < 0.01; t = 3.37, p < 0.05; t = 4.32, p < 0.001; t = 3.71, p < 0.01
and t = 4.93, p < 0.0001 respectively).
SN79 pretreatment is significantly able to attenuate METH-induced caspase-8
activation at the 9 hour time point (Figure 5.8B). Two way ANOVA showed a significant effect
of METH treatment (F(4,278) = 88.61, p < 0.0001), SN79 pretreatment (F(3,278) = 19.50, p <
0.0001) and METH × SN79 pretreatment interaction (F(12,278) = 3.60, p < 0.0001).
Bonferroni’s multiple comparison post-hoc tests showed that the following concentrations of
SN79 can attenuate caspase-8 activation caused by METH 10 µM (100 nM: t = 3.26, p <
0.05), 100 µM (1 nM: t = 4.22, p < 0.001; 10 nM: t = 4.25, p < 0.001 and 100 nM: t = 3.36, p <
0.05) and 1000 µM (1 nM: t = 3.43, p < 0.05; 10 nM: t = 3.92, p < 0.01 and 100 nM: t = 3.05, p
< 0.05) treatment.
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Figure 5.8 A. Dose response and time course of METH treatment on Caspase-8 activation B.
Effect of SN79 pretreatment on METH-induced Caspase-3 activation at 9 hours. (A) Differentiated
NG108-15 cells were treated with METH (0-1000 µM) and caspase-8 activation determined using
Caspase-8 Glo Luminescence assay at 1.5, 3, 6, 9, 12, 24 hour time points. At 9 hour time point, METH
(1, 10, 100 and 1000 µM) caused significant increase in caspase-8 activation. (B) Differentiated NG10815 cells were pretreated with SN79 (0-100 nM), 15 min prior to adding METH (1, 10, 100, 1000 µM). At
9 hour time point, SN79 attenuated the caspase-8 activation caused by METH at 10, 100 and 1000 µM
without significantly altering the caspase-8 activation on its own (*p<0.05, **p < 0.01, ***p < 0.001, ****p
< 0.0001, #p < 0.05, ##P<0.01,###P<0.001; post hoc tests, * vs. no treatment control, # vs. METH).

122

5.3.4.3. Caspase-9 activation: METH treatment caused a significant increase in caspase-9
activation in differentiated NG108-15 cells (Figure 5.9A). Two way ANOVA showed a
significant effect of METH treatment (F(4,511) = 52.31, p < 0.0001), time (F(6,511) = 19.18, p
< 0.0001) and METH treatment × time interaction (F(24,511) = 3.13, p < 0.0001). Bonferroni’s
multiple comparison post-hoc tests confirmed that1000 µM concentration of METH caused a
significant increase in caspase-9 activation at the 3 hour (t = 2.74, p < 0.05), 6 hour (t = 3.32,
p < 0.01), 9 hour (t = 2.76, p < 0.05), 12 hour (t = 5.73, p < 0.001), 18 hour (t = 3.81, p < 0.01)
and 24 hour (t = 20.93, p < 0.001). METH 100 µM concentration also caused caspase-9
activation at 9 hour (t = 4.12, p < 0.001) and 24 hour (t = 6.24, p < 0.001).
B
SN79 pretreatment is significantly able to attenuate
METH-induced caspase-9
activation at the 24 hour time point (Figure 5.9B). Two way ANOVA showed a significant effect
of METH treatment (F(4,269) = 82.60, p < 0.0001), SN79 pretreatment (F(3,269) = 13.00, p <
0.0001) and METH × SN79 pretreatment interaction (F(12,269) = 3.89, p < 0.0001).
Bonferroni’s multiple comparison post-hoc tests showed that 10 nM SN79 concentration can
attenuate caspase-9 activation caused by METH 1000 µM (t = 5.24, p < 0.001) and 100 nM
SN79 concentration can attenuate caspase-9 activation caused by METH 100 µM (t = 2.91, p
< 0.05) and 1000 µM (t = 7.69, p < 0.001) treatment.
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Figure 5.9 A. Dose response and time course of METH treatment on Caspase-9 activation B.
Effect of SN79 pretreatment on METH-induced Caspase-9 activation at 24 hours. (A)
Differentiated NG108-15 cells were treated with METH (0-1000 µM) and caspase-9 activation
determined using Caspase-9 Glo Luminescence assay at 1.5, 3, 6, 9, 12, 18, 24 hour time points. At 9
hour time point, METH (1, 10, 100 and 1000 µM) caused significant increase in caspase-8 activation.
(B) Differentiated NG108-15 cells were pretreated with SN79 (0-100 nM), 15 min prior to adding METH
(1, 10, 100, 1000 µM). At 24 hour time point, SN79 attenuated the caspase-9 activation caused by
METH at 10, 100 and 1000 µM without significantly altering the caspase-8 activation on its own
(*p<0.05, **p < 0.01, ***p < 0.001, #p < 0.05, ###P<0.001; post hoc tests, * vs. no treatment control, #
vs. METH).
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5.3.5 Reactive oxygen/nitrogen species:
SN79 pretreatment was able to significantly attenuate the ROS generated by METH
(Figure 5.10). Two-way ANOVA shows a significant effect of SN79 pretreatment (F(4,824) =
35.27, p < 0.0001), METH or H2O2 treatment (F(9,824) = 75.77, p < 0.0001) and SN79
pretreatment × METH or H2O2 treatment interaction (F(36,824) = 2.24, p < 0.001). Dunnett’s
post-hoc tests confirmed that the following concentrations of METH and H2O2 generated ROS:
1 µM (q = 5.96, p < 0.01), 3 µM (q = 4.46, p < 0.01), 10 µM (q = 4.57, p < 0.01), 30 µM (q =
4.82, p < 0.01), 100 µM (q = 6.32, p < 0.01), 300 µM (q = 7.03, p < 0.01), 1000 µM (q = 7.15, p
< 0.01), 3000 µM (q = 5.71, p < 0.01) and 100 µM H2O2 (q = 14.86, p < 0.01). Bonferroni’s
post-hoc tests confirmed that SN79 can inhibit the ROS/RNS generated by the following
concentration of METH: 1 µM (1 nM: t = 2.99, p < 0.05), 3 µM (1 nM: t = 3.56, p < 0.01; 10
nM: t = 3.18, p < 0.05), 30 µM (1 nM: t = 2.91, p < 0.05; 10 nM: t = 3.71, p < 0.01; 100 nM: t =
3.30, p < 0.05 and 1000 nM: t = 4.08, p < 0.001), 100 µM (1 nM: t = 3.54, p < 0.01), 300 µM (1
nM: t = 5.09, p < 0.001; 10 nM: t = 4.88, p < 0.001; 100 nM, t = 4.63, p < 0.001 and 1000 nM: t
= 5.29, p < 0.001), 1000 µM (1 nM: t = 3.07, p < 0.05; 10 nM: t = 3.64, p < 0.01 and 1000 nM: t
= 2.88, p < 0.05), 3000 µM (1 nM: t = 3.96, p < 0.001; 10 nM: t = 4.23, p < 0.001; 100 nM: t =
3.95, p < 0.001 and 1000 nM: t = 3.77, p < 0.01). SN79 (1000 nM) is able to attenuate the
ROS generated by H2O2 (t = 4.26, p < 0.001).
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Figure 5.10 Effect of SN79 pretreatment on METH-induced ROS/RNS generation. The production
of ROS capable of oxidizing CM-H2DCFDA was assessed in differentiated NG108-15 cells in the
presence of 0 to 300 µ

µM H2O2 or 100 µM Na2Cr2O7 (Cr) in the absence (solid bars) or

presence (cross hatched bars) of SN79 (1-1000 nM) as described in the methods. Data represent
averages of relative fluorescence units (rfu) from 3-6 different experiments (n = 3-4/experiment)
obtained 20 min after addition of drug ± SEM. Significant differences are noted as **p < 0.01 (control vs.
METH or H2O2 treated) and #p < 0.05, ##p < 0.01, ###p < 0.001 (METH alone vs. METH with SN79).
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5.4 Discussion
This study showed that METH caused apoptosis in differentiated NG108-15 cells at
physiologically relevant micromolar concentrations and necrosis at higher milimolar
concentrations. At earlier time points, caspase-3, -8, and -9 activation, and ROS/RNS
generation were also observed. SN79, a σ receptor antagonist, attenuated METH-induced cell
death as well as the toxicity mediators. The implications of these findings are further
discussed below.
In the first part of the study, the neurotoxic concentration range of METH in
differentiated NG108-15 cells was determined. METH caused apoptosis at physiologically
relevant micromolar concentrations. In contrast to apoptosis, necrotic cell death was observed
at higher micromolar concentrations. SN79 attenuated the apoptotic cell death which is
consistent with the role of σ receptors in this type of cell death in tumor models (Bowen, 2000;
Marrazzo et al., 2011). SN79 also attenuated the necrotic cell death caused by METH. Even
though there is not much evidence for the role of σ receptors in necrotic cell death, the
following explanations may help in the better understanding of the results: First, studies
suggest there is a considerable overlap between the two forms of cell death as evidenced by
coining of terms like ‘necroptosis’ and ‘aponecrosis’ (Formigli et al., 2000; Papucci et al.,
2004; Yakovlev and Faden, 2004; Galluzzi and Kroemer, 2008; Kroemer et al., 2009; Berghe
et al., 2010; Christofferson and Yuan, 2010; Dunai et al., 2011; Jiang et al., 2011; Wu et al.,
2011). Second, since the in vitro system lacks the phagocyte cells, these apoptotic cells may
appear necrotic at later time points.
Another confirmation that METH-induced cell death is σ receptor sensitive comes from
the ability of DTG to shift the dose response curve of METH-induced cell death towards the
left. At higher concentrations DTG displayed toxicity on its own which is consistent with the
ability of σ receptor (especially σ-2 receptor subtype) agonist to cause toxicity (Vilner et al.,
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1995a; Bowen, 2000; Crawford and Bowen, 2002). In this study, the necrotic type of cell death
was more sensitive to DTG’s effect on METH. This is most likely because NG108-15 is a
sensitive cell line and induction of stressors/pro-death mediators beyond a certain threshold
may shift the cell death from apoptosis to necrosis (Leist et al., 1997; Nicotera et al., 1998;
Leist et al., 1999; Proskuryakov et al., 2003; Soti et al., 2003; Nicotera and Melino, 2004).
The next part of the study was conducted to determine whether METH-induced
apoptosis in NG108-15 cells is caspase-dependent or independent event. Studies in the
literature suggest involvement of both caspase-dependent as well as independent pathways
(Jayanthi et al., 2004). Caspase-3 activation was observed at the 24 hour time point,
indicating that caspase dependent mechanism is involved in this apoptotic cell death. SN79
attenuated METH-induced caspase-3 activation, which is consistent with the role of σ
receptors in caspase-dependent cell death mechanisms (Crawford and Bowen, 2002; Hornick
et al., 2010; Jonhede et al., 2010).
Caspase-3 can be activated via extrinsic death receptors or intrinsic mitochondrial
death pathways. Activation of caspase-8 at 9 hour time point confirms the involvement of an
extrinsic cell death pathway. Caspase-8 activation was followed by caspase-9 activation which
peaked at the 24 hour time point. This indicates that NG108-15 cells may be type II cells that
involve mitochondrial death loop for the processing of apoptotic cell death. One of the most
likely mechanisms of METH-induced caspase-8 activation in NG108-15 cells is ROS/RNS
production which can increase the cellular death receptor expression (Bauer et al., 1998), and
also ROS-induced death receptor independent caspase-8 activation via p38 MAPK pathway
(El Mchichi et al., 2007). Once activated, caspase-8 can cleave Bid and cause cytochrome c
release from the mitochondria, resulting in apoptosome formation with Apaf1 and hence
caspase-9 activation (Li et al., 1998).
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The ability of SN79 to attenuate caspase-8 activation at 9 hour time point is most likely
due to the role of σ receptors in modulation of cellular ROS levels (Ostenfeld et al., 2005;
Schetz et al., 2007). In addition, the localization of σ receptors in lipid rafts (Hayashi and Su,
2003b; Gebreselassie and Bowen, 2004; Gajate and Mollinedo, 2011) may allow them to
modulate death receptor signaling (Cahuzac et al., 2006). σ-2 Receptors may play a
predominant role in this pathway as a previous study using SK-N-SH neuroblastoma cells
showed that activation of σ-2 receptors caused caspase-10 activation which in turn cleaved
Bid thereby causing activation of mitochondrial death cascade (Wang and Bowen, 2006). The
decrease in METH-induced caspase-9 activation at 24 hour time point may be due to the
ability of SN79 to attenuate the caspase-8 signal. Alternately, σ receptors are located in the
ER and mitochondria and can regulate the calcium signaling between these organelles (Vilner
and Bowen, 2000; Wei et al., 2006; Cassano et al., 2009). Previous studies in tumor models
have indicated a role of σ receptor in the modulation of mitochondrial death cascades (Wei et
al., 2006). Caspase-9 can also be generated by other cellular stress signals like ROS/RNS
generation in the cell (Kadenbach et al., 2004) which is activated by METH, which may also
be regulated by σ receptors.
ROS/RNS generation is one of the main mediators of METH’s neurotoxicity, which
occurs through various sources including excessive dopamine release, microglial activation,
excessive glutamate release, and mitochondrial dysfunction (Krasnova and Cadet, 2009).
These ROS/RNS generated can injure neurons and surrounding cells via oxidative damage to
cellular components such as lipids, proteins, and DNA, or cause ER stress and activation of
mitochondrial death cascades, ultimately leading to nerve terminal degeneration or cell death
(Krasnova and Cadet, 2009). In this study, METH was shown to cause ROS/RNS generation.
SN79 pretreatment attenuated the ROS/RNS generated by METH. This effect of SN79 does
not seem to be a general antioxidant effect as it is not able to prevent the H2O2 -mediated
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ROS signal. Although, at high concentration of 1000 nM, SN79 causes decrease in H2O2mediated ROS, which may be due to some intrinsic antioxidant activity at this concentration or
due to potential upregulation of cellular antioxidant defenses. Mechanistically, SN79 can act
via σ receptors to modulate cellular ROS/RNS generation and antioxidant systems. Previous
studies in tumor cells have shown that σ-2 receptor activation causes ROS generation
(Ostenfeld et al., 2005). σ-1 Receptors are involved in oxidative stress mediated toxicities and
have been shown to provide protective effects (Schetz et al., 2007). σ Receptors also play a
regulatory role in the redox state of the cell, and can also modulate the nNOS and iNOS
enzyme activity (Vagnerova et al., 2006; Tsai et al., 2009; Yang et al., 2010).
In addition to modulating the cellular redox system, σ receptors can also regulate other
systems that are involved in ROS/RNS generation by METH. First, σ receptors can regulate
glutamate/NMDA release which in turn causes nNOS activation and nitrosative stress
(DeCoster et al., 1995). Second, σ receptors can modulate microglial activation through
calcium dependent mechanisms, which can contribute to the release of inflammatory
cytokines and ROS/RNS generation (Hall et al., 2009). Third, σ receptors can regulate the
release of dopamine which in turn undergoes autooxidation and is a major cause of METH’s
ROS generation (Gonzalez-Alvear and Werling, 1994; Derbez et al., 2002).
Apart from the activation of cellular death cascades, METH also caused hyperthermia
in vivo. In order to separate the contribution of METH, hyperthermia and their interaction,
NG108-15 cells were treated with METH at 37 or 40 °C. The results demonstrated that by
maintaining the cells at elevated temperature, an increase in cell death (apoptosis and
necrosis) was observed. The type of cell death shifted from apoptotic to necrotic cell death.
This is consistent with the effect observed with treatment with DTG, where beyond a certain
level of stress cell death in NG108-15 cells may be predominantly necrotic. The combination
of METH and elevated temperature synergistically enhanced cell death (especially necrosis).
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This potentiation effect is most likely due to high temperature induced increase in DAT activity
and enhanced ROS/RNS levels (Fleckenstein et al., 1997; Xie et al., 2000; Kiyatkin et al.,
2007; Numachi et al., 2007; Sharma et al., 2007). The ability of SN79 to attenuate both the
elevated temperature induced toxicity as well as the enhanced toxicity caused my interaction
of METH and elevated temperature is consistent with the potential role of σ receptors in
various cell stress and death mechanisms. σ Receptors, due to their properties of intracellular
translocation, protein-protein interaction and chaperone activity can help normalize a
disordered system (Tsai et al., 2009).
In summary, the data from both aims of the in vitro studies demonstrates that
physiologically significant concentrations of METH can cause apoptosis in an in vitro system
representative of a differentiated neuronal cell, which mechanistically involves dopamine
release and induction of reactive oxygen/nitrogen radicals, activation of caspase-8, -9 and -3.
Additionally, σ receptor antagonist, SN79, can attenuate METH-induced cell death and the
causative neurotoxic cascade. σ Receptor antagonists can also attenuate the elevated
temperature-induced toxicity as well as toxicity caused by the interaction of METH and
elevated temperature, which can have important implications in vivo. The ability of σ receptor
antagonists to intervene at multiple points and mechanisms in the neurotoxic cascade is
consistent with the location of σ receptors in various subcellular organelles like the ER,
mitochondria, lysosomes, cell membrane, and nucleus (McCann et al., 1994; Zeng et al.,
2007) and its functional role as a chaperone, with subcellular translocation and participation in
protein-protein interactions (Su et al., 2010). Future studies are needed to elucidate the
individual contributions of the two subtypes of σ receptors, as better tools are developed.

5.5 Contributions: Nidhi Kaushal conducted all the studies in this chapter. Abagail Rosen
helped with the data analysis for some of the apoptosis and necrosis assays.
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CHAPTER 6
EVALUATION OF σ-2 RECEPTOR ANTAGONIST AGAINST METHINDUCED NEUROTOXICITY IN VITRO
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6.1 Introduction
Recent studies suggest that σ-1 receptors function as a chaperone modulating interorganelle signaling (Su et al., 2010). In comparison, activation of σ-2 receptors in tumor cells
causes cell death by increasing cellular levels of calcium, ceramide and sphingolipids (Bowen,
2000). This effect is inhibited by the administration of σ receptor antagonists confirming the
role of σ-2 receptors in these effects (Vilner and Bowen, 2000; Crawford and Bowen, 2002;
Crawford et al., 2002). From independent experiments, it has also been shown that σ receptor
antagonists can attenuate METH’s neurotoxicity (Matsumoto et al., 2008; Kaushal et al.,
2011b; Seminerio et al., 2011). Taking all this into consideration, σ-2 receptors seem to play a
more dominant role in the neurotoxic effects of METH.
Table 6.1 displays a series of putative selective sigma-2 ligands. CM398 possesses
highest affinity and selectivity for sigma-2 receptors over sigma-1 receptors. In vivo functional
assay suggests that CM398 is functioning as an antagonist. In this part of the study therefore,
it was determined whether METH induced cytotoxicity can be attenuated by CM398 in
differentiated NG108-15 cells. This will further help in demonstrating the role of σ-2 receptors
in METH toxicity and also the various signaling pathways that will be involved.
Table 6.1 Binding affinity of compounds for σ-1 and σ-2 receptors

CM360
CM361
NF12
CM781
CM397
SN230
CM775
CM777
CM699
CM398

σ-1 (Ki in nM)
139.47 ± 3.51
3834.33 ± 580.30
273.5 ± 1.33
724.6 ± 15.7
86.41 ± 2.02
3128.00 ± 70.89
2274 ± 186.8
752.4 ± 51.44
16.56 ± 1.09
560.4 ± 8.72

σ-2 (Ki in nM)
1.26 ± 0.06
30.53 ± 13.79
1.81 ± 0.019
4.55 ± 0.21
0.48 ± 0.02
14.70 ± 1.18
4.27 ± 0.29
0.66 ± 0.01
0.014 ± 0.0003
0.43 ± 0.015
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Ratio (σ-1/ σ-2)
110.98
125.59
151
159.12
181.28
212.79
532.55
1140
1183
1303

6.2. Materials and Methods
6.2.1. Cell line and culture
6.2.1.1. Cell growth: The neuroblastoma x glioma, hybridoma cell line NG108-15
(Hamprecht et al., 1985) were obtained from ATCC (Rockville, MD). Cells were maintained in
25 cm2 (T25) or 75 cm2 (T75) culture flasks (Corning-Costar, Lowell, MA) in hi-glucose (4.5
g/L) DMEM (Dulbecco’s modified Eagle’s medium) supplemented with 10% FBS (fetal bovine
serum), penicillin, streptomycin, and HAT (hypoxanthine-aminopterin-thymidine) at 37⁰C in a
humidified incubator in 5% CO2.
6.2.1.2. Cell differentiation: Culture medium was replaced with differentiation medium
(DMEM with 0.5% FBS, penicillin, streptomycin, HAT and 1% DMSO) and the cells allowed to
grow for a further 3-4 days.

6.2.2. Hoechst and propidium iodide staining: NG108-15 cells were grown and
differentiated in 96-well culture plates and exposed to various concentrations of METH (01000 µM), CM398 (1-100 nM), CM398 (1-100 nM)+METH (0-1000 µM) for 24 hrs at 37 °C.
Hoechst stain (20 µg/ml final concentration) and propidium iodide stain (20 µg/ml final
concentration) were added to each well and incubated at room temperature for 10 min. Three
images are taken/well using an UV light microscope. Cells with brightly stained and
fragmented nuclei were counted as apoptotic and cells that were red were counted as
necrotic. The percentage of apoptotic and necrotic cells were counted with the help of Image J
cell counter (NIH). The sum of percentage of apoptotic and necrotic cells was referred to as
“total cell death”.
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6.3. Results
6.3.1. CM398 and METH
Apoptosis: One-way ANOVA showed that METH treatment caused a significant
increase in the percentage of apoptotic cells (F(7,144) = 29.38, p < 0.0001). Post-hoc
Dunnett’s tests confirmed that the following concentrations of METH caused a significant
increase in the percentage of apoptotic cells: 10 µM (q = 2.77, p < 0.05), 30 µM (q = 4.23, p <
0.01), 100 µM (q = 5.55, p < 0.01), 300 µM (q = 7.90, p < 0.01) and 1000 µM (q = 12.34, p <
0.01). CM398 pretreatment significantly attenuated the apoptotic effects of METH (Figure
6.1A). Two-way ANOVA showed a significant effect of METH treatment (F(7,519) = 46.77, p <
0.0001), CM398 pretreatment (F(3,519) = 26.15, p < 0.0001), and CM398 pretreatment ×
METH treatment (F(21,519) = 3.68, p < 0.0001). Bonferroni’s post-hoc tests showed that
CM398 (1, 10 and 100 nM) pretreatment is able to attenuate the apoptotic effects of the
following concentrations of METH: 300 µM (t = 4.10, p < 0.001; t = 4.49, p < 0.0001 and t =
3.03, p < 0.05 respectively) and 1000 µM (t = 4.28, p < 0.001; t = 7.35, p < 0.001 and t = 8.90,
p < 0.001 respectively).
Necrosis: One-way ANOVA showed that METH treatment caused a significant
increase in the percentage of necrotic cells (F(7,143) = 4.76, p < 0.0001). Post-hoc Dunnett’s
tests confirmed that 1000 µM METH caused a significant increase in the percentage of
necrotic cells (q = 5.50, p < 0.01). CM398 pretreatment significantly attenuated the necrotic
effects of METH (Figure 6.1B). Two-way ANOVA showed a significant effect of CM398
pretreatment (F(3,508) = 10.82, p < 0.0001), METH treatment (F(7,508) = 12.95, p < 0.0001).
Bonferroni posttests confirmed that 1 nM CM398 attenuated the necrotic effects of 1000 µM
METH (t = 3.74, p < 0.01).
Total cell death: One-way ANOVA showed that METH treatment caused a significant
increase in the percentage of total cell death (F(7,146) = 17.65, p < 0.0001). Post-hoc
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Dunnett’s tests confirmed that the following concentrations of METH caused a significant
increase in the percentage of total cell death: 10 µM (q = 3.54, p < 0.01), 30 µM (q = 5.10, p <
0.01), 100 µM (q = 4.10, p < 0.01), 300 µM (q = 5.55, p < 0.01) and 1000 µM (q = 10.25, p <
0.01). CM398 pretreatment significantly attenuated METH-induced cell death (Figure 6.1CB).
Two-way ANOVA showed a significant effect of CM398 pretreatment (F(3,512) = 30.88, p <
0.0001), METH treatment (F(7,512) = 43.05, p < 0.0001) and CM398 pretreatment × METH
treatment interaction (F(21,512) = 1.96, p < 0.01). Bonferroni posttests confirmed that CM398
(1, 10, 100 nM) attenuate cell death caused by the following concentrations of METH: 10 µM
(1 nM: t = 3.08, p < 0.05; 10 nM: t = 3.61, p < 0.01; 100 nM: t = 2.94, p < 0.05), 30 µM (1 nM: t
= 4.83, p < 0.001; 10 nM: t = 3.84, p < 0.01), 100 µM (100 nM: t = 3.05, p < 0.05), 300 µM (1
nM: t = 4.08, p < 0.001; 10 nM: t = 3.73, p < 0.01; 100 nM: t = 3.49, p < 0.01) and 1000 µM
METH (1 nM: t = 5.24, p < 0.001; 10 nM: t = 4.24, p < 0.001; 100 nM: t = 5.79, p < 0.001).
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Figure 6.1 Effect of CM398 pretreatment on METH-induced (A) apoptosis, (B) necrosis and (C)
total cell death. CM398 protects against methamphetamine (METH)-induced apoptosis (A), necrosis
(B) and total cell death (C). Differentiated NG108-15 cells were pretreated with CM398 (0-100 nM) prior
to exposure to METH (0-1000 µM) for 24 hr. After 24 hr, the wells were incubated with Hoechst 33342
and propidium iodide stains (20 µg/ml each) to obtain percentages of apoptotic and necrotic cells. Total
cell death = Apoptotic cell death + Necrotic cell death. Data represent means from two separate
experiments (n = 3/experiment) ± SEM. Significant differences are indicated by *p < 0.05, **p < 0.01
(control vs. METH); #p < 0.05, ##p < 0.01, ###p < 0.001 (METH alone vs. METH with CM398).
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6.3.2. CM775 and METH
Apoptosis: One-way ANOVA showed that METH treatment caused a significant
increase in the percentage of apoptotic cells (F(7,78) = 12.38, p < 0.0001). Post-hoc Dunnett’s
tests confirmed that the following concentrations of METH caused a significant increase in the
percentage of apoptotic cells: 100 µM (q = 3.58, p < 0.01), 300 µM (q = 3.35, p < 0.01) and
1000 µM (q = 8.46, p < 0.001). CM775 pretreatment significantly attenuated the apoptotic
effects of METH (Figure 6.2A). Two-way ANOVA showed a significant effect of METH
treatment (F(7,286) = 23.35, p < 0.0001), CM775 pretreatment (F(3,286) = 23.35, p < 0.0001),
and CM775 pretreatment × METH treatment (F(21,286) = 3.89, p < 0.0001). Bonferroni’s posthoc tests showed that CM775 (1, 10 and 100 nM) pretreatment is able to attenuate the
apoptotic effects of the following concentrations of METH: 3 µM (10nM CM775; t = 3.44, p <
0.05), 100 µM (t = 4.29, p < 0.001; t = 4.39, p < 0.001 and t = 3.94, p < 0.01 respectively), 300
µM (t = 3.85, p < 0.01 and t = 3.78, p < 0.01 respectively) and 1000 µM (t = 9.95, p < 0.0001; t
= 5.61, p < 0.0001 and t = 9.32, p < 0.0001 respectively).
Necrosis: One-way ANOVA showed that METH treatment caused a significant
increase in the percentage of necrotic cells (F(7,77) = 3.63, p < 0.005). Post-hoc Dunnett’s
tests confirmed that 300 and 1000 µM METH caused a significant increase in the percentage
of necrotic cells (q = 3.00, p < 0.05 and q = 4.29, p < 0.001 respectively). CM775 pretreatment
did not significantly attenuate the necrotic effects of METH (Figure 6.2B).
Total cell death: One-way ANOVA showed that METH treatment caused a significant
increase in the percentage of total cell death (F(7,79) = 10.65, p < 0.0001). Post-hoc
Dunnett’s tests confirmed that the following concentrations of METH caused a significant
increase in the percentage of total cell death: 10 µM (q = 3.58, p < 0.01), 300 µM (q = 3.71, p
< 0.01) and 1000 µM (q = 7.71, p < 0.001). CM775 pretreatment significantly attenuated
METH-induced cell death (Figure 6.2C). Two-way ANOVA showed a significant effect of
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CM775 pretreatment (F(3,287) = 13.09, p < 0.0001), METH treatment (F(7,287) = 20.67, p <
0.0001) and CM775 pretreatment × METH treatment interaction (F(21,287) = 2.39, p < 0.001).
Bonferroni posttests confirmed that CM775 (1, 10, 100 nM) attenuate cell death caused by the
following concentrations of METH: 10 µM (1 nM: t = 3.24, p < 0.05; 10 nM: t = 4.06, p < 0.01)
and 1000 µM METH (1 nM: t = 6.07, p < 0.0001; 10 nM: t = 5.20, p < 0.0001; 100 nM: t = 3.52,
p < 0.05).
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Figure 6.2 Effect of CM775 pretreatment on METH-induced (A) apoptosis, (B) necrosis and (C)
total cell death. CM775 protects against methamphetamine (METH)-induced apoptosis (A), necrosis
(B) and total cell death (C). Differentiated NG108-15 cells were pretreated with CM775 (0-100 nM) prior
to exposure to METH (0-1000 µM) for 24 hr. After 24 hr, the wells were incubated with Hoechst 33342
and propidium iodide stains (20 µg/ml each) to obtain percentages of apoptotic and necrotic cells. Total
cell death = Apoptotic cell death + Necrotic cell death. Data represent means from one experiment (n =
3/experiment) ± SEM. Significant differences are indicated by *p < 0.05, **p < 0.01, ***p < 0.001 (control
vs. METH); #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 (METH alone vs. METH with CM775).
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6.3.3. CM699 and METH
Apoptosis: METH treatment on its own caused a significant increase in apoptotic cell
death in differentiated NG108-15 cells. One way ANOVA showed a significant effect of METH
treatment (F(6,67) = 14.43, p < 0.0001). Dunnett’s post-hoc tests confirmed that the following
concentrations of METH cause a significant increase in apoptosis: 100 µM (q = 3.60, p < 0.01)
and 1000 µM (q = 8.41, p < 0.001).
Figure 6.3A shows that CM699 pretreatment displayed a trend towards a shift in the
dose response curve of METH-induced apoptosis towards the left; however, the effect was not
significant.
Necrosis: METH treatment on its own caused a significant increase in necrotic cell
death in differentiated NG108-15 cells. One way ANOVA showed a significant effect of METH
treatment (F(6,249) = 4.84, p < 0.0001). Dunnett’s post-hoc tests confirmed that METH 100
and 1000 µM caused a significant increase in necrosis (q = 3.47, p < 0.01 and q = 8.75, p <
0.001 respectively).
Figure 6.3B shows that CM699 pretreatment at intermediate concentrations shifts the
dose response curve of METH towards the left. Two way ANOVA showed a significant effect
of METH treatment (F(6,242) = 23.23, p < 0.0001) and CM699 pretreatment (F(3,242) =
11.42, p < 0.0001). Bonferroni’s post-hoc tests confirm that the following concentrations of
CM699 in combination with METH are significantly different than METH treatment alone:
CM699 1 nM (0.1 µM: t = 3.60, p < 0.01 and 1 µM: t = 4.14, p < 0.01) andCM699 10 nM (0.1
µM: t = 3.70, p < 0.01; 1 µM: t = 3.30, p < 0.05).
Total cell death: METH treatment on its own caused a significant increase in cell death
in differentiated NG108-15 cells. One way ANOVA showed a significant effect of METH
treatment (F(6,67) = 35.67, p < 0.0001). Dunnett’s post-hoc tests confirmed that the following
concentrations of METH caused a significant increase in total cell death: 100 µM (q = 4.81, p
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< 0.001) and 1000 µM (q = 11.78, p < 0.001). Figure 6.3C shows that CM699 pretreatment at
intermediate concentrations shifted the dose response curve of METH-induced cell death
towards the left. Two way ANOVA showed a significant effect of METH treatment (F(6,242) =
35.45, p < 0.0001) and CM699 pretreatment (F(3,242) = 10.38, p < 0.0001). Bonferroni’s posthoc tests confirm that the following concentrations of CM699 in combination with METH are
significantly different than METH treatment alone: CM699 1 nM (0.1 µM: t = 3.09, p < 0.05 and
1 µM: t = 3.59, p < 0.01) and CM699 10 nM (0.1 µM: t = 3.10, p < 0.05 and 1 µM: t = 3.30, p <
0.05).

142

A

B
CM699 (0 nM)
CM699 (1 nM)
CM699 (10 nM)

8

***

CM699 (100 nM)

6

**

4
2
0
0

0.01

0.1

CM 699 (0 nM)
CM699 (1 nM)
CM699 (10 nM)
CM699 (100 nM)

25

% Necrotic Cells

% Apoptotic Cells

10

1

10

20
15

##
##

***
##
#

10

**

5
0

100 1000

0

METH (M)

0.01

0.1

1

10

100 1000

METH (M)

C

% Total Cell Death

40

CM 699 (0 nM)
CM699 (1 nM)
CM699 (10 nM)
CM699 (100 nM)

30
20

#

***

##
#

#

***

10
0
0

0.01

0.1

1

10

100 1000

METH (M)

Figure 6.3 Effect of CM699 pretreatment on METH-induced (A) apoptosis, (B) necrosis and (C)
total cell death. NG108-15 cells were exposed to CM699 (1 -100 nM) and/or METH (0-1000 µM) for 24
hr. After 24 hr, the wells were incubated with Hoechst 33342 and propidium iodide stains (20 µg/ml
each) to obtain percentages of apoptotic and necrotic cells. Total cell death = Apoptotic cell death +
Necrotic cell death. Data represent means from one experiment (n = 3/experiment) ± SEM. Significant
differences are indicated by *p < 0.05, **p < 0.01, ***p < 0.001 (control vs. METH); #p < 0.05, ##p <
0.01 (CM699+METH vs. METH).
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6.4 Discussion
This study demonstrated that σ-2 receptors may be an important subtype for mediating
the effects of METH. CM398 and CM775 attenuated predominantly the apoptotic effect of
METH in differentiated NG108-15 cells which is consistent with reports in the literature
suggesting activation of σ-2 receptors can activate apoptotic type of cell death (Bowen, 2000;
Crawford and Bowen, 2002). In addition CM669 seems to shift the dose response curve of
METH-induced cell death towards the left, indicating that σ-2 receptors are an important
subtype through which METH mediates its effects. This also provides additional evidence that
the leftward dose response shift observed with DTG in the previous chapter is most likely due
to the engagement of σ-2 receptor subtype. Additionally, σ-2 Receptors may play a
predominant role in this cell death pathway as a previous study using SK-N-SH
neuroblastoma cells showed that activation of σ-2 receptors caused caspase-10 activation
which in turn cleaved Bid thereby causing activation of mitochondrial death cascade (Wang
and Bowen, 2006). Similar phenomenon was observed with METH is the previous chapter,
whereby METH caused caspse-8 activation followed by mitochondrial death cascase
activation in NG108-15 cells. Studies have also shown that activation of σ-2 receptors has
been shown to cause elevation of ceramide levels in the cell which can be linked with caspase
activation (Crawford et al., 2002; Wang and Bowen, 2006). Ceramide levels are also elevated
by the activation of death receptors like Fas (Cifone et al., 1994; Tepper et al., 1995;
Skowronski et al., 1996). Additionally, The localization of both the death receptors and σ-2
receptors in the cellular lipid raft compartment indicates potential regulation of the death
receptor signaling by σ-2 receptors. In the previous chapter, activation of caspase-8 levels
was observed after METH treatment. This could also involve METH interaction with σ-2
receptors which in turn may regulate the death receptors to cause caspase-8 activation.
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A recent study has proposed σ-2 receptors to be a binding site in the PGRMC1 (progesterone
receptor membrane component 1) complex (Xu et al., 2011). PGRMC1 like σ-2 receptors are
highly expressed in tumor cells in comparison to normal cells (Bowen, 2000; Cahill, 2007).
They both are studied as important cancer biomarkers and potential therapeutic targets for
anticancer drugs (Bowen, 2000; Cahill, 2007; Mir et al., 2011). This study is very promising
given the lack of molecular biology tools to study σ- 2 receptors. The novel compounds used
in this study are selective for σ-2 over σ-1 receptors. However, additional selectivity profile of
those tested compounds over other non-σ sites may have to be determined in order to further
establish the claim.
Additional studies may be performed using other σ-2 receptor agonists like CB-64D to
observe dose response shifts in METH-induced cytotoxicity. In addition, further future studies
may be required to fully elucidate and compare the potential involvement of σ-1 receptors in
the neurotoxic effects of METH.

6.5 Contribution: Nidhi Kaushal conducted the apoptosis and necrosis assays. Cory Weaver
helped with the data analysis of some of the experiments.
Radioligand binding assays were conducted by Dr. Yantong Xu and Michael Seminerio
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CHAPTER 7
OVERALL CONCLUSIONS AND FUTURE STUDIES
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7.1 Summary:

In summary, the studies conducted herewith have demonstrated that:


σ Receptor antagonism (using AC927, CM156 and SN79) attenuated METH-induced
striatal dopaminergic and serotonergic neurotoxicity in vivo (measured as depletion in
dopamine and 5-HT levels and DAT and SERT expression levels). The presence of σ
receptors on the dopaminergic and serotonergic neurons along with their role in cell
death pathways explains these neuroprotective effects (Campbell et al., 1989;
Bastianetto et al., 1995; Derbez et al., 2002; Bowen, 2000). Therefore, AC927, CM156
and SN79 may provide neuroprotection by acting through σ receptors and
competitively or non-competitively intervening at the previously described (in Chapter
1) METH’s downstream mechanisms (Kaushal and Matsumoto, 2011).



σ

Receptor

antagonists

attenuated

METH-induced

hypertheria

in

mice.

Mechanistically, dopaminergic and serotonergic systems are implicated in METHinduced body temperature alterations (Numachi et al., 2007). In addition, the
production of ROS and release of cytokines like IL1β have been implicated in the
generation of METH’s hyperthermia (Bowyer et al., 1994; Imam et al., 1999; Riedel
and Maulik, 1999; Yamashita et al., 2000; Fukami et al., 2004). Moreover, σ Receptor
ligands, with their ability to modulate these neurotransmitter systems, cytokines, as
well as ROS, can attenuate elevations in body temperature (Campbell et al., 1989;
Bastianetto et al., 1995; Derbez et al., 2002; Schetz et al., 2007; Matsumoto et al.,
2008). Additionally, σ receptors are located in the hypothalamic brain region and have
previously been shown to modulate body temperature (Gundlach et al., 1986; Rawls et
al., 2002). A combination of all these factors may explain how AC927, CM156 and
SN79 can prevent METH-induced hyperthermia.
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Striatal dopamine and serotonin levels in all the treatment groups correlated with their
body temperature during the experiment. This indicates that the METH-induced
neurotoxicity is related to the body temperature of the mice during treatment. In
addition, the ability of AC927, CM156 and SN79 to attenuate the depletions in
dopamine and 5-HT levels may be related to their ability to decrease the hyperthermic
effects of METH. However, correlation does not always mean causation. As discussed
earlier, sigma receptors may be able to attenuate the hyperthermic effects of METH
through various mechanisms; they may also be able to prevent METH-induced
neurotoxicity at a cellular level independent of temperature influence. However, the
separation of these effects in an in vivo system may not be possible or very difficult to
interpret.



σ Receptor antagonism provided protection against METH-induced cell death
(apoptosis and necrosis) in differentiated NG108-15 cells. Both AC927 and SN79
attenuated METH-induced cell death which is consistent with the role of σ receptors in
cell death mechanisms (Bowen, 2000; Marrazzo et al., 2011).



METH caused dopamine release, ROS/RNS generation, caspase-8, -9 and -3
activation in differentiated NG108 cells. Sigma receptor antagonism attenuated all the
above mentioned METH-induced neurotoxic endpoints. Figure 7.1 depicts the time
frame of METH-induced neurotoxic cascade activation observed using NG108-15
cells. The green boxes indicate the events that were blocked by SN79 and/or AC927.
The ability of σ receptor antagonists to intervene at multiple points and mechanisms in
the neurotoxic cascade is consistent with the location of σ receptors in various
subcellular organelles like the ER, mitochondria, lysosomes, cell membrane, and
nucleus (McCann et al., 1994; Zeng et al., 2007) and its functional role as a
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chaperone, with subcellular translocation and participation in protein-protein
interactions (Su et al., 2010).

Figure 7.1 Time course of METH-induced activation of neurotoxic cascades in
differentiated NG108-15 cells
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Elevated temperature (40 ºC) exacerbated METH-induced neurotoxicity. Sigma
receptor antagonism (using SN79) attenuated the enhanced toxicity caused by the
interaction of METH and elevated temperature. Figure 7.2 below depicts the
enhancement of METH-induced cell death in differentiated NG108-15 cells which may
also have implications in vivo. Green boxes indicate that SN79 was able to attenuate
this enhanced toxicity caused by the combination of elevated temperature and METH.
The combination of METH and elevated temperature synergistically enhanced cell
death (especially necrosis). This potentiation effect is most likely due to high
temperature induced increase in DAT activity and enhanced ROS/RNS levels
(Fleckenstein et al., 1997; Xie et al., 2000; Kiyatkin et al., 2007; Numachi et al., 2007;
Sharma et al., 2007). The ability of SN79 to attenuate both the elevated temperature
induced toxicity as well as the enhanced toxicity caused my interaction of METH and
elevated temperature is consistent with the potential role of σ receptors in various cell
stress and death mechanisms. σ Receptors, due to their properties of intracellular
translocation, protein-protein interaction and chaperone activity can help normalize a
disordered system (Tsai et al., 2009).
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Figure 7.2 Effect of elevated temperature on METH-induced cell death in differentaited
NG108-15 cells
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σ- 2 Receptor antagonism (using CM398 and CM775) is able to attenaute METHinduced cell death in differentiated NG108-15 cells, indicating an important role of σ-2
receptors in METH mediated toxicity. σ- 2 Receptor subtype has previously been
shown to play an important role in cell death pathways in tumor cells (Bowen, 2000),
further indicating a greater significance of this subype in METH’s effects. Further
studies may be needed to compare the role of the two σ receptor subtypes in METHinduced neurotoxicity.

Overall, the ability of σ receptor antagonsits in attenuating multiple end points in METHinduced toxicity may be due to its presence in multiple organelles like ER, mitochondria,
lysosomes, nucleus, plasma membrane, and ability to undergo intracellular translocation,
protein-protein interaction and chaperone activity which can help normalize a disordered
system (Tsai et al., 2009). Alternately, the protective effects may be due to inhibition of early
mediators like dopamine release or ROS/RNS generation. In order to determine this,
additional posttreatment studies may have to be conducted whereby σ receptor antagonist will
be administered at various time points after METH administration.
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